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SUMMARY 
The Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact 
with Food (the Panel) is asked to advise the Commission on the implications for human health of 
chemically defined flavouring substances used in or on foodstuffs in the Member States. In 
particular, the Panel is asked to evaluate 32 flavouring substances in the Flavouring Group 
Evaluation 25 (FGE.25), using the Procedure as referred to in the Commission Regulation (EC) No 
1565/2000. These 32 flavouring substances belong to chemical group 31, Annex I of the 
Commission Regulation (EC) No 1565/2000. 
The present Flavouring Group Evaluation deals with 32 aliphatic and aromatic hydrocarbons which 
have been divided into eight subgroups: I) acyclic alkanes, II) acyclic alkenes, III) cyclohexene 
hydrocarbons, IVa) benzene hydrocarbons, IVb) napthalene hydrocarbons, IVc) diphenylmethane, 
V) bi-and tricyclic, non-aromatic hydrocarbons and VI) macrocyclic, non-aromatic hydrocarbons. 
Seventeen of the 32 flavouring substances possess chiral centres and 16 can exist as geometrical 
isomers due to presence and position of double bonds. For eight of these flavouring substances the 
stereoisomeric composition has not been specified. 
Of the 32 flavouring substances 27 are classified into structural class I, two into structural class II, 
and three into structural class III according to the decision tree approach presented by Cramer et al. 
(1978). 
Twenty-nine of the flavouring substances in the present group have been reported to occur naturally 
in a wide range of food items. 
                                                 
1  For citation purposes: Scientific Opinion of the Panel on Food Additives, Flavourings, Processing Aids 
and Materials in Contact with Food on a request from Commission on Flavouring Group Evaluation 87, (FGE.87) 
bicyclic secondary alcohols, ketones and related esters. The EFSA Journal (2008) 918, 1-109 
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In its evaluation, the Panel as a default used the Maximised Survey-derived Daily Intake (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when 
the Panel examined the information provided by the European Flavour Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
 consequence, the Panel had reservations about the data on use and use levels provided and the 
intake estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an 
estimate of the daily intakes per person using a modified Theoretical Added Maximum Daily Intake 
(mTAMDI) approach based on the normal use levels reported by the Industry. In those cases where 
the mTAMDI approach indicated that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, the Panel decided not to carry out a formal safety assessment 
using the Procedure. In these cases the Panel requires more precise data on use and use levels. 
According to the default MSDI approach, the 32 flavouring substances in this group have intakes in 
Europe from 0.0012 to 2.7 microgram/capita/day, which are below the threshold of concern value 
for structural class I (1800 microgram/person/day), structural class II (540 microgram/person/day) 
and structural class III (90 microgram/person/day) substances. 
Data on the genotoxicity of the flavouring substances in this group are limited and the genotoxicity 
could not be assessed adequately for these substances. For one candidate substance, 2-methylbuta-
1,3-diene (synonym: isoprene) [FL-no: 01.049], there is evidence of an in vivo genotoxic potential. 
Therefore, the Panel concluded that the Procedure could not be applied to this substance. The 
available data do not preclude evaluating the remaining 31 candidate substances using the 
Procedure. 
The available information on metabolism of the 31 flavouring substances evaluated through the 
Procedure or on structurally related substances for this FGE was very limited. Overall, only for 
eight of the flavouring substances it can be concluded that they will be metabolised into innocuous 
metabolites. For 18 of the flavouring substances the information is too limited and it cannot be 
assumed that they are metabolised to innocuous metabolites. For the remaining five of the 
flavouring substances there are data, which show that they may be metabolised to toxic metabolites. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure. 
It is concluded that the eight flavouring substances which are expected to be metabolised to 
innocuous substances would not give rise to safety concerns at their estimated intakes arising from 
their use as flavouring substances based on the MSDI approach. For the remaining 23 flavouring 
substances, which cannot be anticipated to be metabolised to innocuous products, or for structurally 
related substances, no adequate No Observed Adverse Effect Level (NOAEL) were available. 
Therefore, additional toxicological data are required. 
The mTAMDI values for the 31 flavouring substances, evaluated using the Procedure, are 3300 
microgram/person/day for one substance and 3700 microgram/person/day for each of the remaining 
30 flavouring substances. These values are above the threshold for structural class I, II and III of 
1800, 540 and 90 microgram/person/day, respectively.  
Accordingly, intake estimates according to the mTAMDI for the 31 candidate substances in this 
flavouring group evaluation exceed the thresholds of concern for the three structural classes, and 
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more reliable exposure data are requested. On the basis of such additional data, the flavouring 
substances should be considered using the Procedure. Subsequently, additional data might become 
necessary. 
 
In order to determine whether this evaluation could be applied to the materials of commerce, it is 
necessary to consider the available specifications. 
Specifications including complete purity criteria and identity tests for the materials of commerce 
have been provided for 23 flavouring substances. For eight substances [FL-no: 01.027, 01.032, 
01.034, 01.035, 01.050, 01.055, 01.056 and 01.060] information on stereoisomerism is missing. 
Thus, the final evaluation of the materials of commerce cannot be performed for eight substances 
[FL-no: 01.027, 01.032, 01.034, 01.035, 01.050, 01.055, 01.056 and 01.060], pending further 
information on isomerism. For 23 flavouring substances [FL-no: 01.022, 01.023, 01.030, 01.031, 
01.032, 01.035, 01.036, 01.037, 01.042, 01.043, 01.044, 01.047, 01.050, 01.051, 01.052, 01.053, 
01.055, 01.056, 01.058, 01.060, 01.064, 01.066 and 01.067] additional toxicity data are required. 
For six flavouring substances [FL-no: 01.028, 01.033, 01.038, 01.039, 01.054 and 01.057] the Panel 
concluded that they would present no safety concern at the level of intake estimated on the basis of 
the MSDI approach. One flavouring substance, 2-methylbuta-1,3-diene [FL-no: 01.049], is 
genotoxic in vitro and in vivo and carcinogenic in experimental animals. Accordingly, the use as 
chemically defined flavouring substance is toxicologically not acceptable for this substance. 
Keywords 
Hydrocarbons, aliphatic, alicyclic, aromatic, flavourings, safety. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996) lays down a 
Procedure for the establishment of a list of flavouring substances, the use of which will be 
authorised to the exclusion of all other substances in the EU. In application of that Regulation, a 
Register of flavouring substances used in or on foodstuffs in the Member States was adopted by 
Commission Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 
2006/252/EC (EC, 2006). Each flavouring substance is attributed a FLAVIS-number (FL-number) 
and all substances are divided into 34 chemical groups. Substances within a group should have 
some metabolic and biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation 
programme laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is 
broadly based on the Opinion of the Scientific Committee on Food (SCF, 1999). For the submission 
of data by the manufacturer, deadlines have been established by Commission Regulation (EC) No 
622/2002 (EC, 2002b).  
After the completion of the evaluation programme the positive list of flavouring substances for use 
in or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996). 
TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on 
flavouring substances prior to their authorisation and inclusion in a positive list according to 
Commission Regulation (EC) No 1565/2000 (EC, 2000a). 
ASSESSMENT 
1. Presentation of the Substances in the Flavouring Group Evaluation 25 
1.1. Description 
The present Flavouring Group Evaluation 25, FGE.25, using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) (The Procedure – shown in schematic 
form in Annex I), deals with 32 aliphatic and aromatic hydrocarbons (candidate substances) from 
chemical group 31, Annex I of Commission Regulation (EC) No 1565/2000 (EC, 2000a). The 
candidate substances in the group have been divided into eight subgroups: I) acyclic alkanes, II) 
acyclic alkenes, III) cyclohexene hydrocarbons, IVa) benzene hydrocarbons, IVb) naphthalene 
hydrocarbons, IVc) diphenylmethane, V) bi- and tricyclic, non-aromatic hydrocarbons and VI) 
macrocyclic, non-aromatic hydrocarbons. 
The 32 candidate substances under consideration, with their chemical Register names, FLAVIS - 
(FL-), Chemical Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and Extract 
Manufacturers Association- (FEMA-) numbers, structure and specifications, are listed in Table 1 
and Table 2. 
The 32 candidate substances are closely related structurally to 19 flavouring substances (supporting 
substances) evaluated at the 63rd JECFA meeting (JECFA, 2005c) in the groups of “Aliphatic and 
alicyclic hydrocarbons” and “Aromatic hydrocarbons”. The supporting substances are listed in 
Table 3. 
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1.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. 
Their flavour may be different, they may have different chemical properties resulting in possible 
variation of their absorption, distribution, metabolism, elimination and toxicity. Thus, information 
must be provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for 
candidate substances for which stereoisomers may exist can be applied to the material of commerce. 
Flavouring substances with different configurations should have individual chemical names and 
codes (Chemical Abstract Service number (CAS number), FLAVIS number, etc.). 
Seventeen of the 32 candidate substances possess chiral centres. For 10 of these chiral substances 
the chemical names and CAS numbers specify the stereoisomers. For six of the substances [FL-no: 
01.027, 01.034, 01.050, 01.055, 01.056 and 01.060] the stereoisomeric composition has not been 
specified, and for one substance [FL-no: 01.067] no CAS number has been provided. 
Due to the presence and the position of double bonds, 16 of the 32 candidate substances can exist as 
geometrical isomers. In three cases [FL-no: 01.027, 01.032 and 01.035] no indication of the 
configuration of the double bond is given.  
1.3. Natural Occurrence in Food 
Twenty-nine out of the 32 candidate substances have been reported to occur in various types of 
alcoholic beverages, chicken, egg (boiled), fish (raw), shrimps, guinea hen, lamb fat, cheese, milk, 
butter, various herbs, various fruits and vegetables, tea, mace, and wort. Quantitative data on the 
natural occurrence in foods have been reported for 23 of these substances (TNO, 2000). 
These reports include: 
• alpha-Cedrene [FL-no: 01.022]: 0.0007 mg/kg in artichoke. 
• 1(5),11-Guaiadiene [FL-no: 01.023]: 1.5 mg/kg in mango, trace amounts in basil and in pepper.  
• beta-Bisabolene [FL-no: 01.028]: 33.3 mg/kg in parsley, up to 1.18 mg/kg in carrot, 0.003 
mg/kg in artichoke, 0.0003 mg/kg in guava fruit, trace amounts in mace and in nutmeg. 
• beta-Cubebene [FL-no: 01.030]: 0.08 mg/kg in grapefruit juice, up to 0.08 mg/kg in guava fruit, 
trace amounts in mace and in nutmeg. 
• 1,2-Dihydro-1,1,6- trimethylnaphthalene [FL-no: 01.031]: 0.25 mg/kg in rum, up to 0.042 
mg/kg in white wine.  
• 2,2-Dimethylhexane [FL-no: 01.033]: up to 0.9 mg/kg in tea. 
• 2,4-Dimethylhexane [FL-no: 01.034]: up to 2 mg/kg in tea. 
• 2,6-Dimethylocta-2,4,6-triene [FL-no: 01.035]: 0.45 mg/kg in mango, 0.03 mg/kg in orange 
juice, up to 0.08 mg/kg in blackcurrants, trace amounts in sage.  
• Dodec-1-ene [FL-no: 01.037]: up to 0.4 mg/kg in butter, up to 0.01 mg/kg in loquat, up to 0.01 
mg/kg in passiflora. 
• Dodecane [FL-no: 01.038]: up to 3.5 mg/kg in butter, up to 0.1 mg/kg in passiflora, 0.1 mg/kg 
in beans, 0.1 mg/kg in cocoa, 0.1 mg/kg in tea, up to 0.1 mg/kg in lamb, 0.08 mg/kg in dill, up 
to 0.05 mg/kg in strawberry, 0.02 mg/kg in chicken, up to 0.01 mg/kg in loquat, up to 0.01 
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mg/kg in papaya, 0.01 mg/kg in pea, up to 0.004 mg/kg in egg, 0.009 mg/kg in Guinea hen, 
0.0006 mg/kg in raw fish, trace amounts in liquorice. 
• delta-Elemene [FL-no: 01.039]: trace amounts in mandarin juice. 
• Germacra-1(10),4(14),5-triene [FL-no: 01.042]: 0.001 mg/kg in mandarin juice. 
• 3,7,10-Humulatriene [FL-no: 01.043]: up to 1.3 mg/kg in mango, up to 1.2 mg/kg in tea, up to 
1.05 mg/kg in guava, 0.12 mg/kg in carrot, up to 0.12 in cheese, 0.2 mg/kg in grapefruit juice, 
up to 0.09 mg/kg in blackcurrants, 0.02 mg/kg in tamarind, up to 0.01 mg/kg in orange juice, up 
to 0.0002 mg/kg in artichoke, 0.0004 mg/kg in mandarin, trace amounts in nutmeg, in raspberry 
and in celery. 
• Longifolene [FL-no: 01.047]: 0.0003 mg/kg in artichoke. 
• 2-Methylbuta-1,3-diene [FL-no: 01.049]: 0.004 mg/kg in beer.  
• 2-Methylnaphthalene [FL-no: 01.051]: 0.1 mg/kg in tea, 0.08 mg/kg in capsicum, up to 0.05 
mg/kg in raspberry, up to 0.01 mg/kg in papaya, up to 0.01 mg/kg in passiflora, trace amounts 
in port wine.  
• alpha-Muurolene [FL-no: 01.052]: 7.9 mg/kg in green tea, up to 0.009 mg/kg in mango, 0.005 
mg/kg in bilberry, trace amounts in nutmeg. 
• Naphthalene [FL-no: 01.053]: 0.1 mg/kg in tea, up to 0.06 mg/kg in capsicum annum (sweet 
pepper), 0.05 mg/kg in cocoa, up to 0.035 mg/kg in cheese, 0.02 mg/kg in raw fish, 0.02 mg/kg 
in beer, 0.01 mg/kg in grapefruit juice, up to 0.01 mg/kg in passiflora, up to 0.01 mg/kg in 
papaya, 0.008 mg/kg in soybean, up to 0.007 mg/kg in plumcot, 0.005 mg/kg in peanut, 0.005 
mg/kg in peas, up to 0.005 mg/kg in plum, 0.005 mg/kg in bilberry, up to 0.005 mg/kg in 
raspberry, 0.004 mg/kg in water buffalo milk, 0.003 mg/kg in beans, 0.0029 mg/kg in skim milk 
powder, 0.001 mg/kg in kiwifruit, up to 0.001 mg/kg in mango, up to 0.0005 mg/kg in chicken, 
0.0008 mg/kg in shrimps, trace amounts in peach, trace amounts in port wine.  
• Pentadecane [FL-no: 01.054]: up to 2.3 mg/kg in butter, up to 0.4 mg/kg in mango, up to 0.346 
mg/kg in cheese, 0.1 mg/kg in chicken, 0.1 mg/kg in tea, up to 0.05 mg/kg in strawberry, up to 
0.03 mg/kg in raw fish, 0.029 mg/kg in Guinea hen, up to 0.02 mg/kg in egg (boiled), 0.014 
mg/kg in milk powder, up to 0.01 mg/kg in papaya, 0.02 mg/kg in tamarind, 0.00001 mg/kg in 
aubergine, trace amounts in liquorice. 
• beta-Phellandrene [FL-no: 01.055]: up to 85 mg/kg in dill, up to 0.66 mg/kg in tea, up to 0.5 
mg/kg in black currants, up to 0.4 mg/kg in mango, up to 0.1 mg/kg in papaya, 0.025 mg/kg in 
grapefruit juice, up to 0.01 mg/kg in passiflora, up to 0.005 mg/kg in plumcot, up to 0.002 
mg/kg in redcurrants, trace amounts in cinnamomum, trace amounts in nectarine. 
• Tetradecane [FL-no: 01.057]: up to 1.9 mg/kg in butter, 0.3 mg/kg in liquorice, up to 0.3 mg/kg 
in mango, up to 0.3 mg/kg in dill, 0.021 mg/kg in guinea hen, up to 0.15 mg/kg in cheese, 0.1 
mg/kg in cocoa, 0.1 mg/kg in tea, 0.088 mg/kg in passiflora, up to 0.05 mg/kg in strawberry, up 
to 0.01 mg/kg in papaya, up to 0.003 mg/kg in egg, 0.001 mg/kg in milk 0.0005 mg/kg in 
chicken, 0.0008 mg/kg in raw fish, trace amounts in thymus, aubergine, coconut and lamb. 
• 1,1,7-Trimethyltricyclo[2.2.1.0(2,6)]heptane [FL-no: 01.060]: up to 50 mg/kg in pepper, trace 
amounts in cardamom. 
• cis-3,7-Dimethyl-1,3,6-octatriene [FL-no: 01.064]: up to 13.6 mg/kg in guava fruit, up to 7.5 
mg/kg in mango, 5.3 mg/kg in celery, 2.7 mg/kg in parsley, 2 mg/kg in dill, up to 0.6 mg/kg in 
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tea, up to 0.5 mg/kg in papaya, up to 0.2 mg/kg in blackcurrant, 0.18 mg/kg in grapefruit, 0.05 
mg/kg in cocoa, up to 0.01 mg/kg in passiflora, trace amounts in nectarine. 
According to TNO three of the substances, bisabola-1,8,12-triene [FL-no: 01.027], 2-cedrene [FL-
no: 01.066], and 8(14)-cedrene [FL-no: 01.067] have not been reported to occur naturally in any 
food items (TNO, 2000).  
2. Specifications 
Purity criteria for the 32 substances have been provided by the Flavour Industry (EFFA, 2005a) 
(Table 1). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000), the information is adequate for the 32 candidate substances. However, information on 
geometrical stereoisomerism and chirality is needed for three [FL-no: 01.027, 01.032 and 01.035] 
and six candidate substance [FL-no: 01.027, 01.034, 01.050, 01.055, 01.056 and 01.060], 
respectively (see Section 1.2 and Table 1). 
3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999). 
However, the Panel noted that due to year-to-year variability in production volumes, to 
uncertainties in the underreporting correction factor and to uncertainties in the percentage of 
consumers, the reliability of intake estimates on the basis of the MSDI approach is difficult to 
assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, 
which is calculated on the basis of standard portions and upper use levels (SCF, 1995) for 
flavourable beverages and foods in general, with exceptional levels for particular foods. This 
method is regarded as a conservative estimate of the actual intake in most consumers because it is 
based on the assumption that the consumer regularly eats and drinks several food products 
containing the same flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper 
use levels of the flavouring substances. This modified approach is less conservative (e.g. it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
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reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The Maximised Survey-derived Daily Intake (MSDI) (SCF, 1999) data are derived from surveys on 
annual production volumes in Europe. These surveys were conducted in 1995 by the International 
Organization of the Flavour Industry, in which flavour manufacturers reported the total amount of 
each flavouring substance incorporated into food sold in the EU during the previous year (IOFI, 
1995). The intake approach does not consider the possible natural occurrence in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population2 (Eurostat, 1998). This is derived for candidate substances 
from estimates of annual volume of production provided by Industry and incorporates a correction 
factor of 0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999). 
In the present FGE.25 the total annual production volume of the 32 candidate substances from use 
as flavouring substances in Europe was reported to be approximately 90 kg (EFFA, 2005b). For the 
19 supporting substances the total annual volume of production in Europe is approximately 390000 
kg (d-limonene [FL-no: 01.045] accounts for 280000 kg and 106000 kg is accounted for by seven 
other supporting substances: [FL-no: 01.003, 01.004, 01.005, 01.006, 01.007, 01.008 and 01.020]) 
(JECFA, 2005c).  
On the basis of the annual volumes of production reported for the 32 candidate substances, the 
MSDI values for each of these flavourings have been estimated (Table 2).  
 
Approximately 90 % of the total annual volume of production for the candidate substances is 
accounted for by eight substances [FL-no: 01.023, 01.028, 01.033, 01.034, 01.036, 01.043, 01.054, 
01.066]. The estimated combined daily per capita intake of these eight candidate substances from 
use as flavouring substance is 10 microgram. The daily per capita intakes for each of the remaining 
substances are less than 0.24 microgram (Table 2). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) 
values is based on the approach used by SCF up to 1995 (SCF, 1995).  
The assumption is that a person may consume a certain amount of flavourable foods and beverages 
per day. 
For the present evaluation of the 32 candidate substances, information on food categories and 
normal and maximum use levels3,4 were submitted by the Flavour Industry (EFFA, 2005a; EFFA, 
2007a). The 32 candidate substances are used in flavoured food products divided into the food 
categories, outlined in Annex III of the Commission Regulation (EC) No 1565/2000 (EC, 2000a), 
as shown in Table 3.1. For the present calculation of mTAMDI, the reported normal use levels were 
                                                 
2 EU figure 375 millions (Eurostat, 1998). This figure relates to EU population at the time for which production data are 
available, and is consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production 
data are available for the enlarged EU. 
3 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile of 
reported usages (EFFA, 2002i). 
4 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures 
derived from 12 model flavouring substances (EFFA, 2004e). 
 Flavouring Group Evaluation 25 (FGE.25)
Aliphatic and aromatic hydrocarbons from chemical group 31
 
 
  The EFSA Journal (2008) 918, 10-109 
used. In the case where different use levels were reported for different food categories the highest 
reported normal use level was used. 
 
Table 3.1 Use of Candidate Substances 
Food category Description Flavourings used 
Category 1 Dairy products, excluding products of category 2 All 32 
Category 2 Fats and oils, and fat emulsions (type water-in-oil) All 32 
Category 3 Edible ices, including sherbet and sorbet All 32 
Category 4.1 Processed fruits All 32 
Category 4.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and 
legumes), and nuts & seeds 
None 
Category 5 Confectionery All 32 
Category 6 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
All 32 
Category 7 Bakery wares All 32 
Category 8 Meat and meat products, including poultry and game All 32 
Category 9 Fish and fish products, including molluscs, crustaceans and echinoderms  All 32 
Category 10 Eggs and egg products None 
Category 11 Sweeteners, including honey None 
Category 12 Salts, spices, soups, sauces, salads, protein products etc. All 32 
Category 13 Foodstuffs intended for particular nutritional uses All 32 
Category 14.1 Non-alcoholic ("soft") beverages, excl. dairy products All 32 
Category 14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts None 
Category 15 Ready-to-eat savouries All except for [FL-no: 01.044] 
Category 16 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 1 – 15 
All 32 
According to the Flavour Industry the normal use levels for the 32 candidate substances are in the 
range of 2 - 20 mg/kg food, and the maximum use levels are in the range of 10 - 100 mg/kg (EFFA, 
2002i; EFFA, 2005a; EFFA, 2007a), Table II.1.2, Annex II. 
The mTAMDI values for the 27 candidate substances from structural class I (see Section 5) are for 
one substance [FL-no: 01.044] 3300 microgram/person/day and 3700 microgram/person/day for 
each of the remaining 26 candidate substances. For each of the two candidate substances from 
structural class II and the three candidate substances from structural class III (see Section 5) the 
mTAMDI is also 3700 microgram/person/day. 
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 6 and Annex II. 
4. Absorption, Distribution, Metabolism and Elimination 
Generally, the available data indicate that the aliphatic and aromatic hydrocarbons may participate 
in similar metabolic pathways. Being lipophilic and of relatively low molecular weight, these 
hydrocarbons may be assumed to be absorbed in the gastrointestinal tract. Subsequently, they can 
be oxidised to polar oxygenated metabolites, e.g. by CYP-450 enzymes. The phase I metabolites 
can then be conjugated and excreted mainly in the urine. The candidate and supporting substances 
are expected to be metabolised either by side chain oxidation or epoxidation of the exocyclic or 
endocyclic double bonds. Alkyl oxidation initially yields hydroxylated metabolites that may be 
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excreted in conjugated form or undergo further oxidation, yielding more polar metabolites, which 
can also be excreted. If a double bond is present, intermediate epoxide metabolites may be formed, 
which are transformed either by hydrolysis to yield diols or by conjugation with glutathione to yield 
mercapturic acid derivatives. For the naphthalene hydrocarbons, in addition to epoxidation, 
formation of reactive quinones can be expected. The aromatic hydrocarbons that do not contain 
alkyl substituents can undergo ring hydroxylation to form phenolic metabolites that are 
subsequently conjugated with sulphate or glucuronic acid and excreted in the urine. The saturated 
alkanes in this group may be anticipated to be metabolised via omega and omega-1, -2, -3 or -4 
oxidation. Whereas omega oxidation would ultimately lead to the formation of carboxylic acids, the 
other oxidations would give rise to secondary alcohols and ketones. The carboxylic acids may be 
expected to participate in the endogenous fatty acid metabolism. 
However, for most of the eight subgroups (see Section 1.1 and Annex III) the information available 
was scarce and the similarity between candidate and supporting substances was limited. In addition, 
proper mass balance data were not available. The few mass balance data available indicated only 
slow elimination. For several subgroups no data were available at all. In Table 4.1 the final 
conclusion for each of the candidate substances have been presented, together with a brief 
explanatory statement. For subgroup III there are only data for one supporting substance, d-
limonene [FL-no: 01.045], which is oxidised in both side chains to yield alcohols and carboxylic 
acids, which may be conjugated and eliminated in the urine.  
For a more extensive discussion, see Annex III. 
 
Table 4.1 Can innocuous metabolites be expected to be formed based on available data? 
FL–no: Substance name Innocuous metabolites? 
Subgroup I:  ACYCLIC ALKANES 
01.033 2,2-Dimethylhexane Yes 
01.034 2,4-Dimethylhexane Yes 
01.038 Dodecane Yes 
01.050 3-Methylhexane No (potential formation of neurotoxic gamma-
diketone) 
01.054 Pentadecane Yes 
01.057 Tetradecane Yes 
Subgroup II:  ACYCLIC ALKENES 
01.032 2,3-Dihydrofarnesene No (lack of supporting data) 
01.035 2,6-Dimethylocta-2,4,6-triene No (lack of supporting data) 
01.037 Dodec-1-ene No (presence of terminal double bond which may give 
rise to reactive metabolites without counteracting 
metabolic options) 
01.049 2-Methylbuta-1,3-diene No (known biotransformation to reactive metabolite 
responsible for toxicity and genotoxicity) 
01.064 cis-3,7-Dimethyl-1,3,6-octatriene No (presence of terminal double bond which may give 
rise to reactive metabolites without counteracting 
metabolic options)  
Subgroup III:  CYCLOHEXENE HYDROCARBONS 
01.055 beta-Phellandrene No (lack of supporting data) 
01.027 Bisabola-1,8,12-triene Yes 
01.028 beta-Bisabolene Yes 
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Table 4.1 Can innocuous metabolites be expected to be formed based on available data? 
FL–no: Substance name Innocuous metabolites? 
01.039 delta-Elemene Yes  
Subgroup IV: AROMATIC HYDROCARBONS 
Subgroup IVa:  BENZENE HYDROCARBONS 
01.031 1,2-Dihydro-1,1,6-trimethylnaphthalene No (lack of supporting data) 
01.058 1,2,3,4-Tetrahydro-1,1,6-trimethylnaphthalene No (lack of supporting dat) 
Subgroup IVb:  NAPHTHALENE HYDROCARBONS  
01.051 2-Methylnaphthalene No (known metabolism to toxic metabolites) 
01.053 Naphthalene No (known metabolism to toxic metabolites) 
Subgroup IVc: DIPHENYLMETHANE  
01.036 Diphenylmethane No (lack of supporting data) 
Subgroup V: BI- and TRICYCLIC, NON-AROMATIC HYDROCARBONS 
01.022 alpha-Cedrene No (lack of supporting data) 
01.023 1(5),11-Guaiadiene No (lack of supporting data) 
01.030 beta-Cubebene No (lack of supporting data) 
01.044 Isolongifolene No (lack of supporting data) 
01.047 Longifolene No (lack of supporting data) 
01.052 alpha-Muurolene No (lack of supporting data) 
01.056 alpha-Santalene No (lack of supporting data) 
01.060 1,1,7-Trimethyltricyclo[2.2.1.0.(2.6)]heptane No (lack of supporting data) 
01.066 2-Cedrene No (lack of supporting data) 
01.067 8(14)-Cedrene No (lack of supporting data) 
Subgroup VI: MACROCYCLIC, NON-AROMATIC HYDROCARBONS 
01.042 Germacra-1(10),4(14),5-triene No (lack of supporting data) 
01.043 3,7,10-Humulatriene No (lack of supporting data) 
 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. For 
comparison of the intake estimations based on the MSDI approach and the mTAMDI approach, see 
Section 6. 
The candidate substance 2-methyl-1,3-butadiene (isoprene) [FL-no: 01.049] showed genotoxic 
potential in vivo and carcinogenic effects in experimental animals. Therefore, the Panel concluded 
that the Procedure could not be applied to this flavouring substance.  
For the safety evaluation of the remaining 31 candidate substances from chemical group 31, the 
Procedure as outlined in Annex I was applied, based on the MSDI approach. The stepwise 
evaluations of the 31 substances are summarised in Table 2. 
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Step 1 
Twenty-six of the 31 candidate substances evaluated using the Procedure are classified into 
structural class I [FL-no: 01.022, 01.023, 01.027, 01.028, 01.030, 01.032, 01.033, 01.034, 01.035, 
01.037, 01.038, 01.039, 01.042, 01.043, 01.044, 01.047, 01.050, 01.052, 01.054, 01.055, 01.056, 
01.057, 01.060, 01.064, 01.066 and 01.067], two into structural class II [FL-no: 01.031 and 01.058], 
and three into structural class III, [FL-no: 01.036, 01.051 and 01.053], according to the decision tree 
approach presented by Cramer et al. (1978). 
Step 2  
On the basis of the metabolism information available, five of the six candidate substances of 
subgroup I [FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057] and three of the four candidate 
substances of subgroup III [FL-no: 01.027, 01.028 and 01.039] may be predicted to be metabolised 
to innocuous products at the estimated levels of intake based on the MSDI approach, and 
accordingly their evaluation proceeds along the A-side of the Procedure.  
One candidate substance from subgroup I [FL-no: 01.050] may be biotransformed to a neurotoxic 
gamma-diketone. Two candidate substances from subgroup II [FL-no: 01.037 and 01.064] contain 
terminal double bonds in the absence of other functional groups that may provide alternative routes 
of detoxication. For the two candidate substances from subgroup IVb [FL-no: 01.051 and 01.053] it 
has been shown that they may be converted to toxic metabolites. Therefore, for these five 
substances it cannot be concluded that they will be metabolised to innocuous products, and 
accordingly they proceed along the B-side of the Procedure.  
For the remaining 18 candidate substances [FL-no: 01.022, 01.023, 01.030, 01.031, 01.032, 01.035, 
01.036, 01.042, 01.043, 01.044, 01.047, 01.052, 01.055, 01.056, 01.058, 01.060, 01.066 and 
01.067] there are not sufficient data available on biotransformation to conclude that they will be 
metabolised to innocuous products, and therefore their evaluation will proceed along the B-side of 
the Procedure. 
Step A3 
The five candidate substances from subgroup I [FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057] 
and the three candidate substances from subgroup III [FL-no: 01.027, 01.028 and 01.039] 
proceeding via the A-side have been assigned to structural class I and have estimated European 
daily per capita intakes ranging from 0.012 to 2.7 microgram (Table 6.1). These intakes are below 
the threshold of concern of 1800 microgram/person/day for structural class I. Accordingly, these 
eight candidate substances do not pose a safety concern as flavouring substances when used at 
estimated levels of intake, based on the MSDI approach. 
Step B3 
The 18 candidate substances [FL-no: 01.022, 01.023, 01.030, 01.032, 01.035, 01.037, 01.042, 
01.043, 01.044, 01.047, 01.050, 01.052, 01.055, 01.056, 01.060, 01.064, 01.066 and 01.067] 
proceeding via the B-side and which have been assigned to structural class I have estimated 
European daily per capita intakes between 0.012 and 1.2 microgram (Table 6.1). These intakes are 
below the threshold of concern of 1800 microgram/person/day for structural class I. Two of the 
candidate substances proceeding along the B-side have been assigned to structural class II [FL-no: 
01.031 and 01.058]. These two substances have estimated European daily per capita intakes of 
0.0012 and 0.12 micrograms, respectively. These intakes are below the threshold of concern of 540 
microgram/person/day for structural class II. Three candidates proceeding along the B-side [FL-no: 
01.036, 01.051 and 01.053] have been assigned to structural class III have European daily per 
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capita intakes ranging between 0.0012 and 1.2 microgram. These are below the threshold of 
concern for structural class III of 90 microgram/person/day. Accordingly, these 23 substances all 
proceed to step B4 of the Procedure. 
Step B4 
No adequate data on No Observed Adverse Effect Levels (NOAELs) are available for any of these 
23 candidate substances [FL-no: 01.022, 01.023, 01.030, 01.031, 01.032, 01.035, 01.036, 01.037, 
01.042, 01.043, 01.044, 01.047, 01.050, 01.051, 01.052, 01.053, 01.055, 01.056, 01.058, 01.060, 
01.064, 01.066 and 01.067] or have been submitted for any structurally related substances. 
Therefore, the Panel concluded that additional data are required for these substances. 
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
The mTAMDI values for the 26 candidate substances from structural class I and evaluated using the 
Procedure are 3300 microgram/person/day for one candidate substance and 3700 
microgram/person/day for each of the remaining 25 candidate substances. For each of the two 
candidate substances from structural class II and the three candidate substances from structural class 
III the mTAMDI is also 3700 microgram/person/day. These values are all above the thresholds for 
structural class I, II and III of 1800, 540 and 90 microgram/person/day, respectively.  
For comparison of the intake estimates based on the MSDI approach and the mTAMDI approach, 
see Table 6.1. 
For all 31 candidate substances evaluated using the Procedure further information is required. This 
would include more reliable intake data and then, if required, additional toxicological data. 
 
Table 6.1  Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI (μg/capita/day) mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
01.022 alpha-Cedrene 0.012 3700 Class I 1800 
01.023 1(5),11-Guaiadiene 1.2 3700 Class I 1800 
01.027 Bisabola-1,8,12-triene 0.024 3700 Class I 1800 
01.028 beta-Bisabolene 2.7 3700 Class I 1800 
01.030 beta-Cubebene 0.012 3700 Class I 1800 
01.032 2,3-Dihydrofarnesene 0.12 3700 Class I 1800 
01.033 2,2-Dimethylhexane 1.2 3700 Class I 1800 
01.034 2,4-Dimethylhexane 1.2 3700 Class I 1800 
01.035 2,6-Dimethylocta-2,4,6-triene 0.013 3700 Class I 1800 
01.037 Dodec-1-ene 0.024 3700 Class I 1800 
01.038 Dodecane 0.012 3700 Class I 1800 
01.039 delta-Elemene 0.012 3700 Class I 1800 
01.042 Germacra-1(10),4(14),5-triene 0.012 3700 Class I 1800 
01.043 3,7,10-Humulatriene 1.2 3700 Class I 1800 
01.044 Isolongifolene 0.012 3300 Class I 1800 
01.047 Longifolene 0.17 3700 Class I 1800 
01.049 2-Methylbuta-1,3-diene 0.061 3700 Class I 1800 
01.050 3-Methylhexane 0.061 3700 Class I 1800 
01.052 alpha-Muurolene 0.24 3700 Class I 1800 
01.054 Pentadecane 0.61 3700 Class I 1800 
01.055 beta-Phellandrene 0.012 3700 Class I 1800 
01.056 alpha-Santalene 0.012 3700 Class I 1800 
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Table 6.1  Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI (μg/capita/day) mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
01.057 Tetradecane 0.012 3700 Class I 1800 
01.060 1,1,7-Trimethyltricyclo[2.2.1.0.(2.6)]heptane 0.012 3700 Class I 1800 
01.064 cis-3,7-Dimethyl-1,3,6-octatriene 0.049 3700 Class I 1800 
01.066 2-Cedrene 0.97 3700 Class I 1800 
01.067 8(14)-Cedrene 0.012 3700 Class I 1800 
01.031 1,2-Dihydro-1,1,6-trimethylnaphthalene 0.0012 3700 Class II 540 
01.058 1,2,3,4-Tetrahydro-1,1,6-trimethylnaphthalene 0.12 3700 Class II 540 
01.036 Diphenylmethane 1.2 3700 Class III 90 
01.051 2-Methylnaphthalene 0.0012 3700 Class III 90 
01.053 Naphthalene 0.013 3700 Class III 90 
 
7. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this Flavouring Group Evaluation may also be 
metabolised through the same pathways, the combined intake estimates presented here are only 
preliminary. Currently, the combined intake estimates are only based on MSDI exposure estimates, 
although it is recognised that this may lead to underestimation of exposure. After completion of all 
FGEs, this issue should be readdressed.  
The total estimated combined daily per capita intake of structurally related flavourings is estimated 
by summing the MSDI for individual substances. 
The candidate substance 2-methylbuta-1,3-diene [FL-no: 01.049] is genotoxic in vitro and in vivo 
and carcinogenic in experimental animals and accordingly its use as flavouring substance is 
toxicologically not acceptable. Therefore, this substance [FL-no: 01.049] is not included in the 
calculation of the combined intake estimate. The 23 candidate substances, for which additional data 
are requested, will also not be included. The combined intakes have been calculated for the 
remaining candidate and supporting substances (only for subgroup I (acyclic alkanes) and subgroup 
III (cyclohexene hydrocarbons)). 
The combined intakes have been calculated on the basis of the annual production volumes from use 
as flavouring substances in Europe (EFFA, 2005a; JECFA, 2005c). 
Subgroup I (acyclic alkanes): The combined intake of the five candidate substances, all from 
structural class I, is 3.0 microgram/capita/day, which does not exceed the threshold of 1800 
microgram/person/day. There are no supporting substances in subgroup I. 
Subgroup III (cyclohexene hydrocarbons): The combined intake of the three candidate substances, 
all from structural class I, is 2.7 microgram/capita/day, which does not exceed the threshold of 1800 
microgram/person/day. The total combined intake of the candidate and six supporting substances 
(also from structural class I) is approximately 35500 microgram/capita/day. This intake exceeds the 
threshold of 1800 microgram/person/day for a structural class I substance. However, d-limonene 
(supporting substance [FL-no: 01.045]) accounts for approximately 34000 microgram/capita/day. 
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As JECFA has established an acceptable daily intake (ADI) “not specified” for d-limonene (JECFA, 
2005c) the Panel concluded that there is no safety concern for this total combined intake. 
8. Toxicity 
8.1. Acute Toxicity 
Data are available for eight candidate and 17 supporting substances. Oral LD50 values in rat and 
mouse ranged from 500 – 13000 mg/kg body weight (bw).  
The acute toxicity data are summarised in Annex IV, Table IV.1. 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
Data are available for three candidate substances, 2-methylbuta-1,3-diene (isoprene) [FL-no: 
01.049] (subgroup II), naphthalene [FL-no: 01.053] and 2-methylnaphthalene [FL-no: 01.051] 
(subgroup IVb), and for five supporting substances.  
Subgroup II 
For the candidate substance 2-methylbuta-1,3-diene (isoprene) [FL-no: 01.049] it has been 
concluded that there is sufficient evidence of carcinogenicity in experimental animals and that the 
substance is “possibly carcinogenic to humans” (group 2B) (IARC, 1999a). The structurally related 
substance 1,3-butadiene has been concluded to be genotoxic and carcinogenic, and to be “probably 
carcinogenic to humans” (group 2A) (IARC, 1999b).  
The Panel agrees that 2-methylbuta-1,3-diene [FL-no: 01.049] is of concern with respect to 
carcinogenicity (and genotoxicity) and accordingly cannot be evaluated using the Procedure. 
Subgroup IVb  
Naphthalene: 
For naphthalene [FL-no: 01.053] two unpublished 13-week oral studies on rats and mice were only 
available as summaries, referred to in US EPA (1998). Since the original data were not available it 
was not possible to evaluate the quality of the study. Groups of 20 rats, male and female, were 
given doses of 0, 25, 50, 100, 200 or 400 mg naphthalene/kg bw by gavage five days a week for 13 
weeks. The No Observed Adverse Effect Level (NOAEL) in this study was 100 mg/kg body weight 
(bw) based on mean terminal bw decreases. Other findings were low incidence of lesions in 
exposed male kidneys and female thymuses. In the mouse, study groups of 10 male and 10 female 
mice were given doses of 0, 12.5, 25, 50, 100 or 200 mg/kg bw following the same design as the rat 
study. Transient signs of toxicity occurred in the 200 mg/kg groups. No exposure-related lesions 
were observed in any organs examined. The authors considered the highest dose level to be a 
NOAEL, whereas the EPA judged the highest dose level to be a Low Observed Adverse Effect 
Level (LOAEL) for transient signs of toxicity.  
Naphthalene was given six times per week in food to 28 rats at a dose level varying between 10 and 
20 mg/rat/day. Treatment was stopped after 700 days after reaching a total dose of 10 g/rat. Rats 
were observed until spontaneous death. The conclusion by the author was that naphthalene did not 
cause cancer in the study. It is however not possible to draw conclusions on carcinogenicity or 
chronic toxicity from the study since it is deficient in design and poorly reported (Schmähl, 1955).  
Groups of male (76-112) and female (40-76) mice were given naphthalene by gavage at dose levels 
of 0, 5.3, 53 or 133 mg/kg bw/day for 90 consecutive days. The study identified a LOAEL of 133 
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mg/kg bw/day and a NOAEL of 53 mg/kg bw/day based upon the significant decreases in absolute 
weight of brain, liver, and spleen and relative weight of spleen in female mice. Histopathology was 
not conducted in this study (Shopp et al., 1984).  
Naphthalene [FL-no: 01.053] was studied in a two-year NTP inhalation study in B6C3F mice. The 
result showed no evidence of carcinogenic activity in male mice exposed to naphthalene, but some 
evidence of carcinogenic activity in female mice. Groups of male and female mice were exposed to 
0 (75/group), 10 (75/group) or 30 ppm (150/group) naphthalene for six hours daily, five days/week 
for 105 weeks. No increased tumour incidence related to exposure was observed in male mice, but 
in females the incidence of pulmonary alveolar/bronchiolar adenomas was significantly greater in 
the high-dose group than in controls. In both male and female mice exposure to naphthalene caused 
increased incidences and severity of chronic inflammation, metaplasia of the olfactory epithelium 
and hyperplasia of the respiratory epithelium in the nose and chronic inflammation in the lungs 
(NTP, 1992g). 
In a two-year NTP inhalation study in F344/N rats on the toxicology and carcinogenesis of 
naphthalene [FL-no: 01.053] it was concluded by NTP that there was clear evidence of carcinogenic 
activity based on increased incidences of respiratory epithelial adenoma and olfactory epithelial 
neuroblastoma of the nose. Groups of 49 male and female rats were exposed to naphthalene by 
inhalation at concentrations of 0, 10, 30 or 60 ppm for six hours plus 12 minutes per day five days 
per week for 105 weeks. The highest exposure concentration is the maximum without naphthalene 
condensation. Additional groups of nine male and female rats were exposed to 10, 30 or 60 ppm for 
up to 18 months for evaluation of toxicokinetic parameters. At the exposure concentrations in the 
study approximately 20-30 % of the inhaled dose was metabolised by the rats. Naphthalene that was 
not absorbed during exposure was presumed to be exhaled.The daily doses were estimated to be 0, 
3.6-3.9, 10.7-11.4 and 20.1-20.6 mg/kg bw. Survival of all exposed groups was similar to that of 
controls. Mean body weights of exposed animals were less than those of controls. Incidences of 
adenoma of the respiratory epithelium were associated with exposure and increased with dose, as 
did incidences of neuroblastoma of the olfactory epithelium. Increased incidences of non-neoplastic 
lesions of the nose associated with exposure to naphtalene included atypical hyperplasia, atrophy, 
chronic inflammation, hyaline degradation of epithelium, hyperplasia, squamous metaplasia, goblet 
hyperplasia of respiratory epithelium and glandular hyperplasia and squamous metaplasia. There 
were no ocular abnormalities in the rats, although naphthalene is a known ocular irritant. Unlike 
mice, naphthalene was not carcinogenic in the rat lung. Higher rates of metabolism in the mouse 
lung compared to the rat lung may have been a contributing factor to this species difference in 
response (NTP, 2000d). 
Conclusion on carcinogenicity for naphthalene 
The Panel agreed with the European Union Risk Assessment Report (EU-RAR, 2003) in its 
evaluation of the long-term carcinogenicity studies on naphthalene. It was concluded that overall 
the balance of evidence indicates that naphthalene is not genotoxic. In the two-year rat study, 
inhalation of naphthalene produced an increase in the incidence of respiratory epithelial adenomas 
and olfactory epithelial neuroblastomas in both males and females. All these tumours occurred at 
sites where dose-related non-neoplastic inflammatory changes in the nose and respiratory 
epithelium also occurred. In view of the negative results obtained in the in vivo genotoxicity studies, 
these tumours are considered to arise via a non-genotoxic, thresholded mechanism. In mice an 
increase in the incidence of benign alveolar/bronchiolar adenomas in females was observed after 
inhalation of naphthalene. These tumours are similarly considered to arise via a non-genotoxic 
procedure, and are unlikely to be of relevance to human health due to the well-known species 
differences in pulmonary metabolism, mouse lung preparations being able to metabolise 
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naphthalene at a substantially greater rate (up to 100-fold) than those from hamster, rat or monkey. 
Although the significance of these inhalation studies for the evaluation of naphthalene used as a 
flavouring substance in food is questionable, the Panel noted that they did not provide a NOAEL for 
the non-neoplastic toxic effects on the olfactory and respiratory tissues preceding the tumour 
formation. 
2-Methylnaphthalene: 
In a valid study by Murata et al. (1997) groups of 50 male and 50 female mice were fed diets 
containing 0, 0.075 % or 0.15 % 2-methylnaphthalene for 81 weeks. The doses were calculated to 
correspond to 50-53 and 108-114 mg/kg bw/day, respectively. Pulmonary alveolar proteinosis 
developed in all treated animals differing significantly from controls. No tumours were seen. No 
NOAEL could be derived from this study (Murata et al., 1997). 
Cutaneous application of methylnaphthalene, a mixture of 1-methylnaphthalene and 2-
methylnaphthalene in acetone, at doses of 29.7 or 118.8 mg/kg bw painted on the shaved backs of 
B6C3F1 mice twice a week for life was followed by lesions in the lungs. Control mice received 
acetone in the same manner. The lesions were diagnosed as endogenous lipid pneumonia. 
Frequency of pneumonia was 0/4 control, 3/11 low dose and 31/32 high dose animals (Emi & 
Konishi, 1985). The results suggest that lipid pneumonia could result from systemic administration, 
and that the lung may be a site for naphthalene toxicity in mice as is discussed in the NTP studies 
reported above. 
Conclusion on carcinogenicity for 2-methylnaphthalene 
The data available, principally from a valid 81-week feeding study in mice, do not indicate that 2-
methylnaphthalene is carcinogenic. 
The toxicity data are summarised in Annex IV, Table IV.2. 
8.3. Developmental / Reproductive Toxicity Studies 
Developmental and reproductive studies are available for one candidate substance, naphthalene 
[FL-no: 01.053] (subgroup IVb). Studies have been performed on mice, rats and rabbits. Pregnant 
mice were given 0 or 300 mg naphthalene/kg/day on gestation days 7-14. The conclusion was 
drawn that naphthalene toxicity is manifest before a high level of developmental toxicity occurs. 
The study does not assess skeletal or visceral foetal development and it is not possible to derive a 
NOAEL from the study (Booth et al., 1983; Plasterer et al., 1985).  
Groups of 25-26 pregnant rats were administered naphthalene by gavage at dose levels of 0, 50, 150 
or 450 mg/kg bw on gestational days 6-15. Clinical signs of toxicity were observed in all dams, but 
they subsided in the two lowest dose groups. Decreased body weight and body weight gain were 
observed in the two highest dose groups. Foetal growth, viability and morphological development 
were not significantly affected by treatment. There was no significant treatment related effect on 
implantation, foetal survival or resorption. The authors concluded that the lowest dose level was a 
LOAEL for maternal toxicity and that 450 mg/kg bw was a NOAEL for foetal developmental 
toxicity (Navarro et al., 1991).  
Groups of 25-27 pregnant rabbits were administered naphthalene by gavage at dose levels of 0, 20, 
80 or 120 mg/kg bw on gestational days 6-19. No treatment-related signs of maternal toxicity were 
observed. No statistically significant differences were found between control and treated groups in 
average live litter size, foetal body weight or incidence of malformations. The developmental 
NOAEL was considered to be 120 mg/kg bw/day in this study.  
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Groups of 18 pregnant rabbits were given naphthalene by gavage at doses of 0, 40, 200 or 400 
mg/kg bw on gestational days 6-18. Treatment-related clinical signs were observed in a dose-related 
manner. Maternal NOAEL was not determined. No statistically significant changes were apparent 
in the mean number of corpora lutea, foetal body weights, viable foetuses, total implantations, post-
implantational loss or foetal sex distribution when comparing control or treatment groups. No 
treatment-related effects were found on examining foetuses for visceral and skeletal abnormalities. 
Foetal developmental NOAEL was determined as 400 mg/kg bw (Naismith & Matthews, 1986). 
Conclusion 
In the tested animal species, mice, rats and rabbits, clinical symptoms of maternal toxicity appeared 
before signs of reproductive or developmental toxicity were apparent. Developmental NOAELs 
varied between 120 mg/kg bw/day (rabbit) and 450 mg/kg bw/day (rat, rabbit).  
The developmental/reproductive toxicity data are summarised in Annex IV, Table IV.3. 
8.4. Genotoxicity Studies 
Data from in vitro tests are available for six candidate substances [subgroup I: FL-no: 01.038 and 
FL-no: 01.057; subgroup II: FL-no: 01.037 and 01.049; subgroup IVb: FL-no: 01.051 and 01.053], 
and 10 supporting substances [one from subgroup II, three from subgroup III, one from subgroup 
IVb, five from subgroup V]. Three of these studies on candidate substances [FL-no: 01.049 
(subgroup II), 01.051 and 01.053 (subgroup IVb)] and one on a supporting substance [FL-no: 01.014 
(subgroup IVb)] are considered valid.  
Data from in vivo tests are available for two candidate substances [subgroup II: FL-no: 01.049; 
subgroup IVb: FL-no: 01.053] and for two supporting substances (one from subgroup II and one 
from subgroup III). 
There are no data available on substances from subgroups IVa, IVc and VI. 
Subgroup I 
The two candidate substances [FL-no: 01.038 and 01.057] tested in vitro for bacterial gene 
mutations gave negative results in Ames tests and for mammalian cell gene mutations.  
Subgroup II 
The available in vivo studies on the candidate substance 2-methylbuta-1,3-diene (isoprene) [FL-no: 
01.049] reported a negative result in a valid chromosomal aberration assay in the bone marrow of 
mice after 12 days of inhalatory exposure to isoprene. However, isoprene induced sister chromatid 
exchanges (SCE) in the bone marrow and micronuclei in peripheral blood cells of mice after 12 
days of inhalatory exposure in two valid studies carried out within NTP. Induction of micronuclei in 
peripheral blood cells of mice has also been reported after inhalatory exposure for 13 weeks. In 
contrast, inhalatory exposure of isoprene to male and female rats for four weeks did not result in an 
increase in the frequency of micronuclei in the lung fibroblasts. The validity of the latter two studies 
cannot be evaluated due to limited details available. Isoprene has been reported to bind covalently 
to haemoglobin in vivo (IARC, 1999a). 
The genotoxic and carcinogenic potential of isoprene has been evaluated by IARC (1999a). It was 
concluded that there is sufficient evidence of carcinogenicity in experimental mammalians and that 
isoprene is 'possibly carcinogenic to humans' (Group 2B) (IARC, 1999a). Isoprene has been 
classified in the EU as a ‘Muta. Cat. 3; R68’ and ‘Carc. Cat. 2; R45’ (ECB, 2005). 
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The available data on in vivo genotoxicity of 2-methylbuta-1,3-diene (synonym: isoprene) [FL-no: 
01.049] indicate a genotoxic potential of the substance. In the light of the evidence of carcinogenic 
activity of isoprene in rats and mice (NTP, 1999d) and the genotoxic effects of isoprene in mice and 
the fact that the structurally related substance 1,3-butadiene is classified as a genotoxic carcinogen, 
the Panel concluded that there is reason for concern with respect to genotoxicity and carcinogenicity 
of isoprene. The structurally related substance myrcene [FL-no: 01.008] like isoprene has two 
conjugated, terminal double bonds (but has a longer chain length, with 10 carbon atoms). The 
genotoxicity data available on myrcene do not give rise to concern with respect to genotoxicity. For 
the remaining four candidate substances in subgroup II [FL-no: 01.032, 01.035, 01.037 and 01.064] 
there are, except for one negative bacterial mutagenicity test (Ames test), no genotoxicity data 
available, but it was noted that these substances do not contain conjugated terminal double bonds. 
The Panel concluded that, except for 2-methylbuta-1,3-diene [FL-no: 01.049], data available do not 
preclude to evaluate the candidate substances in subgroup II through the Procedure. 
Subgroup IVb 
Naphthalene 
Naphthalene [FL-no: 01.053], which was negative in all bacterial gene mutation tests (Ames tests, 
Rec assay, Inductest) and in a unscheduled DNA synthesis (UDS) test in primary rat hepatocytes, 
gave a weakly positive result in a valid SCE test both in the presence and absence of metabolic 
activation and a positive result in a valid chromosomal aberration test in the presence of S9. A 
positive result was also reported in a mammalian cell gene mutation test (mouse lymphoma assay). 
However, the validity of this study cannot be evaluated.  
The available in vivo studies on the candidate substance naphthalene [FL-no: 01.053] reported 
negative results in a valid UDS test and in two micronucleus tests, for one of which the validity 
cannot be evaluated due to insufficiently reported experimental details.  
The genotoxicity of naphthalene [FL-no: 01.053] and 2-methylnaphthalene [FL-no: 01.051] has 
been evaluated by international expert bodies (WHO, 1998; EU-RAR, 2003; US ATSDR, 2005a). 
Results of the in vitro genotoxicity studies that were evaluated are in line with the data summarised 
in the present evaluation. Negative results were reported for all the evaluated bacterial gene 
mutation tests (Ames tests, Rec assays, Inductests/SOS response tests). For in vitro mammalian 
gene mutation, cytogenetic, or DNA damage assays, equally mixed results were reported as in the 
present evaluation. In addition to the studies cited in the present evaluation, negative results were 
reported for mutations at the hprt and tk locus in a human B-lymphoblastoid cell line (Sasaki et al., 
1997) and for single-strand breaks in an alkaline elution test with rat hepatocytes (Sina et al., 1983) 
as well as for some other less relevant endpoints (different cell transformation assays). Positive 
results were reported for naphthalene in a non-standard chromosomal aberration assay (Gollahon, 
1991) and for the naphthalene metabolites 1,2- and 1,4-naphthoquinone in a SCE test (Wilson et al., 
1996). For in vivo genotoxicity, besides the negative results from studies examining commonly 
accepted endpoints (micronuclei formation in mouse bone marrow, DNA single strand breaks and 
UDS in rat hepatocytes) as reported in the present evaluation, some positive results were reported 
for somatic mutations in D. melanogaster (Delgado-Rodriques et al., 1995), micronuclei in 
salamander larvae erythrocytes (Djomo et al., 1995), and DNA fragmentation in liver and brain 
tissue from mice and rats orally exposed to naphthalene (Bagchi et al., 2000). However, DNA 
fragmentation per se cannot be considered a specific endpoint of genotoxicity, being rather an 
indicator of cytotoxicity, in this case due to oxidative stress. Therefore, the study by Bagchi et al. 
(2000) has no relevance for the evaluation of the genotoxic potential of naphthalene. WHO (1998) 
noted that naphthalene was inactive in all short-term mutagenicity tests evaluated by IARC in 1983 
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(WHO, 1998). US ATSDR (2005) concluded that the available data suggest that genotoxic action 
by the naphthalene metabolite, 1,2-naphthoquinone, is plausible and that the mutagenic/genotoxic 
potential of naphthalene and its metabolites may be weak (US ATSDR, 2005a). In the EU-RAR 
(2003) it was concluded that overall, the balance of evidence indicates that naphthalene is not 
genotoxic (EU-RAR, 2003). 
Conclusion on genotoxicity for naphthalene 
For naphthalene there is indication of in vitro genotoxicity especially at chromosome level. 
However, this genotoxic activity is not expressed in valid in vivo assays covering different end-
points (e.g. micronucleus, UDS and DNA single strand breaks). 
The Panel concluded that the available in vivo genotoxicity data on naphthalene do not preclude an 
evaluation of this substance through the Procedure. 
2-Methylnaphthalene 
The weak increases of chromosome aberrations (chromatid breaks only at the highest concentration) 
and of the SCE in cultured human lymphocytes in the presence of S9 are of doubtful relevance 
(Kulka et al., 1988). According to the authors, these effects do not indicate that 2-
methylnaphthalene is a potentially genotoxic substance. 
The genotoxicity of 2-methylnaphthalene has been evaluated by international expert bodies (WHO, 
1998; EU-RAR, 2003; US ATSDR, 2005a). Results of the in vitro genotoxicity studies that were 
evaluated are in line with the data summarised in the present evaluation. Negative results were 
reported for all the evaluated bacterial gene mutation tests (Ames tests, Rec assays, Inductests/SOS 
response tests). 
Conclusion on genotoxicity for 2-methylnaphthalene 
The available data on 2-methylnaphthalene, limited to the in vitro data referred to in the present 
evaluation, were considered not to give evidence for a genotoxic activity.  
The Panel concluded that the available genotoxicity data on 2-methylnaphthalene do not preclude 
an evaluation of this substance through the Procedure. 
Supporting substances 
From the various in vitro genotoxicity studies carried out with supporting substances, there is no 
indication of a mutagenic activity of these substances in bacterial cells or of a direct clastogenic 
effect on mammalian cells. For all substances only negative results were reported in the available 
studies except for delta-3-carene (subgroup V) and 1-methylnaphthalene (subgroup IVb) (see Table 
IV.4). Delta-3-carene was reported to be positive in TA100 and TA102 strains in an insufficiently 
reported Ames test in the absence of metabolic activation at high concentrations only, while it was 
negative in the presence of metabolic activation. 1-Methylnaphthalene gave a weak increase, of 
doubtful biological relevance, of SCE in cultured human lymphocytes in the present of S9 (Kulka et 
al., 1988). This effect was interpreted by the authors not to be an indication of genotoxic potential. 
Furthermore, 1-methylnaphthalene gave negative results in two gene mutation tests (Ames tests) 
(Florin et al., 1980; Oberly et al., 1993a) and in a chromosomal aberration assay in human 
lymphocytes (Kulka et al., 1988). 
The in vivo genotoxicity studies available on supporting substances gave all negative results; 
however, only a micronucleus test in peripheral blood cells with myrcene [FL-no: 01.008] 
(subgroup II) is considered valid. 
Genotoxicity data are summarised in Annex IV, Table IV.4 and IV.5. 
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Overall conclusion on genotoxicity:  
Data on the genotoxicity of the flavouring substances in this group are limited and the genotoxicity 
could not be assessed adequately for these substances. For one candidate substance, 2-methylbuta-
1,3-diene (synonym: isoprene) [FL-no: 01.049], there is evidence of an in vivo genotoxic potential. 
Therefore, the Panel concluded that the Procedure could not be applied to this substance. The 
available data do not preclude evaluating the remaining 31 candidate substances using the 
Procedure.  
9. Conclusions 
The 32 candidate substances are aliphatic and aromatic hydrocarbons from chemical group 31, 
which have been divided into eight subgroups: I) acyclic saturated hydrocarbons, II) acyclic 
unsaturated hydrocarbons, III) cyclohexene hydrocarbons, IVa) benzene hydrocarbons, IVb) 
napthalene hydrocarbons, IVc) diphenylmethane derivatives, V) bi- and tricyclic, non-aromatic 
hydrocarbons and VI) macrocyclic, non-aromatic hydrocarbons. 
Seventeen of the 32 candidate substances possess chiral centres and 16 of the 32 candidate 
substances can exist as geometrical isomers due to presence and the position of double bonds. For 
eight of these candidate substances the stereoisomeric composition has not been specified [FL-no: 
01.027, 01.032, 01.034, 01.035, 01.050, 01.055, 01.056 and 01.060].  
Of the 32 candidate substances 27 are classified into structural class I [FL-no: 01.022, 01.023, 
01.027, 01.028, 01.030, 01.032, 01.033, 01.034, 01.035, 01.037, 01.038, 01.039, 01.042, 01.043, 
01.044, 01.047, 01.049, 01.050, 01.052, 01.054, 01.055, 01.056, 01.057, 01.060, 01.064, 01.066 
and 01.067], two into structural class II [FL-no: 01.031 and 01.058], and three into structural class 
III [FL-no: 01.036, 01.051 and 01.053], according to the decision tree approach presented by 
Cramer et al. (1978). 
Twenty-nine out of the 32 candidate substances have been reported to occur naturally in a wide 
range of food items. 
According to the default MSDI approach, the 32 flavouring substances in this group have intakes in 
Europe from 0.0012 to 2.7 microgram/capita/day, which are below the threshold of concern value 
for structural class I (1800 microgram/person/day), structural class II (540 microgram/person/day) 
and structural class III (90 microgram/person/day) substances. 
Combined intakes can bee calculated for the substances in subgroup I (acyclic alkanes) and 
subgroup III (cyclohexene hydrocarbons). 
Subgroup I (acyclic alkanes): The combined intake of the five candidate substances, all from 
structural class I, is 3.0 microgram/capita/day, which does not exceed the threshold of 1800 
microgram/person/day. The are no supporting substances in subgroup I. 
Subgroup III (cyclohexene hydrocarbons): The combined intake of the three candidate substances, 
all from structural class I, is 2.7 microgram/capita/day, which does not exceed the threshold of 1800 
microgram/person/day. The total combined intake of the candidate and six supporting substances 
(also from structural class I) is 35500 microgram/capita/day. This intake exceeds the threshold of 
1800 microgram/person/day for a structural class I substance. However, d-limonene (supporting 
substance [FL-no: 01.045]) accounts for approximately 34000 microgram/capita/day. As JECFA 
has established an ADI “not specified” for d-limonene the Panel has concluded there is not safety 
concern due to this combined intake. 
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Data on the genotoxicity of the flavouring substances in this group are limited and the genotoxicity 
could not be assessed adequately for these substances. For one candidate substance, 2-methylbuta-
1,3-diene [FL-no: 01.049], there is evidence of an in vivo genotoxic and carcinogenic potential. 
Therefore, the Panel concluded that the Procedure could not be applied to this substance. The 
available data do not preclude an evaluation of the remaining 31 candidate substances using the 
Procedure.  
The available information on metabolism of the 31 candidate substances evaluated through the 
Procedure or the supporting substances for this FGE was very limited. Overall, only for the 
following eight candidate substances it can be concluded that they will be metabolised into 
innocuous metabolites: [FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057] from subgroup I and 
[FL-no: 01.027, 01.028 and 01.039] from subgroup III. For 19 candidate substances [FL-no: 
01.022, 01.023, 01.030, 01.031, 01.032, 01.035, 01.036, 01.042, 01.043, 01.044, 01.047, 01.052, 
01.055, 01.056, 01.058, 01.060, 01.064, 01.066 and 01.067], the information is too limited and it 
cannot be assumed that they are metabolised to innocuous metabolites. For the remaining five 
candidate substances there are data which show that they may be metabolised to toxic metabolites 
[FL-no: 01.037, 01.049, 01.050, 01.051 and 01.053]. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure. 
It is concluded that the eight candidate substances which are expected to be metabolised to 
innocuous substances, [FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057] from subgroup I and 
[FL-no: 01.027, 01.028 and 01.039] from subgroup III, would not give rise to safety concerns at 
their estimated intakes arising from their use as flavouring substances based on the MSDI approach. 
For the remaining 23 candidate substances, [FL-no: 01.022, 01.023, 01.030, 01.031, 01.032, 01.035, 
01.036, 01.037, 01.042, 01.043, 01.044, 01.047, 01.050, 01.051, 01.052, 01.053, 01.055, 01.056, 
01.058, 01.060, 01.064, 01.066 and 01.067], evaluated through the Procedure, or structurally related 
supporting substances, no adequate NOAEL were available. Therefore, additional toxicological data 
are required. 
The mTAMDI values for the 26 candidate substances from structural class I and evaluated using the 
Procedure are 3300 microgram/person/day for one candidate substance and 3700 
microgram/person/day for each of the remaining 25 candidate substances. For each of the two 
candidate substances from structural class II and the three candidate substances from structural class 
III the mTAMDI is also 3700 microgram/person/day. These values are above the threshold for 
structural class I, II and III of 1800, 540 and 90 microgram/person/day, respectively.  
Accordingly, intake estimates according to the mTAMDI for the 31 candidate substances in this 
flavouring group evaluation exceed the thresholds of concern for the three structural classes, and 
more reliable exposure data are requested. On the basis of such additional data, the flavouring 
substances should be considered using the Procedure. Subsequently, additional data might become 
necessary. 
In order to determine whether this conclusion could be applied to the materials of commerce, it is 
necessary to consider the available specifications:  
Specifications including complete purity criteria and identity tests for the materials of commerce 
have been provided for 23 flavouring substances. For eight substances [FL-no: 01.027, 01.032, 
01.034, 01.035, 01.050, 01.055, 01.056 and 01.060] information on stereoisomerism is missing.  
Thus, the final evaluation of the materials of commerce cannot be performed for eight substances 
[FL-no: 01.027, 01.032, 01.034, 01.035, 01.050, 01.055, 01.056 and 01.060], pending further 
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information on isomerism. For 23 candidate substances [FL-no: 01.022, 01.023, 01.030, 01.031, 
01.032, 01.035, 01.036, 01.037, 01.042, 01.043, 01.044, 01.047, 01.050, 01.051, 01.052, 01.053, 
01.055, 01.056, 01.058, 01.060, 01.064, 01.066 and 01.067] additional toxicity data are required. 
For six candidate substances [FL-no: 01.028, 01.033, 01.038, 01.039, 01.054 and 01.057] the Panel 
concluded that they would present no safety concern at their levels of intake estimated on the basis 
of the MSDI approach. One flavouring substance, 2-methylbuta-1,3-diene [FL-no: 01.049], is 
genotoxic in vitro and in vivo and carcinogenic in experimental animals. Accordingly, the use as 
chemically defined flavouring substance is toxicologically not acceptable for this substance.  
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 25 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 25 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4)
Spec.gravity 5) 
Specification comments 
01.022 
 
alpha-Cedrene HH
 
 
10985 
469-61-4 
Liquid 
C15H24 
204.35 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
119 (13 hPa) 
 
MS 
95 % 
1.500-1.506 
0.932-0.938 
 
 
01.023 
 
1(5),11-Guaiadiene 
 
 
11003 
3691-12-1 
Liquid 
C15H24 
204.35 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
78 (3 hPa) 
 
MS 
95 % 
1.493-1.499 
0.897-0.903 
 
 
01.027 
 
Bisabola-1,8,12-triene   6) 
 
 
 
17627-44-0 
Liquid 
C15H24 
204.35 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
99 (5 hPa) 
 
MS 
95 % 
1.483-1.489 
0.912-0.918 
 
CASrn in Register refers to the 
racemate, (Z)- or (E)-isomer 
not specified. 
01.028 
 
beta-Bisabolene 
 
 
 
495-61-4 
Liquid 
C15H24 
204.35 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
130 (13 hPa) 
 
MS 
95 % 
1.489-1.495 
0.879-0.885 
 
 
01.030 
 
beta-Cubebene 
 
 
10989 
13744-15-5 
Solid 
C15H24 
204.35 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
284 
60 
MS 
95 % 
n.a. 
n.a. 
 
 
01.031 
 
1,2-Dihydro-1,1,6-trimethylnaphthalene 
 
 
 
30364-38-6 
Liquid 
C13H16 
172.27 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
115 (24 hPa) 
 
MS 
95 % 
1.542-1.548 
0.942-0.948 
 
 
01.032 
 
2,3-Dihydrofarnesene   6) 
 
 
 
7681-88-1 
Liquid 
C15H26 
206.37 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
130 (15 hPa) 
 
NMR 
95 % 
1.468-1.474 
0.817-0.823 
 
CASrn in Register does not 
specify configuration of double 
bond. 
01.033 
 
2,2-Dimethylhexane 
 
 
 
590-73-8 
Liquid 
C8H18 
114.23 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
107 
 
MS 
95 % 
1.390-1.396 
0.693-0.699 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 25 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4)
Spec.gravity 5) 
Specification comments 
01.034 
 
2,4-Dimethylhexane   6) 
 
 
 
589-43-5 
Liquid 
C8H18 
114.23 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
109 
 
MS 
95 % 
1.390-1.396 
0.697-0.703 
 
CASrn in Register refers to the 
racemate. 
01.035 
 
2,6-Dimethylocta-2,4,6-triene   6) 
 
 
 
673-84-7 
Liquid 
C10H16 
136.24 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
75 (13 hPa) 
 
MS 
95 % 
1.539-1.545 
0.809-0.815 
 
CASrn in Register does not 
specify configuration of double 
bonds. 
01.036 
 
Diphenylmethane 
 
 
11847 
101-81-5 
Solid 
C13H12 
168.24 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
262 
27 
MS 
95 % 
n.a. 
n.a. 
 
 
01.037 
 
Dodec-1-ene 
 
 
10992 
112-41-4 
Liquid 
C12H24 
168.23 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
213 
 
MS 
95 % 
1.425-1.431 
0.755-0.761 
 
 
01.038 
 
Dodecane 
 
 
 
112-40-3 
Liquid 
C12H26 
170.34 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
216 
 
MS 
95 % 
1.417-1.423 
0.746-0.752 
 
 
01.039 
 
delta-Elemene 
 
 
10996 
20307-84-0 
Liquid 
C15H24 
204.35 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
107 (13 hPa) 
 
MS 
95 % 
1.480-1.486 
0.856-0.862 
 
 
01.042 
 
Germacra-1(10),4(14),5-triene 
 
 
 
23986-74-5 
Liquid 
C15H24 
204.35 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
308 
 
MS 
95 % 
1.507-1.513 
0.896-0.892 
 
 
01.043 
 
3,7,10-Humulatriene 
 
 
11004 
6753-98-6 
Liquid 
C15H24 
204.35 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
123 (13 hPa) 
 
MS 
95 % 
1.499-1.505 
0.889-0.895 
 
 
01.044 
 
Isolongifolene 
 
 
 
1135-66-6 
Liquid 
C15H24 
204.35 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
120 (16 hPa) 
 
MS 
95 % 
1.495-1.501 
0.926-0.932 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 25 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4)
Spec.gravity 5) 
Specification comments 
01.047 
 
Longifolene 
H
H
H
 
 
 
475-20-7 
Liquid 
C15H24 
204.35 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
115 (13 hPa) 
 
MS 
95 % 
1.498-1.504 
0.929-0.935 
 
 
01.049 
 
2-Methylbuta-1,3-diene 
 
 
 
78-79-5 
Liquid 
C5H8 
68.12 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
34 
 
MS 
95 % 
1.415-1.421 
0.677-0.683 
 
 
01.050 
 
3-Methylhexane   6) 
 
 
 
589-34-4 
Liquid 
C7H16 
100.20 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
92 
 
MS 
95 % 
1.385-1.391 
0.684-0.690 
 
CASrn in Register refers to the 
racemate. 
01.051 
 
2-Methylnaphthalene 
 
 
11010 
91-57-6 
Solid 
C11H10 
142.20 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
241 
35 
MS 
95 % 
n.a. 
n.a. 
 
 
01.052 
 
alpha-Muurolene 
 
 
11011 
10208-80-7 
Liquid 
C15H24 
204.35 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
118 (17 hPa) 
 
MS 
95 % 
1.502-1.508 
0.911-0.917 
 
 
01.053 
 
Naphthalene 
 
 
11014 
91-20-3 
Solid 
C10H8 
128.17 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
218 
80 
MS 
95 % 
n.a. 
n.a. 
 
 
01.054 
 
Pentadecane 
 
 
 
629-62-9 
Liquid 
C15H32 
212.42 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
270 
10 
MS 
95 % 
1.428-1.434 
0.765-0.771 
 
 
01.055 
 
beta-Phellandrene   6) 
 
 
11017 
555-10-2 
Liquid 
C10H16 
136.24 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
174 
 
MS 
95 % 
1.476-1.482 
0.839-0.845 
 
CASrn in Register refers to the 
racemate. 
01.056 
 
alpha-Santalene   6) 
 
 
 
512-61-8 
Liquid 
C15H24 
204.35 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
112 (9 hPa) 
 
MS 
95 % 
1.480-1.486 
0.895-0.901 
 
CASrn in Register refers to the 
(-)-enantiomer. 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 25 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4)
Spec.gravity 5) 
Specification comments 
01.057 
 
Tetradecane 
 
 
 
629-59-4 
Liquid 
C14H30 
198.39 
Practically insoluble or 
insoluble 
1 m l in 1 ml 
252 
5 
MS 
95 % 
1.422-1.428 
0.759-0.765 
 
 
01.058 
 
1,2,3,4-Tetrahydro-1,1,6-
trimethylnaphthalene 
 
 
 
475-03-6 
Liquid 
C13H18 
174.29 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
245 
 
MS 
95 % 
1.519-1.525 
0.932-0.938 
 
 
01.060 
 
1,1,7-
Trimethyltricyclo[2.2.1.0.(2.6)]heptane   
6)  
 
 
508-32-7 
Solid 
C10H16 
136.24 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
152 
66 
MS 
95 % 
n.a. 
n.a. 
 
CASrn in Register refers to the 
racemate. 
01.064 
 
cis-3,7-Dimethyl-1,3,6-octatriene 
 
 
 
3338-55-4 
Liquid 
C10H16 
136.24 
Practically insoluble or 
insoluble 
1 ml 1in 1 ml 
177 
 
MS 
95 % 
1.483-1.489 
0.796-0.802 
 
Synonym: cis-beta-ocimene. 
01.066 
 
2-Cedrene 
 
 
 
 
Liquid 
C15H24 
204.35 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
82 (11 hPa) 
 
MS 
95 % 
1.495-1.501 
0.928-0.934 
 
CASrn 35944-22-0 to be 
introduced in the Register. 
01.067 
 
8(14)-Cedrene 
 
 
 
 
Liquid 
C15H24 
204.35 
Practically insoluble or 
insoluble 
1 ml in 1 ml 
118 (13 hPa) 
 
MS 
95 % 
1.498-1.504 
0.930-0.936 
 
CASrn is lacking. 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95%  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
6) Stereoisomeric composition not specified. 
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TABLE 2: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI 
APPROACH) 
Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1)  
(μg/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the named 
compound  
[4) or 5)] 
Outcome on the 
material of commerce 
[6), 7), or 8)] 
Evaluation remarks 
01.027 
 
Bisabola-1,8,12-triene 
 
0.024 
 
Class I 
A3: Intake below threshold 
4) 7)  
01.028 
 
beta-Bisabolene 
 
2.7 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.033 
 
2,2-Dimethylhexane 
 
1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.034 
 
2,4-Dimethylhexane 
 
1.2 
 
Class I 
A3: Intake below threshold 
4) 7)  
01.038 
 
Dodecane 
 
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.039 
 
delta-Elemene 
 
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.054 
 
Pentadecane 
 
0.61 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.057 
 
Tetradecane 
 
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.022 
 
alpha-Cedrene HH
 
0.012 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.023 
 
1(5),11-Guaiadiene 
 
1.2 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1)  
(μg/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the named 
compound  
[4) or 5)] 
Outcome on the 
material of commerce 
[6), 7), or 8)] 
Evaluation remarks 
01.030 
 
beta-Cubebene 
 
0.012 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.032 
 
2,3-Dihydrofarnesene 
 
0.12 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.035 
 
2,6-Dimethylocta-2,4,6-triene 
 
0.013 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.037 
 
Dodec-1-ene 
 
0.024 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.042 
 
Germacra-1(10),4(14),5-triene 
 
0.012 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.043 
 
3,7,10-Humulatriene 
 
1.2 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.044 
 
Isolongifolene 
 
0.012 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.047 
 
Longifolene 
H
H
H
 
0.17 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.050 
 
3-Methylhexane 
 
0.061 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.052 
 
alpha-Muurolene 
 
0.24 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1)  
(μg/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the named 
compound  
[4) or 5)] 
Outcome on the 
material of commerce 
[6), 7), or 8)] 
Evaluation remarks 
01.055 
 
beta-Phellandrene 
 
0.012 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.056 
 
alpha-Santalene 
 
0.012 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.060 
 
1,1,7-
Trimethyltricyclo[2.2.1.0.(2.6)]heptane 
 
0.012 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.064 
 
cis-3,7-Dimethyl-1,3,6-octatriene 
 
0.049 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.066 
 
2-Cedrene 
 
0.97 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.067 
 
8(14)-Cedrene 
 
0.012 
 
Class I 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.049 
 
2-Methylbuta-1,3-diene 
 
0.061 
 
Class I 
No evaluation 
  a) 
01.031 
 
1,2-Dihydro-1,1,6-
trimethylnaphthalene 
 
0.0012 
 
Class II 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.058 
 
1,2,3,4-Tetrahydro-1,1,6-
trimethylnaphthalene 
 
0.12 
 
Class II 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.036 
 
Diphenylmethane 
 
1.2 
 
Class III 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.051 
 
2-Methylnaphthalene 
 
0.0012 
 
Class III 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
01.053 
 
Naphthalene 
 
0.013 
 
Class III 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data required   
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day 
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2) Thresholds of concern: Class I = 1800, Class II = 540, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
a) Due to genotoxic concern the Procedure cannot be applied. 
 
 
 Flavouring Group Evaluation 25 (FGE.25)
Aliphatic and aromatic hydrocarbons from chemical group 31
 
 
  The EFSA Journal (2008) 918, 33-109 
 TABLE 3: SUPPORTING SUBSTANCES SUMMARY (JECFA, 2006A) 
Table 3: Supporting Substances Summary (JECFA, 2006a) 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
01.003 Pin-2(10)-ene 
 
2903 
2114 
127-91-3 
1330 
JECFA specification (JECFA, 
2005b) 
1323  
No safety concern a) 
Category B b) 
 
01.004 Pin-2(3)-ene 
 
2902 
2113 
80-56-8 
1329 
JECFA specification (JECFA, 
2005b) 
1836  
No safety concern a) 
Category B b) 
 
01.005 Terpinolene 
 
3046 
2115 
586-62-9 
1331 
JECFA specification (JECFA, 
2005b) 
656  
No safety concern a) 
Category B b) 
 
01.006 alpha-Phellandrene 
 
2856 
2117 
99-83-2 
1328 
JECFA specification (JECFA, 
2005b) 
79  
No safety concern a) 
Category B b) 
 
01.007 beta-Caryophyllene 
 
2252 
2118 
87-44-5 
1324 
JECFA specification (JECFA, 
2005b) 
332  
No safety concern a) 
Category B b) 
 
01.008 Myrcene 
 
2762 
2197 
123-35-3 
1327 
JECFA specification (JECFA, 
2005b) 
7100  
No safety concern a) 
Category B b) 
 
01.009 Camphene 
 
2229 
2227 
79-92-5 
1323 
JECFA specification (JECFA, 
2005b) 
14  
No safety concern a) 
Category B b) 
 
01.014 1-Methylnaphthalene 
 
3193 
11009 
90-12-0 
1335 
JECFA specification (JECFA, 
2005b) 
0.77  
No safety concern a) 
 
 
 Flavouring Group Evaluation 25 (FGE.25)
Aliphatic and aromatic hydrocarbons from chemical group 31
 
 
  The EFSA Journal (2008) 918, 34-109 
Table 3: Supporting Substances Summary (JECFA, 2006a) 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
01.016 1,4(8),12-Bisabolatriene 
 
3331 
10979 
495-62-5 
1336 
JECFA specification (JECFA, 
2005b) 
13  
No safety concern a) 
 
 
01.017 Valencene 
 
3443 
11030 
4630-07-3 
1337 
JECFA specification (JECFA, 
2005b) 
53  
No safety concern a) 
 
 
01.018 beta-Ocimene 
 
3539 
11015 
13877-91-3 
1338 
JECFA specification (JECFA, 
2005b) 
55  
No safety concern a) 
 
 
01.019 alpha-Terpinene 
 
3558 
11023 
99-86-5 
1339 
JECFA specification (JECFA, 
2005b) 
27  
No safety concern a) 
 
 
01.020 gamma-Terpinene 
 
3559 
11025 
99-85-4 
1340 
JECFA specification (JECFA, 
2005b) 
1171  
No safety concern a) 
 
 
01.024 beta-Bourbonene H
H H
 
 
11931 
5208-59-3 
1345 
JECFA specification (JECFA, 
2005b) 
ND  
No safety concern a) 
 
 
01.026 1(5),7(11)-Guaiadiene 
S
S
 
 
 
88-84-6 
1347 
JECFA specification (JECFA, 
2005b) 
0.012  
No safety concern a) 
 
 
01.029 delta-3-Carene 
 
3821 
10983 
13466-78-9 
1342 
JECFA specification (JECFA, 
2005b) 
ND  
No safety concern a) 
 
 
01.040 alpha-Farnesene 
 
3839 
10998 
502-61-4 
1343 
JECFA specification (JECFA, 
2005b) 
ND  
No safety concern a) 
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Table 3: Supporting Substances Summary (JECFA, 2006a) 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
01.045 d-Limonene 
 
2633 
491 
5989-27-5 
1326 
JECFA specification (JECFA, 
2005b) 
33542  
No safety concern a) 
 
ADI not specified (JECFA, 
2006a). 
01.061 Undeca-1,3,5-triene 
 
3795 
 
16356-11-9 
1341 
JECFA specification (JECFA, 
2005b) 
0.17  
No safety concern a) 
 
 
ND)  No intake data reported. 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2005c). 
b) (CoE, 1992). 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in 
schematic form in Figure I.1. The Procedure is based on the opinion of the Scientific Committee on 
Food expressed on 2 December 1999 (SCF, 1999), which is derived from the evaluation procedure 
developed by the Joint FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th 
meetings (JECFA, 1995; JECFA, 1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, 
structure-activity relationships, metabolism and, when needed, toxicity. One of the key elements in 
the procedure is the subdivision of flavourings into three structural classes (I, II, III) for which 
thresholds of concern (human exposure thresholds) have been specified. Exposures below these 
thresholds are not considered to present a safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of 
metabolism, which would suggest a low order of oral toxicity. Class II contains flavourings that 
have structural features that are less innocuous, but are not suggestive of toxicity. Class III 
comprises flavourings that have structural features that permit no strong initial presumption of 
safety, or may even suggest significant toxicity (Cramer et al., 1978). The thresholds of concern for 
these structural classes of 1800, 540 or 90 microgram/person/day, respectively are derived from a 
large database containing data on subchronic and chronic animal studies (JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further 
steps address the following questions:  
• can the flavourings be predicted to be metabolised to innocuous products5 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous6 (Step A4)?   
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and 
B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate 
substances), toxicological background information available for compounds structurally related to 
the candidate substances is considered (supporting substances), in order to assure that these data are 
consistent with the results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. 
Therefore, the right is reserved to use alternative approaches if data on specific flavourings 
warranted such actions. 
 
                                                 
5 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the 
estimated intakes of the flavouring agent” (JECFA, 1997a). 
 
6 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997a). 
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Decision tree structural class
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Data must be available on the 
substance or closely related 
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be   
expected to be of safety concern
Is  the substance or are its metabolites endogenous?
Additional data required
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3.
Step B4.
 Yes  No
 Yes 
 No 
No 
No
Yes
No
Yes
Yes 
Yes 
 No
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
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ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and maximum use levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, 
Flavour Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According 
to the Industry the ”normal use” is defined as the average of reported usages and ”maximum use” is 
defined as the 95th percentile of reported usages (EFFA, 2002i). The normal and maximum use 
levels in different food categories (EC, 2000a) have been extrapolated from figures derived from 12 
model flavouring substances (EFFA, 2004e). 
 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
The “normal and maximum use levels” are provided by Industry for the 32 candidate substances in 
the present flavouring group (Table II.1.2). 
 
Table II.1.2 Normal and Maximum use levels (mg/kg) for candidate substances in FGE.25 (EFFA, 2005a;EFFA, 
2007a) 
Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) FL-no 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
01.022 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.023 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.027 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.028 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.030 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.031 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.032 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.033 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.034 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.035 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.036 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.037 7 5 10 7 - 10 5 10 2 2 - - 5 10 5 - 20 5 
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Table II.1.2 Normal and Maximum use levels (mg/kg) for candidate substances in FGE.25 (EFFA, 2005a;EFFA, 
2007a) 
Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) FL-no 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
35 25 50 35 - 50 25 50 10 10 - - 25 50 25 - 100 25 
01.038 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.039 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
4 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.042 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.043 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.044 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
- 
- 
5 
25 
01.047 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.049 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
4 
25 
10 
50 
2 
10 
- 
- 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.050 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.051 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.052 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.053 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.054 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.055 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.056 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.057 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.058 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.060 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.064 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.066 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
- 
- 
20 
100 
5 
25 
01.067 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
 20 
100 
5 
25 
II.2 mTAMDI calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) 
values is based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a 
person consumes the amount of flavourable foods and beverages listed in Table II.2.1. These 
consumption estimates are then multiplied by the reported use levels in the different food categories 
and summed up.  
 
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions 
assumed to be consumed per person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
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The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as 
outlined in Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Industry 
in the following way (see Table II.2.2): 
 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 
16 (EC, 2000a) 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01 Dairy products, excluding products of category 02.0 Food   
02 Fats and oils, and fat emulsions (type water-in-oil) Food   
03 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds Food  
 
05 Confectionery   Exception a 
06 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery Food  
 
07 Bakery wares Food   
08 Meat and meat products, including poultry and game Food   
09 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10 Eggs and egg products Food   
11 Sweeteners, including honey   Exception a 
12 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15 Ready-to-eat savouries   Exception b 
16 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 Food  
 
The mTAMDI values (see Table II.2.3) are presented for each of the 32 flavouring substances in the 
present flavouring group, for which Industry has provided use and use levels (EFFA, 2005a; EFFA, 
2007a). The mTAMDI values are only given for highest reported normal use levels (see Table 
II.2.3). 
 
Table II.2.3 Estimated intakes based on the mTAMDI approach 
 
FL-no EU Register name mTAMDI (μg/person/day) Structural class Threshold of concern 
(µg/person/day) 
01.022 alpha-Cedrene 3700 Class I 1800 
01.023 1(5),11-Guaiadiene 3700 Class I 1800 
01.027 Bisabola-1,8,12-triene 3700 Class I 1800 
01.028 beta-Bisabolene 3700 Class I 1800 
01.030 beta-Cubebene 3700 Class I 1800 
01.032 2,3-Dihydrofarnesene 3700 Class I 1800 
01.033 2,2-Dimethylhexane 3700 Class I 1800 
01.034 2,4-Dimethylhexane 3700 Class I 1800 
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Table II.2.3 Estimated intakes based on the mTAMDI approach 
 
FL-no EU Register name mTAMDI (μg/person/day) Structural class Threshold of concern 
(µg/person/day) 
01.035 2,6-Dimethylocta-2,4,6-triene 3700 Class I 1800 
01.037 Dodec-1-ene 3700 Class I 1800 
01.038 Dodecane 3700 Class I 1800 
01.039 delta-Elemene 3700 Class I 1800 
01.042 Germacra-1(10),4(14),5-triene 3700 Class I 1800 
01.043 3,7,10-Humulatriene 3700 Class I 1800 
01.044 Isolongifolene 3300 Class I 1800 
01.047 Longifolene 3700 Class I 1800 
01.049 2-Methylbuta-1,3-diene 3700 Class I 1800 
01.050 3-Methylhexane 3700 Class I 1800 
01.052 alpha-Muurolene 3700 Class I 1800 
01.054 Pentadecane 3700 Class I 1800 
01.055 beta-Phellandrene 3700 Class I 1800 
01.056 alpha-Santalene 3700 Class I 1800 
01.057 Tetradecane 3700 Class I 1800 
01.060 1,1,7-Trimethyltricyclo[2.2.1.0.(2.6)]heptane 3700 Class I 1800 
01.064 cis-3,7-Dimethyl-1,3,6-octatriene 3700 Class I 1800 
01.066 2-Cedrene 3700 Class I 1800 
01.067 8(14)-Cedrene 3700 Class I 1800 
01.031 1,2-Dihydro-1,1,6-trimethylnaphthalene 3700 Class II 540 
01.058 1,2,3,4-Tetrahydro-1,1,6-trimethylnaphthalene 3700 Class II 540 
01.036 Diphenylmethane 3700 Class III 90 
01.051 2-Methylnaphthalene 3700 Class III 90 
01.053 Naphthalene 3700 Class III 90 
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ANNEX III: METABOLISM 
Table of content 
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III.6 Overall Conclusion on Absorption, Distribution, Metabolism and Excretion 76 
III.1 Introduction 
This group of flavouring substances is very diverse with respect to the chemical structures. In order 
to facilitate the evaluation of the metabolism aspects of the individual substances, the candidate 
substances in the group have been divided into eight subgroups: I) acyclic saturated hydrocarbons 
[FL-no: 01.033, 01.034, 01.038, 01.050, 01.054 and 01.057], II) acyclic unsaturated hydrocarbons 
[FL-no: 01.032, 01.035, 01.037, 01.049 and 01.064], III) cyclohexene hydrocarbons [FL-no: 
01.027, 01.028, 01.039 and 01.055], IVa) benzene hydrocarbons [FL-no: 01.031 and 01.058], IVb) 
naphthalene hydrocarbons [FL-no: 01.051 and 01.053], IVc) diphenylmethane [FL-no: 01.036], V) 
bi- and tricyclic, non-aromatic hydrocarbons [FL-no: 01.022, 01.023, 01.030, 01.044, 01.047, 
01.052, 01.056, 01.060, 01.066 and 01.067] and VI) macrocyclic, non-aromatic hydrocarbons [FL-
no: 01.042 and 01.043]. From the evaluation of flavouring substances as carried out by JECFA in 
2004, a group of supporting substances has been identified. These supporting substances have also 
been allocated to subgroups in the same way as has been indicated for the candidate substances. The 
allocation of the candidate and supporting substances is shown in Table III.1. 
 
Table III.1 Subgroups. The supporting substances are listed in brackets. 
FL-no EU Register name Structural formula Structural class 
I:  ACYCLIC ALKANES 
01.033 2,2-Dimethylhexane    
 
I 
01.034 2,4-Dimethylhexane   
 
I 
01.038 Dodecane     I 
01.050 3-Methylhexane    
 
I 
01.054 Pentadecane    I 
01.057 Tetradecane     I 
II:  ACYCLIC ALKENES 
01.032 2,3-Dihydrofarnesene   
 
I 
01.035 2,6-Dimethylocta-2,4,6-triene 
 
I 
01.037 Dodec-1-ene  I 
01.049 2-Methylbuta-1,3-diene 
 
I 
01.064 cis-3,7-Dimethyl-1,3,6-octatriene 
 
I 
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Table III.1 Subgroups. The supporting substances are listed in brackets. 
FL-no EU Register name Structural formula Structural class 
(01.008) (Myrcene) 
 
I 
(01.018) (beta-Ocimene) 
 
I 
(01.040) (alpha-Farnesene) 
 
I 
(01.061) (Undeca-1,3,5-triene)  
 
 
I 
III:  CYCLOHEXENE HYDROCARBONS 
01.055 beta-Phellandrene 
 
I 
01.027 Bisabola-1,8,12-triene   
 
 
I 
01.028 beta-Bisabolene 
 
I 
01.039 delta-Elemene 
 
I 
(01.005) (Terpinolene) 
 
I 
(01.006) (alpha-Phellandrene) 
 
I 
(01.016) (1,4(8),12-Bisabolatriene) 
 
I 
(01.019) (alpha-Terpinene) 
 
I 
(01.020) (gamma-Terpinene) 
 
I 
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Table III.1 Subgroups. The supporting substances are listed in brackets. 
FL-no EU Register name Structural formula Structural class 
(01.045) (d-Limonene) 
 
I 
IV: AROMATIC HYDROCARBONS 
IVa:  BENZENE HYDROCARBONS 
01.031 1,2-Dihydro-1,1,6-trimethylnaphthalene 
 
I 
01.058 1,2,3,4-Tetrahydro-1,1,6-trimethylnaphthalene  
 
II 
IVb:  NAPHTHALENE HYDROCARBONS 
01.051 2-Methylnaphthalene    
 
III 
01.053 Naphthalene    
 
III 
(01.014) (1-Methylnaphthalene) 
 
III 
IVc: DIPHENYLMETHANE 
01.036 Diphenylmethane   
 
III 
V: BI- and TRICYCLIC, NON-AROMATIC HYDROCARBONS 
01.022 alpha-Cedrene HH
 
I 
01.023 1(5),11-Guaiadiene 
 
I 
01.030 beta-Cubebene 
 
I 
01.044 Isolongifolene 
 
I 
01.047 Longifolene 
H
H
H
 
I 
01.052 alpha-Muurolene 
 
I 
01.056 alpha-Santalene   
 
I 
01.060 1,1,7-Trimethyltricyclo[2.2.1.0.(2.6)]heptane  
 
I 
01.066 2-Cedrene 
 
I 
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Table III.1 Subgroups. The supporting substances are listed in brackets. 
FL-no EU Register name Structural formula Structural class 
01.067 8(14)-Cedrene 
 
I 
(01.003) (Pin-2(10)-ene) 
 
I 
(01.004) (Pin-2(3)-ene) 
 
I 
(01.007) (beta-Caryophyllene) 
 
I 
(01.009) (Camphene) 
 
I 
(01.017) (Valencene) 
 
I 
(01.024) (beta-Bourbonene) H
H H
 
I 
(01.026) (1(5),7(11)-Guaiadiene) 
 
I 
(01.029) (delta-3-Carene) 
 
I 
VI: MACROCYCLIC, NON-AROMATIC HYDROCARBONS 
01.042 Germacra-1(10),4(14),5-triene 
 
I 
01.043 3,7,10-Humulatriene 
 
I 
For the majority of the substances in this group no information of biotransformation had been 
submitted. Also data on structural analogues were scarce. Therefore, an additional search was 
carried out. Some more papers were retrieved, the information from which has been included as far 
as relevant in the following text. 
III.2 Absorption, Distribution and Excretion 
Acyclic Alkanes (Candidate and Structurally Related Supporting Substances from Subgroup 
I)  
No data on absorption, distribution and elimination were submitted for any of the candidate 
substances in this subgroup. Some studies on saturated alkanes were retrieved from the additional 
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data search, but apart from two oral studies (Olson et al., 1986; Serve et al., 1995) and one 
subcutaneous study (Manini et al., 1999), in all other studies retrieved, inhalation was the route of 
exposure. From these studies (Holmberg et al., 1977; Perbellini et al., 1982; Bahima et al., 1984; 
Perbellini et al., 1986; Fedtke & Bolt, 1987), absorption through the membranes of the inhalatory 
tract was observed. Absorption rates and distribution ratios were dependent on blood/air and 
blood/tissue partition coefficients (Imbriani et al., 1985; Nilsen et al., 1988). In addition, one 
inhalation study by Dahl et al. (1989) showed that more branched isomers were less well absorbed 
than less branched or unbranched isomers. More saturated hydrocarbons were less well absorbed 
than unsaturated and more volatile substances were less well absorbed than less volatile (reversely 
correlated to chain length), but this may not be a relevant difference for oral exposure situations. 
The main purpose of these studies was, however, to study metabolism, but these inhalation 
exposure studies do in general not provide appropriate mass balance data. For that reason, apart 
from the two oral and one inhalation study (Dahl, 1989) which give insight in mass balance, the 
studies by Perbellini et al. (1982); Bahima et al., (1984), Perbellini et al. (1986), Fedtke and Bolt 
(1987) and (Manini et al. (1999) will be discussed in the section on biotransformation.  
Male and female rats were given a dose of 2 ml/kg or 1.4 g/kg n-octane by gavage and urine was 
collected for up to 48 hours. Urine samples were treated with glucuronidase/sulphatase and the 
liberated metabolites were analysed by gas chromatography. Several oxidised metabolites in the 
urine could be found, but quantitative data were not given (Olson et al., 1986). A similar study was 
carried out with n-nonane by Serve et al. (1995), but again no quantitative data were provided. 
Groups of three or four male F344 rats were exposed to [4-14C] or [5-14C]-labelled iso-octane (= 
2,2,4-trimethyl pentane) and [1-14C]-octane vapours at approximately 1 and 350 ppm (~ 4.76 or 
1700 mg/m3 for both substances) by the nose for two hours. During the experiment exhalant was 
drawn through a bubbler train for sampling. Urine and faeces were collected at the same times, 
except that none were collected at one and two hours. For iso-octane, all rats exposed to 350 ppm 
were exposed to C4-labeled substance, but three of four low-exposure rats were exposed to C5-
labeled iso-octane. Values for exhaled 14CO2 were 0.36; 0.31; and 0.52 % of inhaled 14C. For the 
single rat exposed to C4-labeled iso-octane the corresponding value was 2 %7. Values for all rats 
were averaged regardless of position of label. The validity of conclusions regarding low production 
of 14CO2 from iso-octane would have been enhanced by exclusive use of C5-labeled material. 
For both n-octane and iso-octane the metabolised fraction was higher at low compared to high 
inhaled concentrations. For octane the major route of elimination was as carbon dioxide (15 % of 
the radioactive dose within 70 hours). For iso-octane the major route of excretion was urine. Half of 
the octane-introduced 14C that was retained at the end of the two-hour exposure period was 
eliminated 5-10 hours post-exposure and the exhalation of radiolabel became undetectable after 30 
hours, after which 75-85 % of the label was eliminated. For iso-octane the time to eliminate half of 
the label was 15 hours and was not completed at the end of the observation period. Based on a 
discussion of papers from other research groups, the study authors suggest that for straight-chain 
hydrocarbons, breakdown of the carbon skeleton with the release of CO2 is an important metabolic 
pathway. The route of excretion for n-octane in this study was markedly affected by the 
concentrations of the inhaled vapour. The ratio of total exhaled 14CO2: total 14C in urine was 5:1 
after inhalation at 1 ppm but about 1:1 after inhalation of 350 ppm (Dahl, 1989). 
                                                 
7 In an additional study (not reported in detail), three rats were exposed to C4- or C5-labeled iso-octane at about 350 
ppm. More 14CO2 was exhaled during exposure to the C4-labeled material (0.07 % of the inhaled amount) than after 
exposure to the C5-labeled material (0.03 %). This observation also confirms that C5 labelled iso-octane is less well 
metabolised to CO2 than C4 labelled iso-octane 
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Acyclic Alkenes (Candidate and Structurally Related Supporting Substances from Subgroup 
II) 
When given to male Japanese White rabbits by gavage at a dose of 670 mg/kg bw per day for two 
days, approximately 25 % of the total administered amount of myrcene [FL no: 01.008] (19 g to six 
rabbits) could be recovered from the urine over a period of three days following administration 
(Ishida et al., 1981). Only metabolites of myrcene were identified. The fate of the remaining part of 
the dose is unclear. 
Following intraperitoneal injection of 64 mg [4-14C]-2-methylbuta-1,3-diene/kg to F344 rats and 
B6C3F1 mice, the majority of radioactivity (≈ 54 and 47 %, respectively) was excreted unchanged 
in the expired air or as urinary metabolites (≈ 32 and 33 %, respectively) over the 24-hour collection 
period. Less than 2 % of the radioactivity was recovered as CO2 for both species, and 0.2 and 7.2 % 
in rats and mice, respectively, of the radioactivity was recovered in the faeces over the same time 
period. Radioactivity remaining in the carcass and tissues amounted to only 3.1 and 1.7 % in rats 
and mice, respectively. From the tissues examined, the highest concentration was found in the 
kidneys but in both species the renal concentration of radioactivity was only twice has high as the 
concentration in blood. Total percentage of the dose recovered was ≈ 91 % for both rats and mice 
(Buckley et al., 1999). 
Cyclohexene Derivatives (Candidate and Structurally Related Supporting Substances from 
Subgroup III)  
Data were only available for one supporting substance in subgroup III, namely d-limonene [FL-no: 
01.045].  
 
Following the oral administration of [9-14C]-d-limonene to male Wistar rats by stomach tube at a 
dose of 800 mg/kg bw, radioactivity was determined in blood, tissues (fat not included), excreta, 
bile and expired air. The animals were sacrificed at 48 hours post-dosing. Radioactivity reached a 
peak plasma level at two hours post-dosing, and after maintaining high levels for 10 hours, declined 
to negligible levels at 48 hours. In most tissues, peak levels of radioactivity were reached within 
two hours post-dosing indicating rapid distribution. The liver, kidney and adrenals contained the 
highest levels of radioactivity (higher than blood or serum); other tissues (including brain) 
contained less than 0.2 % of the administered radioactivity. Hardly any radioactivity could be 
detected at 48 hours post-dosing. Whole body autoradiography confirmed these findings. At 48 
hours post-dosing, about 60 % of the administered radioactivity was recovered from the urine, 5 % 
from faeces and 2 % from exhaled air as CO2. Approximately 25 % of the administered 
radioactivity was excreted in the bile during 24 hours after administration. Total recovery of 
radioactivity was less than 100 % and as there was hardly any radioactivity present in the tissues at 
48 hours, this could point to loss of volatile 14C from the excreta or to the elimination of volatile 
14C-compounds other than CO2 (Igimi et al., 1974). When a similar radioactive dose of [9-14C]-d-
limonene was given to male rabbits, 72 % and 7 % of the radioactivity was excreted in the urine and 
faeces during 72 hours, respectively (Kodama et al., 1974).  
In an additional study with several species (rats, hamsters, guinea pigs, rabbits, dogs and humans) 
dosed orally with [9-14C]-d-limonene, urinary excretion of radioactivity in rodents and rabbits 
comprised 82-96 % of the dose within 72 hours and faecal excretion 2-9 %. The total excretion rate 
in dogs was somewhat lower (77 % via urine and 9 % via faeces within 72 hours), while two human 
volunteers excreted 55-83 % of the administered dose in the urine. Faecal excretion in humans was 
not measured, but may have been considerable in the person with lower urinary excretion as this 
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person developed a diarrhoea shortly after administration. In all species, most excretion occurred 
within the first 24 hours (Kodama et al., 1976). 
In vitro, the solubility of d-limonene in blood and olive oil was high but low in water, which 
suggests a high respiratory uptake and accumulation in adipose tissues (Falk et al., 1990a). Indeed, 
uptake was rapid and high (68 %) in an experiment in which human volunteers were exposed to d-
limonene in air at 225 and 450 mg/m3 for two hours while doing light physical exercise. The 
absorbed d-limonene was metabolised rapidly. Elimination followed a triphasic pattern, with a short 
half-life in blood immediately after exposure (2.6 minutes) but a long half-life during the late 
elimination phase (12.5 hours), which indicates slow elimination from adipose tissues. 
Approximately 1 % of the total uptake was eliminated unchanged in expired air, while 
approximately 0.003 % was eliminated unchanged in urine (Falk-Filipson et al., 1993). 
Aromatic Hydrocarbons (Candidate and Structurally Related Supporting Substances from 
Subgroup IV)  
This subgroup is further divided into three groups, one with benzene derivatives (di- and 
tetrahydronaphthalenes; IVa), one with naphthalene derivatives (IVb) and one with one candidate 
substance: diphenylmethane (IVc). For the candidates of subgroup IVb only one supporting 
substance has been submitted (1-methylnaphthalene), but for both naphthalene and 2-
methylnaphthalene many toxicity data are available, and extensive reviews on these substances 
have been published recently (Shelby & Witt, 1995; EU-RAR, 2003). 
Subgroup IVa (benzene derivatives): 
No data were available on any of the candidate substances in this group. No supporting substances 
were suggested. 
Subgroup IVb (naphthalene derivatives): 
Naphthalene [FL-no: 01.053]: 
Bock et al. (1979) reported that naphthalene was rapidly absorbed from isolated rat intestinal loops 
in situ, predominantly unchanged, into the portal blood. Approximately 84 % of the naphthalene 
related substances in the blood was naphthalene, the remainder were metabolites; mainly 
naphthalene-1,2-dihydrodiol and 1-naphthol, 40 % of which was recovered as conjugates; 
predominantly with glucuronic acid (Bock et al., 1979). 
Three groups of Sprague-Dawley rats were treated orally with a single administration of 2 mg 14C-
naphthalene. The dose per unit body weight was not stated (Bakke et al., 1985). One group of 16 
animals was bile duct cannulated, the second group of four germ-free animals was uncannulated, 
and the third group of 13 animals was standard uncannulated rats. Urine, faeces and bile were 
collected for 72 hours after administration of naphthalene. In the standard uncannulated rats 75.6 % 
of the radioactivity was recovered in the urine in 24 hours. At 72 hours, approximately 83 % of the 
radioactivity had been recovered in the urine, 6 % in the faeces and 4 % remained in the carcass 
with no account made for the remaining radioactivity. In the cannulated rats the 24-hour urine and 
bile contained 30 % and 66.8 % of the 14C dose, respectively (faecal data not presented for 24-hour 
time period). At 72 hours, approximately 30 % of the radioactivity had been recovered in the urine, 
68 % was contained in the bile, less than 1 % was excreted in the faeces and 0.2 % remained in the 
carcass. 
When a single dose of 20 mg/kg bw of naphthalene-[ring-U-3H] was administered intraperitoneally 
in olive oil to outbred male IMP:Wist rats (n = 54), urine and faeces were the main routes of 
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elimination of the radioactivity with more than 88 % of the radioactivity excreted during the first 72 
hours. The maximum level of radioactivity in plasma was observed at two hours post-dosing 
followed by biphasic clearance (t1/2 = 0.8 and 99 hours for phase I and phase II, respectively). The 
highest concentrations during the first hour following dose administration were detected in fat, liver 
and kidneys, with a gradual decline of radioactivity in all tissues examined (Kilanowicz et al., 
1999).  
Male Sprague-Dawley rats were given [1-14C] naphthalene (100 mg/kg) via i.p. injection. Of the 
administered dose, 20-30 % was excreted in the 0-24-hour urine, while 3-11 % was found in the 24-
48-hour urine. Unconjugated metabolites accounted for 5-20 % of the metabolites excreted, while 
80-95 % of the metabolites were excreted, as acidic conjugates (Horning et al., 1980).  
Urinary excretion of premercapturic acids and mercapturic acids represents a major excretory 
pathway for naphthalene in mice and rats (Stillwell et al., 1978; Chen & Dorough, 1979; Pakenham 
et al., 2002). Urine was collected for 24 hours after intraperitoneal administration of 0, 1.56, 3.12, 
6.25, 12.5, 25, 50, 100 and 200 mg/kg radiolabelled [14C]-naphthalene dissolved in corn oil to male 
Sprague-Dawley rats and Swiss Webster mice, four animals in each group. The percentage of the 
administered dose excreted as mercapturic acids in the urine for mice (25–34 %) and rats (24–35 %) 
did not differ with increasing dose (Pakenham et al., 2002). Studies with chimpanzees (Summer et 
al., 1979b) and with rhesus monkeys (Rozman et al., 1982) indicated that urinary excretion of 
mercapturic acids is probably less important in primates. Boyland and Sims reported that only 
traces of mercapturic acids were detected in the urine of three human subjects after oral 
administration of 500 mg naphthalene, while for rats, mice, hamsters and rabbits, 1-naphthyl-
(pre)mercapturic acid was abundantly present in the urine (Boyland & Sims, 1958).  
2-Methylnaphthalene [FL-no: 01.051]: 
Following intraperitoneal injection of C57BL/6J mice with a single 400 mg/kg dose of [8-14C]-2-
methylnaphthalene, the majority of radioactivity was distributed in fat, liver, kidney and lung, in 
order of decreasing concentration. Maximal plasma and tissue levels were achieved one (liver), two 
(plasma; fat) or four (kidneys) hours after dose administration and the t1/2 of elimination of 
radioactivity from blood was approximately three hours (Griffin et al., 1982).  
When 10 mg/kg bw 2-[1-3H]-methylnaphthalene was orally administered to guinea pigs, the highest 
concentrations of radioactivity were found in the gall bladder, kidneys and liver three hours after 
dosing. Lower concentrations were observed in the blood, brain, heart, lung and spleen. At that time 
the total  gastrointestinal tract contained 27 % of the dose while the urine contained 23 %. At 24 
hours only some retention was observed in the liver, gall bladder and kidney, with 11 % in faeces 
and 79 % in the urine. After 48hours 12 % was recovered from faeces and 72 % from the urine, and 
1 % of the dose was recovered from the tissues investigated (Teshima et al., 1983). 
Subgroup IVc (diphenylmethane): 
After intraperitoneal administration of the candidate flavouring substance diphenylmethane [FL-no: 
01.036], metabolites have been shown in urine and faeces. Only a small fraction of the dose (up to 
6.8 %) was recovered after 24 hours (Deloach et al., 1978; Stocklinski et al., 1979). The studies 
were too incomplete to estimate if total elimination is slow, or that this apparently slow elimination 
is indicated because quantitatively important metabolites were not studied.  
Bi- and Tricyclic Non-Aromatic Hydrocarbons (Candidate and Structurally Related 
Supporting Substances from Subgroup V)  
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No data on absorption on candidate substances in this group were submitted. Some data were 
retrieved after database search on the candidate substance longifolene [FL-no: 01.047] and on 
several supporting substances including alpha- and beta-pinene [FL-no 01.004 and 01.003], 
caryophyllene [FL-no: 01.007] and delta-3-carene [FL-no: 01.029].  
Asakawa et al. (1986) studied the metabolism of (+)-longifolene and caryophyllene in rabbits after 
gavage dosing. At two days after administration, metabolites of all of these substances could be 
detected in the urine, from which it can be concluded that these substances are absorbed. As no 
mass balance data were given, the extent of absorption cannot be assessed (Asakawa et al., 1986).  
Male albino rabbits (6/group) were administered single gavage doses of 400 – 700 mg/kg bw of (+)-
alpha-pinene, (-)-alpha-pinene, (±)-alpha-pinene, (-)-beta-pinene, or delta-3-carene. Urine of 
individual animals was collected for three days. The animals excreted bicyclic terpene hydrocarbon 
metabolites as glucuronic acid conjugates or as further oxidised metabolites, notably carboxylic 
acids (Schreiner, 2003).  
In vitro data on the solubility of alpha-pinene [FL-no: 01.004], beta-pinene [FL-no: 01.003] and 
delta-3-carene [FL-no: 01.029] in blood, olive oil and water suggest a high respiratory uptake and 
accumulation in adipose tissues. For alpha-pinene this is supported by a high estimated brain/blood 
partition coefficient of 18 (Falk et al., 1990a). Experiments in which human volunteers were 
exposed to (+)- and (-)-alpha-pinene or delta-3-carene in air at 225 and 450 mg/m3 for 2 hours while 
doing light physical exercise confirmed that uptake was rapid and high for these agents (58-60 % 
for (+)- and (-)-alpha-pinene and 70 % for delta-3-carene), and that they were metabolised rapidly. 
Elimination followed a triphasic pattern, with (+)- and (-)-alpha-pinene exhibiting a rapid initial 
(distribution) phase (4.8 and 5.6 minutes, respectively), a rapid second distribution phase (38 and 40 
minutes, respectively), and a slow elimination phase (695 and 555 minutes, respectively). Triphasic 
elimination was also observed for delta-3-carene with half-lives of 4.5, 35, and 1800 minutes for the 
initial, rapid and slow phases, respectively. It was estimated that it would require over two or six 
days to eliminate alpha-pinene or delta-3-carene, respectively, from the body. The long half-lives 
indicate slow elimination from adipose tissues. Less than 0.001 % of the total uptake of alpha-
pinene or delta-3-carene was eliminated unchanged in the urine, while 7.5-7.8 % and 3 % of the 
inhaled amount of the alpha-pinenes and delta-3-carene were exhaled (Falk et al., 1990b; Falk et al., 
1991).  
In another study, humans were exposed for four or six hours to atmospheres containing a mixture of 
volatile organic substances, which included alpha-pinene, at total concentrations of 12 or 24 mg/m3. 
At a concentration of 24 mg/m3 for the total volatiles, the air concentration of alpha-pinene was 
0.775 mg/m3. The mean pre-exposure blood concentration of alpha-pinene of 0.035 microg/l 
increased to an average concentration of 1.9 microg/l during the 4-hour exposure (50-240 minutes). 
Thereafter (330-450 minutes), the mean blood concentration decreased to 0.15 microg/l. Changes 
proportional to those observed at 24 mg/m3 were recorded at 12 mg/m3 exposure. Similar results 
were recorded for the 6-hour exposure. Plasma elimination for alpha-pinene was best described with 
a three-exponential curve, with half-lives ranging from 0.22-7.8 minutes, 19-58 minutes and >150 
minutes for the initial, mid and terminal phases, respectively (Ashley & Prah, 1997). 
In the urine of sawmill workers exposed to an atmosphere containing 31-210 mg/m3 alpha-pinene 
[FL-no: 01.004], 2-17 mg/m3 beta-pinene [FL-no: 01.003] and 6-90 mg/m3 delta-3-carene [FL-no: 
01.029] for three days, cis and trans-verbenol were identified as metabolites. They were excreted as 
conjugates, probably with glucuronic acid. The authors suggested that these metabolites were 
formed by hydroxylation of alpha-pinene (Eriksson & Levin, 1990). Analysis of urinary metabolites 
eliminated by human volunteers within 4 hours following a 2-hour exposure to 10 - 450 mg alpha-
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pinene/m3 revealed that alpha-pinene is indeed eliminated as cis- and trans-verbenol, in a ratio of 
1:10, within 20 hours following exposure (Levin et al., 1992). In a more extensive metabolic study, 
urine was collected from sawmill workers at the end of an 8-9 hours work shift or from chamber-
exposed individuals. Following hydrolysis of glucuronic acid conjugates, several pinene 
biotransformation products were found (Eriksson & Levin, 1996).  
Macrocyclic Non-Aromatic Hydrocarbons (Candidate and Structurally Related Supporting 
Substances from Subgroup VI)  
No data were submitted on any of the two candidate substances in this subgroup [FL-no: 01.042 and 
01.043]. No supporting substances were identified. 
III.3 Conclusions on Absorption, Distribution and Elimination 
Based on the available studies it may be concluded that the candidate alkane substances (subgroup 
I) will be absorbed after oral exposure. The extent of absorption is not known, but may be high, 
given their lipophilic character and their low molecular weight. The ease with which these 
substances cross the membranes of the respiratory tract further supports the assumption that these 
substances will also be absorbed after oral intake. Data indicate that straight-chain alkanes will 
predominantly be broken down to carbon dioxide at low dose levels. At high dose levels, 
biotransformation becomes saturated and other metabolites will be generated, which will be 
excreted via the urine. As illustrated by for iso-octane, metabolism of (highly) branched alkanes to 
carbon dioxide is less favourable, and their metabolites will be eliminated more slowly via the 
urine. 
For the candidate or supporting substances in subgroup II (acyclic alkenes), data were only 
available for beta-myrcene [FL-no: 01.008] and 2-methylbuta-1,3-diene [FL-no: 01.049]. Given the 
narrow range of molecular weights of the candidate substances (all between ~ 68 and 206 D) and 
their lipophilic nature (Log Kow values e.g. 2.4 (2-methylbuta-1,3-diene), 6.1 (dodec-1-ene), 4.17 
(beta-myrcene) or 4.8 (cis-3,7-dimethyl-1,3,6-octatriene)), it must be assumed that these candidate 
flavouring substances will be absorbed from the gastrointestinal tract, at least to some extent, if not 
completely. Mass balance data are also incomplete. At least for beta-myrcene it has been shown its 
metabolites will be excreted via urine, in an amount of 25 % of the dose within three days after 
dosing. For 2-methylbuta-1,3-diene a fairly complete mass balance of elimination has been 
presented, which shows also elimination via the exhaled air (~ 50 % of the dose), but as this 
substance was administered via the intraperitoneal route, the elimination pattern may be different 
after oral dosing with a lower fraction of the dose exhaled, e.g. because of more efficient first-pass 
biotransformation after oral dosing. 
For the candidate or supporting substances in subgroup group III (cyclohexene derivatives), data 
were only available for d-limonene [FL-no: 01.045 ], which is a supporting substance. For this 
substance, data show a considerable absorption from the gastrointestinal tract. In humans, 
elimination of the substance followed a triphasic pattern, but still 55-83 % of an oral dose could be 
found in the urine within 72 hours post-dosing, with the major part excreted within 24 hours. Also 
in other species urinary elimination was most important accounting for up to 82–96 % of the dose 
within 72 hours. Hence, it may be argued that monocyclic cyclohexene derivatives, such as d-
limonene, administered orally are absorbed and distributed throughout the body. Following oral 
administration to humans, d-limonene was distributed preferentially to fatty tissues, as indicated by 
a high oil-blood partition coefficient and a long half-life during the slow elimination phase. Because 
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of the limited molecular weight of the candidate substances in this group (range ~ 136–204 D) and 
their lipophilic character (e.g. log Kow values for beta-phellandrene, beta-bisabolene and d-
limonene are ca. 4.7, 7.1 or 4.6, respectively) it may be assumed that all of the substances in this 
group will be absorbed to some degree, although the extent of absorption for individual substances 
cannot be accurately estimated from these physico-chemical properties. For the substances in 
subgroup III with conjugated double bonds no data are available, but based on the structural 
similarity with the other substances in subgroup III, it may be anticipated that at the substances will 
also be absorbed. 
No data are available on the absorption, distribution of elimination of any candidate or supporting 
substance in subgroup IVa (benzene hydrocarbons). There are several data on the candidate 
substances in subgroup IVb (naphthalene hydrocarbons). The data show that naphthalene [FL-no: 
01.053] will be absorbed after oral administration and will be eliminated predominantly via the 
urine, in the form of various metabolites, conjugated with e.g. glucuronic acid or with glutathione. 
In bile duct cannulated animals, considerable elimination into the bile was also observed, but as in 
intact animals urinary elimination exceeds by far faecal excretion, the material eliminated via the 
bile is reabsorbed. The glucuronide conjugate of 1-naphthol represents a significant urinary 
metabolite of naphthalene. Glutathione conjugates of naphthalene are catabolised to 
(pre)mercapturic and mercapturic acids, particularly in rodents, before excretion in bile or urine. In 
primates and humans, conjugation with glutathione seems to be less important. Less data are 
available for 2-methylnaphthalene [FL-no: 01.051], but the available data show that 2-
methylnaphthalene is also absorbed from the gastrointestinal tract and eliminated predominantly via 
the urine. For both substances the data indicate that 85–89 % of the dose is excreted within three 
days after dosing. With respect to the one candidate substance (diphenylmethane [FL-no: 01.036]) 
in subgroup IVc, it may be concluded that the metabolites of this substance will be eliminated from 
the body after intraperitoneal injection. No conclusions can be made on absorption from the 
gastrointestinal tract and the rate of elimination as any oral ADME studies and mass-balance data 
are available. 
For the substances in subgroup V (bi- and tricyclic non-aromatic hydrocarbons), the available data 
from oral studies are few. These studies have only addressed the excretion of some supporting and 
one candidate substance (longifolene) in the form of metabolites via the urine. No mass-balance 
data were provided. So these studies only show that these substances will be absorbed to some 
extent. The same may be anticipated for the (other) candidate substances in this subgroup. For the 
supporting substances alpha- and beta-pinene and delta-carene information on kinetics is available 
from humans exposed via inhalation, in occupational settings. These studies show that these 
substances can be absorbed after inhalation exposure and that metabolites will be excreted into the 
urine e.g. as glucuronide conjugates. The elimination follows a triphasic pattern with rather long 
terminal half-lives. The absorbed amount will be eliminated within several days. Based on the 
lipophilic character of these substances it may be anticipated that they will preferentially distribute 
in the adipose tissues, which is supported by the slow terminal elimination rates. 
No data were submitted on candidate or supporting substances in subgroup VI (macrocyclic non-
aromatic hydrocarbons). The two substances in this group have a molecular weight of ~ 204. They 
are also rather lipophilic (estimated log Kow are 4.6 and 7.0 for [FL-no: 01.042] and [FL-no: 
01.043], respectively). Based on these data it may be assumed that these two candidate substances 
will be absorbed from the gastrointestinal tract. For humulatriene, given the rather high Kow, the 
extent of absorption may be relatively low.  
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III.4 Metabolism  
Acyclic Alkanes (Candidate and Structurally Related Supporting Substances from Subgroup 
I)  
Oral 
Male and female rats were given a dose of 1400 mg n-octane/kg bw by gavage and urine was 
collected for up to 48 hours. Urine samples were treated with glucuronidase/sulphatase and the 
liberated metabolites were analysed by gas chromatography. Compounds found in urine were 2-
octanol, 3-octanol, 5-oxohexanoic acid and 6-oxoheptanoic acid. In female rats 2-octanol was found 
to be the major urinary metabolite and 5-oxohexanoic acid was the major metabolite in males. The 
authors state that in contrast to n-hexane and n-heptane, n-octane was not metabolised to a ketone, 
diketone or a diol derivative. The structures of the keto acids that were produced indicate that 
metabolic oxidation is occurring on both ends of the n-octane molecule. A former metabolism study 
of n-heptane did yield gamma-valerolactone, which was presumed to have formed on the GC 
column from 4-hydroxy-1-pentanoic acid, which would involve a 2 carbon loss. The authors 
speculate that with n-heptane, n-octane and perhaps higher straight chain hydrocarbon homologues, 
a major metabolic pathway involves the formation of acids with loss of carbon (Olson et al., 1986). 
The metabolism of n-nonane has been studied in rats after oral administration of 800 mg/kg bw over 
a 48 hours excretion period. In the urine the following metabolites were detected: 2-, 3- and 4-
nonanol, 4-nonanone, 2,5-hexanedione, gamma-valerolactone, delta-hexanolactone and delta-
heptanolactone and 5-methyl-2-(3-oxobutyl)furane. The authors also reported the formation of 1-
heptanol, but no explanation for this metabolite is available. Keto-acids, as observed with n-octane 
could not be detected after administration on n-nonane (Serve et al., 1995). 
Other Routes of Exposure 
Rats were exposed to n-heptane in a concentration of 8100 mg/m3 in the air for six hours/day five 
days/week for 12 weeks. After exposure the animals were kept in a metabolism cage to collect urine 
samples during the next 18 hours for the first week of the experiment and subsequently at the end of 
every five-day exposure period. Primary metabolites of n-heptane in the urine were 1-, 2-, 3,- and 4-
heptanol, of which the 2- and to a lesser extent the 3-isomer were quantitatively the most important. 
Subsequent oxidations of these two secondary alcohols provided 2- and 3-heptanone and the diols 
2,6- and 2,5-heptanediol. In follow-up oxidations, final products were 5-hydroxy-2-heptanone, 6-
hydroxy-2-heptanone, 2,6-and 2,5-heptanedione and 6-hydroxy-3-heptanone, which was de-
acetylated to yield 4-hydroxy-pentanoic acid. This metabolite was detected in the urine as gamma-
valerolactone. The alcoholic metabolites were rapidly excreted as sulphate and glucuronide 
conjugates. Although 2,5-heptanedione is a gamma-diketone, no signs of peripheral neuropathy 
were observed. The authors speculated that the plasma levels of this ketone did not become high 
enough to trigger this effect, because of the rapid conjugation of the precursor alcohols which was 
supported by the minute amounts in which they were present in the urine, although their 
(conjugated) precursors reached much higher concentrations (Bahima et al., 1984). 
In Sprague-Dawley rats exposed to vapours (7680 mg/m3) of n-heptane for six hours, main urinary 
metabolites were 2- and 3-heptanol. Other metabolites detected were 2- and 3- heptanone, 4-
heptanol, 2,5-heptanedione, gamma-valerolactone, 2,6-dimethyl-2,3-dihydropyrane and 2-ethyl-5-
methyl-2,3,-dihydrofurane. In humans, occupationally exposed to n-heptane (5-196 mg/m3) in the 
urine 2- and 3-heptanol were found. Other metabolites detected were 2- and 4-heptanone and 2,5-
heptanedione. In human urinary samples no ring-closure products could be detected, but it is noted 
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that the human exposure was less than that of the rats. In rat tissues (blood, muscle, kidney, nervous 
tissue, liver), levels of 2-heptanol were between 0.2 and 2 mg/l. Levels of n-heptane in the same 
tissues were around 20 mg/l (Perbellini et al., 1986).  
After oral administration of n-octane (1400 mg/kg bw) to rats in the urine the following metabolites 
could be detected within 48 hours after dosing: 2- and 3-octanol and 5-keto-hexanoic and 6-keto-
heptanoic acid. In contrast to heptane, n-octane was not converted into mono- or diketones or into 
diols (Olson et al., 1986). Based on this study and the data for n-heptane, the authors argued that for 
n-heptane and higher straight-chain alkanes, formation of carboxylic acids and subsequent loss of 
carbon may be a major metabolic pathway. However, the quantitative contribution of de-
carboxylation was not thoroughly studied (e.g. no studies with radioactive material) and no mass 
balances were provided. It has been proposed that n-octane is also converted into 1-octanol and 
further into octanoic acid, but no detailed information on these studies was submitted (Low et al., 
1987).  
Groups of three or six rats (Sprague-Dawley, 300-600g), groups of two male rabbits (New Zealand, 
1600-2000g) and one male monkey (Maccaca mulatta, 1600-2000 g) were subjected to single 
inhalatory treatments of 6, 12 and 24 hours to 5000 ppm (~ 18 000 mg/m3) n-hexane. After 
treatment animals were kept in metabolic cages for the following 72 hours. Urine from treated and 
control animals were collected during treatment and at various intervals thereafter. For rats blood 
was collected during and after treatment. Urine samples were subjected to enzymatic and then acid 
hydrolysis and analysed by gas chromatography. In urine of rats 2-hexanol, 3-hexanol, 2,5-
dimethylfurane, gamma-valerolactone and 2,5-hexanedione, along with methyl n-butylketone, were 
found. The metabolites detected in urine from rabbit and monkey were 2-hexanol, 3-hexanol, 
methyl n-butylketone and 2,5-hexanedione. 1-hexanol and 2,5-hexanediol were not detectable in 
any of the species. In rats peaks of 2,5-hexanedione and 2,5-dimethylfurane in urine were preceded 
by analogous peaks in blood, while blood concentrations of n-hexane; methyl n-butylketone and 2-
hexanol peaked immediately after termination of exposure (Perbellini et al., 1982). 
Male rats were exposed to n-hexane by inhalation at concentrations ranging from approximately 
180 to approximately 11000 mg/m3 for 8 hours in an all-glass exposure system. Urinary kinetics for 
the metabolites 1-hexanol, 2-hexanol, 3-hexanol, 2 hexanone, 2,5-hexanedione and 4,5-dihydroxy-
2-hexanone were assessed. Urine samples were collected up to 48 hours following the start of 
exposure. Amounts of metabolites were linearly dependent on the exposure concentrations, up to an 
exposure of about 1070 mg/m3. Above this the metabolite excretion indicated saturation kinetics in 
the metabolism. 2-Hexanol amounted to about twice the excretion of all other metabolites excreted. 
In quantity 4,5-dihydroxy-2-hexanone was the second metabolite, the amount in urine being about 
ten times higher than that of excreted 2,5-hexanedione. 2-Hexanol and 4,5-dihydroxy-2-hexanone 
accounted for 90 % of the total excretion (Fedtke & Bolt, 1987). 
A male volunteer was exposed to a mean n-hexane atmosphere of 217 ppm (~ 800 mg/m3) for 4 
hours. The occurrence of 4,5-dihydroxy-2-hexanone as a metabolite in urine of the man was 
confirmed. Twenty-six hours after exposure the excretion of 4,5-dihydroxy-2-hexanone reached a 
level that was four times higher than the excretion of 2,5-hexanedione. The authors conclude that 
formation of 4,5-dihydroxy-2-hexanone may be viewed as a route of detoxification, and also state 
that it is clear that 4,5-dihydroxy-2-hexanone is responsible for an artificial appearance of 2,5-
hexanedione after drastic acid treatment of human urine, presumably via 2,5-dimethylfuran as 
intermediate (Fedtke & Bolt, 1987). 
Groups of three or four male F344 rats were exposed to [4-14C]-labelled iso-octane (2,2,4-trimethyl 
pentane) and [1-14C]-octane vapours at approximately 1 and 350 ppm (~ 4.76 or 1700 mg/m3 for 
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both substances) for two hours. During the experiment exhalant was drawn through a bubbler train 
for sampling. Urine and faeces were collected at the same times, except that none were collected at 
one or two hours. Exhalation of 14CO2 appeared to be much more important for n-octane than for 
iso-octane, from which a larger part of the radioactivity is eliminated via urine. Based on this 
observation and on a discussion of papers from other research groups, the study authors suggest that 
for straight-chain hydrocarbons, breakdown of the carbon skeleton with the release of CO2 is an 
important metabolic pathway. The route of excretion for n-octane in this study was markedly 
affected by the concentrations of the inhaled vapour. The ratio of 14CO2: 14C in urine was 5:1 after 
inhalation at 1 ppm but 1:1 after inhalation of 350 ppm (Dahl, 1989). The radioactivity eliminated 
via the urine was not identified.  
Hexane was given to rats via subcutaneous injections during three consecutive days. Urinary 
metabolites were various hexanols, 5-hydroxy-2-hexanone, 4,5-dihydroxy-2-hexanone, 2,5-
hexanedione, 2-hexanone and the ring closure products gamma-valerolactone and 2,5-
dimethylfurane. It was noted that most of the alcoholic metabolites were excreted as conjugates (in 
particular glucuronide) (Manini et al., 1999). Such conjugation has also been reported in the other 
alkane biotransformation studies discussed in this Annex. The study authors (Manini et al., 1999) 
further demonstrated that the cyclization products (i.e. the lactones and furans) may be formed 
under the acidic conditions during deconjugation procedures for sample treatment. 
Conclusions on the metabolism of subgroup I substances 
The substances in subgroup 1 can be expected to be metabolised through omega-oxidation, which 
will lead to the formation of alcohols, and after oxidation to carboxylic acids, which may be further 
oxidised via beta-oxidation to yield carbon dioxide. Extensive mass balance data are not available, 
but in some of the studies described above some excretion of carboxylic acids and carbon dioxide 
has been reported. Formation of keto-acids has also been reported, and these may be formed from 
omega-oxidation at one end of the molecule and omega-1 or -2 oxidation at the other end. More 
interest has been put in the identification of metabolites which did not undergo substantial chain 
shortening. These metabolites will arise from oxidation of the non-terminal carbon atoms, e.g. via 
omega-1, -2, -3 or even -4 oxidations. The resulting secondary alcohols can be conjugated with e.g. 
glucuronic acid and excreted via the urine, or can be further oxidised to yield ketones. A subsequent 
introduction of another secondary hydroxyl group may result in the formation of diketones. With n-
hexane the resulting 2,5-hexanedione (a gamma-diketone) has been demonstrated to be responsible 
for hexane-induced neurotoxicity. Neurotoxicity is a common feature of gamma-diketones, and for 
that reason, the candidate substance 3-methylhexane [FL-no: 01.050] cannot be anticipated to be 
metabolised into innocuous compounds. In addition, it is known that methyl-branching of the 
carbon chain potentiates the neurotoxicity of the gamma-diketone (Topping et al., 1994; EFSA, 
2004e). The two other hexane derivatives in this group [FL-no: 01.033 and 01.034] cannot be 
oxidised to gamma-diketone, due to the presence of methyl groups on the C2 and C5 carbon atoms. 
Therefore, these substances may be metabolised to innocuous metabolites. For the longer chain 
alkanes in this group, it would require oxidation of the more central carbon atoms in order to be 
converted into gamma-diketones. Such oxidations are less favourable than omega, omega-1 or -2 
oxidations, and therefore it is concluded that oxidation of these higher alkanes will not result in 
toxicologically relevant levels of gamma-diketones, also because of rapid conjugation of the 
precursor alcohols. For heptane it was shown that this is substance does not result in neurotoxicity 
(Bahima et al., 1984), although the gamma-diketone itself (2,5-heptanedione) is known to be 
neurotoxic (Topping et al., 1994). The remaining three candidate flavouring substances in this 
group [FL-no: 01.038, 01.054 and 01.057] can be expected to be metabolised to innocuous 
products. 
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Acyclic Alkenes (Candidate and Structurally Related Supporting Substances from Subgroup 
II) 
For the substances in this group, information is only available on the biotransformation of beta-
myrcene ([FL-no: 01.008]; a supporting substance) and candidate substance 2-methylbuta-1,3-diene 
[FL-no: 01.049]. Some additional information on the related industrial chemical 1,3-butadiene has 
also been added. One of the substances in this group (dodec-1-ene; [FL-no: 01.037]) bears a 
terminal double bond without any other structural features (e.g. hydroxyl groups, methyl 
substituents). No further data for this or similar substances are available. The metabolic aspects of 
terminal double bond substances have been discussed in FGE.07 and FGE.18 (EFSA, 2004e; EFSA, 
2006b). The relevant parts of these FGEs will also be included in the current discussion. 
Beta-Myrcene [FL-no: 01.008] 
In the urine of rabbits, orally administered beta-myrcene via gavage (670 mg/kg bw/d for two days), 
25 % of the total amount administered could be recovered from the urine within three days post-
dosing, and > 80 % of the myrcene-derived substances were neutral metabolites; the rest were 
acidic substances. The main metabolites identified were myrcene-3,10-glycol, myrcene-1,2-glycol 
and uroterpenol (as acetate) (40.7, 20.8 and 11.8 %, respectively, of the neutral metabolites). 
Additionally, the glycols underwent further oxidation to yield 2-hydroxymyrcene-1-carboxylic acid 
and 3-hydroxymyrcene-10-carboxylic acid (no quantitative data were given for these acidic 
metabolites). The authors suggested that uroterpenol (or limonene-8,9-diol) may have been formed 
from limonene, which is derived from cyclization of myrcene in the acidic conditions of the rabbit 
stomach (Ishida et al., 1981). A graphic representation of beta-myrcene metabolites has been 
presented in Figure III.1. 
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Figure III.1. Metabolism of beta-myrcene in rats and rabbits. 
When rats were administered 800 mg/kg bw per day of beta-myrcene orally via gavage for 20 days, 
the principal metabolites isolated from the urine were 10-hydroxylinalool (or myrcene-3,10-glycol) 
and, to a lesser extent, 7-methyl-3-methylene-oct-6-ene-1,2-diol (or myrcene-1,2-glycol). Other 
minor metabolites included the hydroxy- acids of both the 3,10- and 1,2-glycols (10-carboxylinalool 
(or 3-hydroxymyrcene-10-carboxylic acid) and 2-hydroxy-7-methyl-3-methylene-oct-6-enoic acid 
(or 2-hydroxymyrcene-1-carboxylic acid), respectively) and a cyclic diol, 1-hydroxymethyl-4-
isopropenylcyclohexanol (or p-menth-8-ene-1,7-diol), formed by intramolecular cyclization of an 
open chain metabolite (Madyastha & Srivatsan, 1987). It was demonstrated that the 
biotransformation of beta-myrcene was cytochrome P450 (CYP)-mediated and that it could be 
enhanced by pretreatment of animals with phenobarbital (Madyastha & Srivatsan, 1987). 
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Aside from being a substrate for CYP enzymes, myrcene has also been shown to induce these 
enzymes at high dose levels (1000 mg/kg bw/d orally for three days), especially those from the 
CYP2B (phenobarbital-inducible) subfamily (De-Oliveira et al., 1997a). At lower dose levels (40 
mg/kg bw/d; intraperitoneally for three days) such induction was not observed (Austin et al., 1988). 
2-Methylbuta-1,3-diene [FL- no: 01.049] 
In a sequence of inhalation exposure studies in which rats and mice were exposed to 2-methylbuta-
1,3-diene in the air in concentration of 13-11 000 mg/m3, the metabolism of isoprene became 
saturated at a level of ca. 700 mg/m3 in the rat and ca. 840 mg/m3 in the mouse. Maximal rates of 
metabolism were 130 micromol/kg bw/h in the rat and 400 micromol/kg bw/h in the mouse. It was 
demonstrated that 2-methylbuta-1,3-diene is also produced endogenously at rates of 1.9 
micromol/(h × kg) in rats and 0.4 micromol/(h × kg) in mice. Part of the endogenous 2-methylbuta-
1,3-diene is exhaled by animals, but it is metabolised extensively. The rate of metabolism of 
endogenously produced and systemically available 2-methylbuta-1,3-diene is 1.6 micromol/(h × kg) 
in rats and 0.3 micromol/(h × kg) in mice, respectively (Peter et al., 1987). The authors quoted 
literature demonstrating that 2-methylbuta-1,3-diene is also endogenously produced in humans 
(Gelmont et al. (1981) as cited in Peter et al., 1987).  
Liver microsomes from mice, rats, rabbits and hamsters metabolise 2-methylbuta-1,3-diene to the 
corresponding monoepoxides, 1,2-epoxy-2-methyl-3-butene (major) and 3,4-epoxy-2-methyl-1-
butene (minor). Both monoepoxides are hydrolysed to their respective diols (for chemical 
structures, see Figure III.2). The main metabolite of 2-methylbuta-1,3-diene (i.e. 1,2-epoxy-2-
methyl-3-butene) exhibited a half-life of 75 minutes in aqueous environments; whereas the minor 
metabolite, 3,4-epoxy-2-methyl-1-butene (14 – 25% with respect to the main metabolite) is more 
stable (half-life not specified). The kinetic constants for the formation of the major epoxide 
metabolite (trans-2-methyl-3-butene-1,2-diol) of 2- methylbuta-1,3-diene were determined in the 
four test species as apparent Km = 0.06 – 0.2 mM and Vmax = 0.24 – 1.79 nmol trans-2-methyl-3-
butene-1,2-diol/mg protein × min. The minor metabolite, 3,4-epoxy-2-methyl-1-butene, was further 
epoxidised to the diepoxide, 2-methyl- 1,2:3,4-diepoxybutane, by microsomes of all rodents 
studied. The authors argued that the latter diepoxide metabolite could be responsible for the 
genotoxic and carcinogenic activity of 2-methylbuta-1,3-diene, as the two mono-epoxies were not 
reported to be genotoxic (Del Monte et al., 1985; Longo et al., 1985).  
The in vitro metabolism of 2-methylbuta-1,3-diene was investigated in rat, mouse and human liver 
microsomes and in microsomes derived from cell lines expressing eight different human 
cytochrome P-450 enzymes. Human CYP2E1 showed the highest rates for formation of the 
monoepoxides, 1,2-epoxy-2-methyl-3-butene and 3,4-epoxy-2-methyl-1-butene, and CYP2B6 
showed the second highest rate. Only CYP2E1 catalysed formation of the diepoxide, 2-methyl-
1,2:3,4-diepoxybutane. With human liver microsomes in the presence of an epoxide hydrolase 
inhibitor, the formation of 1,2-epoxy-2-methyl-3-butene was four times faster than the formation of 
the 3,4-epoxy-2-methyl-1-butene, which is comparable to the results in rats and mice obtained by 
others (e.g. Del Monte et al., 1985; Longo et al., 1985). The rates of monoepoxide formation from 
isoprene and diepoxide formation from either monoepoxide intermediate were strongly correlated 
with the microsomal activity of CYP2E1, rather than with the activities of the other CYP enzymes, 
and both monoepoxides were equally good substrates for the formation of the diepoxide.  
Also, species differences with regard to the role of epoxide hydrolase were investigated by 
comparing the epoxidation of 2-methylbuta-1,3-diene by rat, mouse and human liver microsomes. 
When an epoxide hydrolase inhibitor was used, similar rates of monoepoxide formation in mouse, 
rat and human liver microsome systems were measured. However, without epoxide hydrolase 
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inhibition, the total amount of 3,4-epoxy-3-methyl-1-butene measured at the end of the incubation 
period was twice as high for mouse as for rat liver microsomes and 30 times as high for mouse as 
for human liver microsomes in which formation of this epoxide was reduced to 4 % of the rate in 
presence of the inhibitor. For the 3,4-epoxy 2-methyl-1-butene metabolite the effect of epoxide 
hydrolase inhibition was less dramatic. While hardly any effect was observed in mouse or rat 
microsomes, in the human microsomes the rate was reduced to approximately 25 %. The effect of 
epoxide inhibition on the rate of formation of the diepoxide was not studied. The authors concluded 
that differences in epoxide hydrolase activity between species may be of crucial importance for the 
toxicity of 2-methylbuta-1,3-diene in various species (Bogaards et al., 1996).  
Following intraperitoneal injection of 64 mg [4-14C]-2-methylbuta-1,3-diene/kg to F344 rats, the 
parent compound was excreted unchanged in the breath (> 50 % of the dose together with < 4 % 
unidentified material) or via the urine in the form of metabolites (≈ 32 %) over the 24-hour 
collection period. Only 1.7 % was expired as CO2 and 0.2 % was eliminated via faeces. 3 % 
remained in the carcass. In the urine 2-methylbuta-1,3-diene was excreted primarily as 2-hydroxy-
2-methyl-3-butenoic acid (53 % of total urinary metabolites excreted), 2-methyl-3-buten-1,2-diol 
(23 %), and the C-1 glucuronide conjugate of 2-methyl-3-buten-1,2-diol (13 %). A fraction of 7 % 
of the radioactivity in the urine was (an) unidentified polar material. The principal urinary acidic 
metabolite forms via oxidation of the corresponding 1,2-diol. These metabolites indicate a 
preferential epoxidation of the methyl-substituted vinyl group of 2-methylbuta-1,3-diene (see 
Figure III.2) in the rat (Buckley et al., 1999).  
Following intraperitoneal injection of 64 mg [4-14C]-2-methylbuta-1,3-diene /kg to B6C3F1 mice, 
the parent compound was excreted unchanged in the breath (≈ 44 % of the dose and < 3 % 
unidentified material) or as urinary metabolites (≈ 33 %) over the 24-hour collection period. Only 
1.9 % was expired as CO2 and 7 % was eliminated via faeces. 2 % remained in the carcass. In 
comparison with rat urine (see above), the urine of the mice contained several other metabolites, 
including an unidentified polar fraction which comprised 25 % of the total urinary radioactivity as 
compared to 7 % in rat urine. The major identified metabolite in mouse urine, 2-hydroxy-2-methyl-
3-butenoic acid, accounted for ≈ 15 % of the total urinary radioactivity, whereas 2-methyl-3-buten-
1,2-diol and its glucuronide conjugate accounted for ≈ 3.5 and 2.5 %, respectively (Buckley et al., 
1999). The authors speculated that the unidentified metabolite in the urine of rats and mice could be 
related to glutathione conjugates. They concluded that if this were the case, in rats glutathione 
conjugation of 2-methylbuta-1,3-diene is less important than in mice.  
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Figure III.2. Major metabolic pathways for 2-methylbuta-1,3-diene (after Del Monte et al. (1985) and Buckley et al. 
(1999)). 
 
Special features of terminal double bond oxidation 
Double bonds are usually oxidised by P450 to the corresponding epoxides, which are highly 
reactive molecules. Due to the large strain associated with the three membered ring structure 
epoxides easily react with nucleophilic sites of cellular macromolecules; conversely they are readily 
detoxified either spontaneously or by the action of epoxide hydrolase to diols or conjugated with 
reduced glutathione by glutathione-S-transferases. 1-Alkenes are metabolised by cytochrome P450, 
through double bond oxidation to the corresponding epoxide or alternatively allylic oxidation 
(Chiappe et al., 1998). The rates of the two reactions measured with different cytochrome P450 
isoforms indicate that epoxide formation is generally favoured (Chiappe et al., 1998) and this may 
also apply in particular to the candidate substance dodec-1-ene [FL-no: 01.037]. 
Based on this information and the data available for beta-myrcene and 2-methylbuta-1,3-diene, it 
cannot be excluded that the candidate substances with these terminal double bonds [FL-no: 01.037 
and 01.064] may be metabolised to epoxides.  
Conclusions on the metabolism of subgroup II substances 
The data available on the metabolism of one supporting and one candidate substance in subgroup II 
show that metabolic options for the substances in this group are epoxidation of double bonds 
ultimately resulting in diols, which can be further conjugated. With the supporting substance beta-
myrcene also further metabolism of the diols into carboxylic acids has been reported. Both in rats 
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and rabbits, the principal urinary metabolite following gavage administration of beta-myrcene is 
myrcene-3,10-glycol, formed from the hydration of the epoxide intermediate in both species. 
Epoxidation of the 3,10-double bond was favoured over epoxidation of the 1,2-double bond. 
The studies indicate that the formation of diols from the myrcene-epoxides is very efficient. It is 
noted, however, that the diols and the related carboxylic acids are all the result of epoxidation of 
double bonds in which one of the carbon atoms has only hydrogen substituents, but no further 
carbon chains. In this respect, the candidate substance cis-3,7-dimethyl-1,3,6-octatriene [FL-no: 
01.064] is most similar to beta-myrcene. With beta-myrcene no diepoxide metabolites or further 
reaction products thereof have been reported, but it is noted that mass balance data are incomplete, 
so some metabolites may have been overlooked. 
With the candidate substance 2-methyl-buta-1,3-diene, epoxidation of the 1,2-double bond is 
favoured over epoxidation of the 3,4-double bond. While the 1,2-epoxide is readily hydrolysed, the 
3,4-epoxide is far more stable. Both metabolites can be converted to the corresponding diols and at 
least one hydroxy-carboxylic acid (2-hydroxy-2-methyl-3-butenoic acid) has been identified. In 
addition, in particular the 3,4-epoxide metabolite can be oxidised a second time, resulting in the 
formation of a diepoxide metabolite, which is known to be reactive and has been suggested to be 
responsible for 2-methylbuta-1,3-diene-induced DNA damage. For candidate substance dodec-1-
ene [FL-no: 01.037], diol- and alpha-hydroxy-carboxylic acid formation may also be expected. In 
addition, this substance may also undergo omega and omega-1 or -2 oxidation at the other 
(saturated) end of the carbon chain (similar to the candidate substances in subgroup I). 
Apart from beta-myrcene and 2-methylbuta-1,3-diene, terminal double bonds appear also in 
candidate substances [FL-no: 01.037 and 01.064]. In contrast to corresponding substances in 
FGE.07 and FGE.18 there is no other functional group in the molecule (e.g. hydroxyl- or keto-
group) that could provide a more direct option for detoxication e.g. via conjugation with 
glucuronide or sulphate. In the two FGEs mentioned above, the presence of such groups was an 
argument to consider that the metabolism of the particular candidate substances would go via 
innocuous products. It would not be possible to conclude similarly for the candidate substances in 
FGE.25. The other candidate substances in this subgroup (II) might also be oxidised in the various 
methyl groups but no data are available to substantiate this. Because of these considerations, it 
cannot be concluded that the candidate substances in this subgroup [FL-no: 01.032, 01.035, 01.037, 
01.049 and 01.064] will be metabolised to innocuous products.  
Cyclohexene derivatives (Candidate and structurally related supporting substances from 
subgroup III) 
For the candidate substances in this group, data for one supporting substance (d-limonene; [FL-no: 
01.045]) were submitted.  
More than 10 metabolites were found in the urine of rats given an oral gavage dose of 800 mg/kg 
bw d-limonene (or p-mentha-1,8-diene). Four of the metabolites were identified as perillic acid, p-
menth-1-ene-8,9-diol (= limonene-8,9-diol), perillic acid-8,9-diol and 8-hydroxy-p-menth-1-en-9-
yl-glucuronic acid. The bile of these rats contained three metabolites, the most important of which 
was 8-hydroxy-p-menth-1-en-9-yl-beta-D-glucuronic acid (Igimi et al., 1974). Six metabolites were 
identified in the urine of rabbits given the same oral dose. In addition to the four metabolites 
identified in rat urine, the rabbit urine contained p-mentha-1,8-dien-10-ol (= limonene-10-ol) and p-
mentha-1,8-dien-10-yl-glucuronic acid (= p-mentha-1,8-dien-10-ol-glucuronide). Although not 
determined quantitatively, perillic acid, perillic acid-8,9-diol and both glucuronic acid conjugates 
were the major metabolites in rabbit urine, and no unchanged d-limonene was detected (Kodama et 
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al., 1974). The same authors identified five additional metabolites in the urine of rats and dogs 
treated orally with d-limonene. These were characterised as 2-hydroxy-p-menth-8-en-7-oic acid, 
perillylglycine, perillyl-glucuronide, p-mentha-1,8-dien-6-ol (or limonene-6-ol), and p-menth-1-
ene-6,8,9-triol. They also found some species differences in the nature of the major metabolites in 
urine. Perillic acid-8,9-diol was the main metabolite in rats and rabbits, perillyl-glucuronide in 
hamsters, limonene-8,9-diol in dogs, and limonene-8,9-diol-glucuronide in guinea pigs and humans. 
It should be noted that the fate of only 40-65 % of the d-limonene dose administered orally to these 
animals and humans was accounted for (Kodama et al., 1976). The metabolites of d-limonene are 
shown in Figure III.3. 
Perillic acid, dihydroperillic acid, and limonene-1,2-diol were the major metabolites identified in 
the plasma of humans given an oral dose of d-limonene. Minor metabolites were the methyl esters 
of perillic acid and dihydroperillic acid, and d-limonene itself (Crowell et al., 1994a). Apart from 
the parent compound, Poon et al. (1996) and Vigushin et al. (1998) also identified perillic acid, 
dihydroperillic acid and limonene-1,2-diol as major metabolites in human plasma. However, they 
also found two other metabolites, i.e. p-mentha-1,8-diene-10-carboxylic acid and limonene-8,9-diol, 
whereas they did not detect the methyl esters of perillic acid and dihydroperillic acid. Peak plasma 
levels for all metabolites were achieved 4-6 hours after administration, with the exception of 
limonene-8,9-diol, which reached its peak level one hour after administration (Poon et al., 1996). 
Metabolites in human urine comprised the glucuronic acid conjugates of perillic acid, 
dihydroperillic acid, p-mentha-1,8-diene-10-carboxylic acid, limonene-8,9-diol and limonene-10-ol 
(Poon et al., 1996).  
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M-I limonene-10-ol M-IX glucuronide conjugate of M-III 
M-II limonene-8,9-diol M-X limonene-6-ol 
M-III perillic acid M-XI p-menth-1-ene-6,8,9-triol 
M-IV perillic acid-8,9-diol M-XII dihydroperillic acid 
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M-V glucuronide conjugate of M-I M-XIII limonene-1,2-diol 
M-VI glucuronide conjugate of M-II M-XIV p-mentha-1,8-diene-10-carboxylic acid 
M-VII 2-hydroxy-p-menth-8-en-7-oic acid M-XV glucuronide conjugate of M-XII 
M-VIII perillylglycine M-XVI glucuronide conjugate of M-XIV 
Figure III.3. Metabolism of d-limonene.  
 
Experiments with rat liver microsomes have shown that epoxidation of the C8 double bond (in the 
vinyl substituent) of d-limonene is favoured over epoxidation of the C1-double bond (the one in the 
ring), due to steric hindrance by the 1-methyl group, which was demonstrated by comparison of the 
metabolism of d-limonene with that of 4-vinylcyclohex-1-ene. Upon incubation with rat liver 
microsomes, the majority of d-limonene was converted to the 8,9-epoxide and the 8,9-diol, and to a 
much lesser extent to the 1,2-epoxide and the 1,2-diol (ratio of 8,9- vs.1,2-epoxidation = 4:1). In 
contrast, with 4-vinylcyclohex-1-ene the epoxidation rate of the ring double bond was about four 
times as fast as the epoxidation rate of the vinyl double bond. Because the 1,2-epoxide of d-
limonene is a very poor substrate for microsomal epoxide hydrolase, the 1,2-diol could not be found 
in microsomal incubates, whereas the 8,9-diol could be found (Watabe et al., 1981). Both epoxides 
of d-limonene were tested for mutagenicity in several Salmonella strains and showed to be inactive. 
The mono-epoxides of 4-vinylcyclohex-1-ene were inactive in Salmonella strain TA100, but were 
not tested in the other strains. However, the diepoxide of 4-vinylcyclohex-1-ene was mutagenic in 
this bacterial strain, but this diepoxide was not detected in the microsomal metabolism studies with 
4-vinylcyclohex-1-ene as starting material (Watabe et al., 1981). 
Other in vitro experiments have shown that male rats can convert d-limonene into perillyl alcohol 
(by hydroxylation of the methyl group at C7) and carveol (or limonene-6-ol; by ring C6-
hydroxylation). These reactions are catalysed by CYP2C11 and, when pretreated with 
phenobarbital, CYP2B1. In female rats, the activity for conversion to either alcohol is much lower. 
Apparently, the female-specific CYP2C12 has no activity with respect to d-limonene hydroxylation. 
In males, the hydroxylation activities were not detectable with foetal liver microsomes, but they 
increased after birth, closely related to the developmental increase in CYP2C11 (Miyazawa et al., 
2002). 
In male rats orally administered 3 mmol/kg (408 mg/kg) of [14C]-d-limonene radioactivity was 
detected in the renal cytosol. Forty percent of the total cytosolic radioactivity was reversibly 
associated with the protein fraction and further analysis showed that > 97 % of this activity was 
associated with one single protein, which was identified as α2u-globulin. 1,2-Limonene epoxide, 
1,2-limonene-diol and d-limonene comprised 82, 5 or 13 %, respectively, of the radioactivity 
associated with this protein (Lehman-McKeeman et al., 1989). 
d-Limonene has been shown to induce P450 enzymes of the CYP2B and CYP2C subfamilies and 
epoxide hydrolase in rats (Austin et al., 1988; Maltzman et al., 1991). 
Conclusions on the metabolism of subgroup III substances 
In the subgroup III there are only metabolism data available for one supporting substance, d-
limonene, which in several animal species and humans has been demonstrated to be oxidised in 
both side chains, resulting in alcohols and/or carboxylic acids, which are, at least partly, conjugated 
and eliminated with the urine. It is anticipated that three out of the four candidate substances [FL-
no: 01.027, 01.028 and 01.039] in subgroup III are metabolised in a similar way to innocuous 
products. It cannot be anticipated based on the data available that beta-phellandrene [FL-no: 
01.055] with a double bond directly on the ring and in conjugation with double bond in the 
cyclohexene ring can be metabolised to innocuous products. 
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Aromatic Hydrocarbons (Candidate and Structurally Related Supporting Substances from 
Subgroup IV) 
Subgroup IVa: Benzene Hydrocarbons 
No data are available for the candidate substances in this group. Some information was available on 
the biotransformation of p-cymene ([FL-no: 01.002]; p-isopropyl toluene). Given the structure of 
this substance, which deviates considerably from the candidate substances in this subgroup, the 
information provided was considered to be only of limited relevance for the evaluation of the 
benzene hydrocarbons in this group. In general, the studies indicate that in various animal species p-
cymene undergoes extensive oxidation of the methyl and isopropyl side chain to yield polar 
oxygenated metabolites. These metabolites are either excreted unchanged in the urine or undergo 
phase II conjugation with glucuronic acid and/or glycine, followed by excretion in the urine (Bakke 
& Scheline, 1970; Walde et al., 1983; Matsumoto et al., 1992; Boyle et al., 1999). Only in the 
guinea pig ring hydroxylation products (carvacrol and hydroxycarvacrol) were found in minute 
amounts. Ring hydroxylation in guinea pigs only occurred ortho to the methyl group (Walde et al., 
1983). 
Subgroup IVb: Naphthalene Hydrocarbons 
Naphthalene [FL-no: 01.053 ] 
Metabolism of naphthalene (0.031, 0.062, 0.125, 0.25, 0.50 and 1.0 mM) was studied in lung and 
liver microsomal preparations from Swiss Webster mice, Sprague-Dawley rats, Sprague-Dawley 
hamsters and rhesus macaque monkeys. Naphthalene metabolism to glutathione conjugates and 
diols was 4 to 8-fold higher in mouse lung microsomal incubations than in corresponding 
incubations from hamster and rat lung. Mice lung had a high degree of stereoselectivity in 
metabolism of naphthalene to naphthalene epoxide, where the ratio of 1R,2S- to 1S,2R-naphthalene 
epoxide was 11 to 14:1. Little or no stereoselectivity in the metabolism of naphthalene was found in 
the mouse liver or in the lung and liver from the rat, hamster and monkey. The mouse liver 
metabolises more of the naphthalene to diol than the mouse lung, 12 % and 5 % of the total 
metabolites, respectively. Naphthalene is metabolised in lung tissue microsomal incubations of 
rhesus monkeys at a rate 100-fold less than mice and 10-fold less than rats. Naphthalene is 
metabolised in lung tissue microsomal incubations of rhesus monkeys at a rate 100-fold less than 
mice and 10-fold less than rats. In the primate liver microsomes naphthalene diols comprise 80 % of 
the total metabolites produced (Buckpitt et al., 1992). The olfactory epithelium contained the 
greatest amount of CYP protein of all tissues investigated in the rat. However, CYP2F expression 
levels in primate nasal tissues demonstrate that only the nasal ethmoturbinates contained 
quantifiable amounts of CYP2F with the levels in primates roughly 10- and 20-fold less than the 
corresponding tissues in rats and mice, respectively (Baldwin et al., 2004). Clearly, humans would 
produce less naphthalene-1,2-oxide or produce it at a slower rate than rats or mice in respiratory 
tract tissues. An overview of naphthalene metabolism is presented in Figure III.4. 
Three groups of Sprague-Dawley rats were treated orally with a single administration of 2 mg 14C-
naphthalene. The dose/unit body weight was not stated (Bakke et al., 1985). One group of 16 
animals were bile duct cannulated, the second group of four germ-free animals were uncannulated, 
and the third group of 13 animals were standard uncannulated rats. Urine, faeces and bile were 
collected for 72 hours after administration of naphthalene and the metabolites were identified and 
quantified. In the standard uncannulated rats the urinary metabolites identified at 24 hours were an 
N-acetyl cysteinyl naphthalene conjugate (38.1 % of the administered radioactivity), 1,2-dihydro 
1,2-dihydroxynaphthalene (dihydrodiol) glucuronide (23.9 %), dihydroxynaphthalene (4.9 %), 
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naphthols and naphthol glucuronides (4.6 %) and 1,2-dihydro-1-hydroxy-2-thionaphthalene 
glucuronide [CH3S-metabolite] (4.6 %). At 24 hours in cannulated rats, 14.4 % of the administered 
dose was present in the urine as N-acetyl cysteinyl naphthalene conjugate and 14.5 % as the 
dihydroxynaphthalene glucuronide conjugate. Naphthols, thionaphthols, CH3S-metabolites or their 
respective glucuronides and sulphates were not detected in either the 24-hour urine or bile. The 
major urinary metabolites of germ-free rats were N-acetyl cysteinyl naphthalene (89 %) and 
dihydroxynaphthalene glucuronide (4 %). Only trace amounts of naphthols and no CH3S-
metabolites could be detected indicating that intestinal microflora are probably involved in 
production of these metabolites followed by enterohepatic recirculation. In vitro experiments 
showed that 1,2-dihydroxy-1,2-dihydronaphthalene may be transformed by isolated rat liver 
dihydrodiol dehydrogenase to form the 1,2-naphthoquinone, which reacts rapidly with glutathione 
or cysteine (Smithgall et al., 1986; Smithgall et al., 1988). Naphthalene-1,2-dihydrodiol may be 
oxidised further by CYP enzymes, resulting in an epoxide, 1,2-dihydroxy-3,4-epoxy-1,2,3,4-
tetrahydronaphthalene. Several urinary metabolites, including a number of 
trihydroxytetrahydromethylthio-derivatives (Horning et al., 1980) and 
trihydroxytetrahydromercapturic acid (Pakenham et al., 2002) provide support for the in vivo 
formation of 1,2-dihydroxy-3,4-epoxy-1,2,3,4-tetrahydronaphthalene. Initially, naphthalene 
metabolism involves epoxidation of the aromatic ring by cytochrome (CYP) enzymes yielding 
naphthalene-1,2-oxide. Several studies have shown that a number of CYP isozymes catalyse this 
reaction, including CYP2E1 (Wilson et al., 1996) and CYP2F (Shultz et al., 1999; Buckpitt et al., 
2002).  
Limited information is available regarding the metabolism of naphthalene in humans. Incubation of 
human lung microsomal fractions demonstrated naphthalene metabolism to naphthalene dihydrodiol 
and glutathione conjugates (Buckpitt & Bahnson, 1986). Human and mouse liver microsomes 
exposed to naphthalene produced the 1-naphthol and naphthalene-1,2-dihydrodiol metabolites in the 
ratio 8.6 and 0.4 in human and in phenobarbital-induced mouse microsomes, respectively (Tingle et 
al., 1993). In human liver microsomes naphthalene-1,2-dihydrodiol is formed following epoxidation 
and hydrolysis, whereas rearrangement of the 1,2-epoxide leads to the formation of 1-naphthol 
(Tingle et al., 1993). Preferential formation of the 1S,2R-naphthalene oxide enantiomer in human 
and rat microsomes provides evidence that human metabolism of naphthalene may be more similar 
to rats than mice (Lanza et al., 1999). Naphthalene metabolising enzymes have been demonstrated 
in nasal respiratory epithelial and olfactory epithelial tissue from rodents and humans (Buckpitt et 
al., 1992; Plopper et al., 1992; Thornton-Manning & Dahl, 1997; Buckpitt et al., 2002). 
Waidyanatha et al. (2002) have studied covalent binding of naphthalene metabolites to haemoglobin 
and albumin in vivo. They measured cysteinyl adducts of naphthalene-1,2-oxide and 1,2- and 1,4-
naphthoquinone in rats, 24 hours after dosing them with 100 - 800 mg naphthalene/kg bw. 
Cysteinyl adducts with all three metabolites were produced in a dose-dependent manner. 
Naphthalene-1,2-oxide produced adducts with both proteins and at dose levels > 200 mg/kg bw the 
formation of adducts became saturated. For 1,2-naphthoquinone-albumin adducts were more 
abundant than for 1,4-naphthoquinone. Differences for the haemoglobin adducts were much less 
pronounced. Total naphthoquinone adducts with albumin were also produced in larger amounts than 
with haemoglobin. Naphthoquinone but not naphthalene-1,2-oxide adducts could also be detected in 
albumin and heamoglobin of control animals (Waidyanatha et al., 2002).  
Urine samples were collected from an infant hospitalised because of haemolytic anaemia following 
ingestion of unknown quantities of naphthalene mothballs. 1- and 2-naphthol and 1,2- and 1,4-
naphthoquinone were identified in the samples for up to eight days of hospitalisation. 1-Naphthol 
was present in the largest, unspecified quantities (Mackell et al., 1951, as cited in EU-RAR, 2003).  
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It can be concluded that naphthalene [FL-no: 01.53] is metabolised by cytochrome P450 enzymes, 
yielding naphthalene-1,2-oxide. This epoxide may be metabolised by glutathione S-transferase 
enzymes to a glutathione conjugate that is subsequently converted into a mercapturic acid conjugate 
and excreted in the urine. Naphthalene-1,2-oxide may also rearrange to yield 1- or 2-naphthol, 
which are excreted as glucuronide or sulphate conjugates in the urine. In addition, 1-naphthol may 
be further metabolised by CYP enzymes to 1,2- or 1,4-naphthoquinone, and 2-naphthol may be 
further oxidised to give also 1,2-naphthoquinone. Naphthalene-1,2-oxide may be hydrated by 
epoxide hydrolase, yielding 1,2-dihydroxy-1,2-dihydronaphthalene, which is oxidised by 
dihydrodiol dehydrogenase also to form 1,2-naphthoquinone. CYP enzymes may oxidise 
naphthalene-1,2-dihydrodiol to yield 1,2-dihydroxy-3,4-epoxy-1,2,3,4- tetrahydronaphthalene, 
which can be further metabolised by a number of conjugation pathways. 
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Figure III.4. Pathways for metabolism of naphthalene (adapted from ATSDR, 2005). 
 
2-methylnaphthalene [FL-no: 01.051] 
The oxidative metabolism of 2-methylnaphthalene was investigated using rat liver microsome 
suspensions. One monohydroxylated (2-hydroxymethylnaphthalene) and three isomeric dihydrodiol 
(3,4-dihydrodiol, 5,6-dihydrodiol and 7,8-dihydrodiol) metabolites of 2-methylnaphthalene were 
identified (Breger et al., 1983). Melancon et al. (1985) confirmed that one 2-hydroxymethyl- and 
three isomeric dihydrodiol metabolites of 2-methylnaphthalene are formed in vitro by rat hepatic 
microsomes and purified cytochromes (Melancon et al., 1985).  
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Four female rats were dosed with two subcutaneous injections of 300 mg 2-methyl-[8-14C]-
naphthalene/kg bw and urine was collected for three days. Of the radioactivity injected, 55 % was 
found in the urine and only 3-5 % (ca. 2.2 % of the dose) appeared to be unchanged parent 
compound. Three isomeric dihydrodiol metabolites of 2-methylnaphthalene represented 6-8 % of 
urine 14C (ca. 3.8 % of the dose). More polar metabolites were identified as 2-naphthoic acid and 2-
naphthoylglycine, the latter of which accounted for 30-35 % of urine 14C (ca. 17.5 % of the dose). 
The remainder of the urinary radioactivity was not fully elucidated but 6-8 % were other conjugates 
of naphthoic acid (ca 3.8 % of the dose), and some were identified as hydrolysable with beta-
glucuronidase (not yielding naphthoic acid) (Melancon et al., 1982). 
In guinea pigs, when 10 mg/kg bw 2-[1-3H]-methylnaphthalene was orally administered the major 
metabolites excreted in the urine at 24 h (in total 23 % of the dose) were oxidation products of the 
methyl group (i.e. 2-naphthoic acid (4 %), 2-naphthoylglucuronic acid (11 %), and 2-
naphthoylglycine (61 %)), which accounted for 76 % of the total urinary radioactivity. Dihydrodiols 
could not be detected, but S-(7-methyl-1-naphthyl)cysteine (10 %), and glucuronic acid and 
sulphate conjugates of 7-methyl-1-naphthol (each 4 %) were also identified as minor metabolites 
accounting together for 18 % of the total urinary radioactivity. In incubations of 2-
methylnaphthalene with guinea pig liver S9, formation of S-(7-methyl-1-naphthyl)-glutathione 
could be demonstrated, and 4 hours after oral administration of 500 mg 2-methylnaphthalene/kg bw 
GSH depletion in the liver was observed, but no mercapturic acids could be found in the urine. It 
was speculated that the cysteine conjugate might be an artificial breakdown product of mercapturic 
acid derivatives (Teshima et al., 1983). Other authors have also demonstrated that 2-
methylnaphthalene can deplete liver GSH stores (e.g. Griffin et al., 1982). This depletion has been 
brought into connection with the toxicity of 2-methylnaphthalene (Shelby & Witt, 1995). 
Griffin et al. (1982) have studied the relationship between 2-methylnaphthalene (400 mg/kg bw 
intraperitoneally) -induced lung toxicity and GSH depletion in the lung, liver and kidneys in the 
mouse in relationship to 2-methylnaphthalene covalent tissue binding and metabolic conversion into 
dihydrodiol metabolites, using modifiers of cytochrome P450 activity. Both phenobarbital (PB) and 
3-methylcholanthrene (3MC) reduced lung toxicity of 2-methylnaphthalene, but only PB reduced 
pulmonary covalent binding. In the liver, neither PB nor 3MC had an effect on covalent binding of 
2-methylnaphthalene. In liver microsomes, PB increased formation of dihydrodiols, but it had no 
effect in the lung, whereas 3MC reduced formation of dihydrodiols in lung but not in liver 
microsomes. Piperonyl butoxide decreased covalent binding in the lung, liver and kidney, but did 
not affect lung toxicity. SKF-525A had also no effect on pulmonary necrosis. Diethyl maleate had 
no effect on binding in the liver, but it decreased binding in the lung and kidney. It also did not 
affect the severity of the pulmonary toxicity, but it enhanced the lethality of 2-methylnaphthalene. 
Pretreatment of mice with piperonyl butoxide or diethyl maleate did not affect the hepatic or 
pulmonary microsomal conversion of 2-methylnaphthalene into dihydrodiols. It was also shown 
that 2-methylnaphthalene strongly decrease liver GSH levels, but not GSH levels in the lung or 
kidney. The authors concluded that the pulmonary toxicity of 2-methylnaphthalene may be related 
to metabolism, but that the role of the dihydrodiols or covalent binding as indicators of activity of 
epoxide intermediates in vivo is as yet uncertain (Griffin et al., 1982). 
Subgroup IVc: Diphenylmethane 
The biotransformation of diphenylmethane [FL-no: 01.036] was studied in microsomal fractions 
prepared from rat liver homogenate. It was determined that diphenylmethane is hydroxylated at 
both the aromatic (para-) and aliphatic positions of the molecule. If hydroxylation of the methylene 
group occurs, the resulting diphenylmethanol is further oxidised to diphenylketone (Sípal & 
Zelingerová, 1978). 
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Four male rats were administered 900 mg/kg bw of diphenylmethane via intraperitoneal injection. 
Animals were housed in individual metabolism cages and provided food and water ad libitum. 
Urine and faecal samples were collected after 24 hours and analysed immediately. The urine and 
faecal samples indicated that both free and conjugated forms of p-hydroxydiphenylmethane are 
eliminated with 88 % of the recovered material (in total ca. 6.8 % of the dose) being found in the 
urine (Deloach et al., 1978). The major part of the urinary p-hydroxyphenylmethane was excreted 
as unconjugated material. In a subsequent experiment by the same investigators, six male rats were 
administered 500 mg/kg bw of diphenylmethane via intraperitoneal injection. Animals were housed 
in individual metabolism cages and provided food and water ad libitum. Urine samples were 
collected after 24 hours and analysed immediately. The urine samples indicated that conjugated 
benzhydrol (= diphenyl methanol) is eliminated by rats at 0.6% of the total dose of 
diphenylmethane administered free benzhydrol is not eliminated. The authors indicated that others 
have found that benzhydrol is excreted as glucuronide (Stocklinski et al., 1979). 
 
Conclusions on the metabolism of subgroup IV substances 
No data are available for the two substances in subgroup IVa [FL-no: 01.031 and 01.058]. Based on 
information available on p-cymene, it may be anticipated that these substances may be oxidised at 
the ring-substituent methyl groups (resulting in the formation of hydroxymethyl groups). These 
products may subsequently be excreted after conjugation. Also epoxidation of the 3,4-double bond 
in [FL-no: 01.031] may be expected. Oxidative attack on the aromatic ring seems less likely. 
Nevertheless, due to the lack of experimental data it would be impossible to conclude that these 
substances are metabolised into innocuous products. 
Several data are available on the biotransformation of the naphthalene [FL-no: 01.053] and its 2-
methyl derivative [FL-no: 01.051] in subgroup IVb. With naphthalene, the primary products 
resulting from epoxidation can be further metabolised to naphtoquinones and other metabolites, 
which have been brought into connection with the toxicity of this substance. Whereas epoxidation is 
the main metabolic option for naphthalene, methyl group oxidation is the major metabolic pathway 
in the case of 2-methylnaphthalene. However, also with 2-methylnaphthalene, epoxidation may 
occur to some extent, and 2-methylnaphthalene-induced depletion of glutathione stores, possibly as 
a result of conjugation, has been suggested to be related to epoxidation reactions. However, 
although biotransformation does play a role in the toxicity of 2-methylnaphthalene, the exact 
mechanism of toxicity and the metabolites which are involved have not been clearly identified. 
Hence, neither for naphthalene [FL-no: 01.053] nor for 2-methylnaphthalene [FL-no: 01.051] can it 
be concluded that these are metabolised into innocuous substances. 
For the one candidate substance in subgroup IVc (diphenylmethane [FL-no: 01.036]) only a very 
limited amount of metabolites have been identified in the urine. One of these is an aromatic 
hydroxylation product (i.e. a phenol derivative), which may be generated from epoxidation. 
Because of lack of further data it cannot be concluded that diphenylmethane [FL-no: 01.036] is 
metabolised to innocuous products. 
Bi- and Tricyclic Non-Aromatic Hydrocarbons (Candidate and Structurally Related 
Supporting Substances from Subgroup V) 
Analysis of urinary metabolites eliminated by human volunteers within four hours following a 2-
hour inhalation exposure to 10 – 450 mg (+)-alpha-pinene/m3 in a pharmacokinetic study (Falk et 
al., 1990b) revealed cis- and trans-verbenol in a ratio of 1:10, with 3.8 and 1.7 % being eliminated 
at 10 and 450 mg/m3, respectively. Most of the verbenols were eliminated within 20 hours. In a 
more extensive metabolic study, urine was collected from sawmill workers at the end of an 8-9 hour 
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work shift or from chamber-exposed individuals. Following hydrolysis of glucuronic acid 
conjugates, cis- and trans-verbenol were identified in the urine along with two diols, cis- and trans-
4-hydroxymyrtenol, formed by methyl group hydroxylation of cis- and trans-verbenol. trans-4-
Hydroxymyrtenal was also detected (see Figure III.5) (Eriksson & Levin, 1990).  
Analysis of the urinary metabolites of a patient attempting suicide with 400 – 500 ml pine oil 
containing 57 % alpha-pinene showed the presence of myrtenol, verbenol, and borneol. Renal 
excretion reached a peak level five days after ingestion (Koppel et al., 1981).  
Male albino rabbits (six/group) administered single gavage doses of 400 – 700 mg/kg bw of (+)-
alpha-pinene, (-)-alpha-pinene, (+/-)-alpha-pinene, (-)-beta-pinene, or delta-3-carene, excreted 
bicyclic terpene hydrocarbon metabolites as (glucuronic acid) conjugates or as further oxidised 
metabolites, notably carboxylic acids. Animals were housed individually and urine was collected 
daily for three days.  
The principal neutral metabolite formed by oxidation at the C4 position in the alicyclic ring of each 
of the three alpha stereochemical forms of pinene was trans-verbenol (see Figure III.5). As a minor 
pathway, allylic oxidation of the exocyclic methyl group to yield myrtenol was observed for all 
three alpha-pinene stereoisomers, with also myrtenic acid as minor metabolite (Ishida et al., 1981). 
The presence of an exocyclic alkene function in (-)-beta-pinene provided additional metabolic 
options, and four neutral and one acidic metabolites were identified. Allylic oxidation of the methyl 
group at the C2 position yields (+)-trans-pinocarveol, while epoxidation of the exocyclic alkene 
followed by hydration or rearrangement yields (-)-trans-10-pinanol and (-)-1-p-menthene-7,8-diol, 
respectively. Ring cleavage yields (-)-alpha-terpineol. These metabolites comprised 11, 39, 30 or 5 
% of the total urinary neutral metabolite fraction, respectively. The acidic metabolite identified was 
identical to the one identified for the alpha-pinenes (i.e. myrtenic acid), which was suggested to be 
formed via double bond epoxidation and subsequent rearrangement to give myrtenol and further 
oxidation to the carboxylic acid (Ishida et al., 1981).  
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Figure III.5. Metabolism of α-pinene and β-pinene in animals.  
Trans-verbenol and myrtenic acid have also been found in faeces or urine of brushtail possum fed 
alpha-pinene. When the same species was fed beta-pinene, only myrtenic acid was found in the 
excreta (Southwell et al., 1980).  
It has been stated in a limited review paper that in rabbits, alpha- and beta-pinenes can be excreted 
as glucuronide conjugates of undetermined nature, which can release cymene upon heating in 
diluted acids (Williams, 1959 as cited in Opdyke, 1978c).  
Delta-3-Carene undergoes stereoselective hydroxylation at the gem-methyl group (yielding 3-caren-
9-ol) followed by carboxylation, allylic oxidation of the C10 methyl group followed by 
carboxylation or, as the main route, allylic ring opening and hydroxylation at a secondary carbon 
atom, yielding (-)-m-mentha-4,6-dien-8-ol (72 % of the total urinary neutral metabolite fraction) 
and m-cymen-8-ol (Ishida et al., 1981). 
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In addition to the terpenoids pinene and carene, the group of Ishida has also studied the metabolism 
of the saturated analogues pinane and carane8 (Ishida et al., 1981). Only a relatively small part of 
the dose (in total 18 g given to six rabbits) was identified, among which were 3- and 4-pinalol, 
alpha-terpineol, trans-sobrerol, trans-carveol, and verbenol (some of the structures have been shown 
in Figure 5). In short, these products result from hydroxylations of secondary carbon atoms in the 6-
membered ring, or cleavage of the 4-membered ring in combination with hydroxylation in the 
remaining 6-membered ring. In addition, desaturation of the 6-membered ring was also observed 
and, hence, some of the metabolites may be considered as cyclohexene derivatives. No 
hydroxylation of the primary carbon atom (i.e. the methyl ring substituent) in pinane was observed. 
With carane, however, the hydroxylation of one of the gem-methyl groups and hydroxylation of the 
C10 exocyclic carbon atom was observed, ultimately resulting in the formation of carane-9,10-
dicarboxylic acid. 
In rabbits, beta-caryophyllene undergoes epoxidation of the endocylic 5,6-double bond to yield a 
stable epoxide metabolite and hydroxylation at the gem-dimethyl group. The resulting metabolite 
14-hydroxycaryophyllene-5,6-epoxide and its C14-acetylated conjugate could be detected in the 
urine. A second epoxidation of the 5,6-epoxide’s exocyclic 2,12-double bond, ultimately resulting 
in the 14-hydroxycaryophyllene-5,6-epoxide-2,12-diol, was also reported (Asakawa et al., 1981; 
Asakawa et al., 1986).  
Data were also found on the metabolism of camphene9. Ishida et al. (1979) administered dl-
camphene to five starved male rabbits at a dose level of 800 mg/kg bw via stomach tube. In total 8 g 
of the substance was given. Urinary metabolites, collected over three days post-dosing were 
examined. The following metabolites were identified in urine samples after treatment with beta-
glucuronidase/sulphatase: camphene-2,10-glycol (after epoxidation of the double bond), 6-exo-
hydroxycamphene, 7-hydroxycamphene, 10-hydroxytricyclene and 3-hydroxytricyclene. 
Quantitative information was provided only for the diol which was found in a total amount of 260 
mg which corresponds to ca. 3 % of the dose (Ishida et al., 1979a). 
In a human volunteer and in a young pig, camphene was eliminated from the body by exhalation, 
and via bile as unchanged substance or as glucuronide conjugate via the urine (Opdyke, 1975).  
(+)-Longifolene metabolism was studied following the oral administration of about 2 g/animal as a 
suspension in 0.02 % Tween80 aqueous solution to six male rabbits. Urine samples were collected 
daily for three days and treated with beta-glucuronidase / sulphatase. Due to imprecise description 
of dose and amounts recovered, it is not possible to indicate the extent of metabolism and excretion 
as percentage of the dose. Deconjugated metabolites were extracted in a neutral and an acidic 
fraction. In the neutral fraction (10 % of the dose), many peaks were observed but only one was 
further characterised to be (2S, 7S)-(+)-14-hydroxyisolongifolaldehyde (35 % of the neutral 
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metabolite fraction). It was concluded that (+)-longifolene is metabolised at two sites in two 
subsequent steps: 1) oxidation of the exo-methylene group to form its epoxide with subsequent 
isomerisation to form a stable aldehyde, and 2) hydroxylation of the gem-dimethyl group to form a 
primary alcohol (Ishida et al., 1982; Asakawa et al., 1986; Ford et al., 1992b).  
An in vitro study with rat liver microsomes demonstrated the involvement of cytochrome P450 
enzymes in the metabolism of alpha-pinene. Metabolites present were beta-pinene and d-limonene 
together with smaller amounts of trans-verbenol, myrtenol, verbenone, and pinene oxide (White & 
Agrosin, 1980). 
alpha-Pinene and cadinene, have been shown to induce cytochrome P450 enzymes, especially those 
from the CYP2B subfamily, and to a lesser extent also CYP3A2 (cadinene) and CYP4A2 (alpha-
pinene) (Austin et al., 1988; Hiroi et al., 1995).  
Conclusions on the metabolism of subgroup V substances 
Metabolism data for subgroup V are available for some supporting substances (pinenes, camphene, 
caryophyllene, delta-3-carene, pinane and carane) and the candidate substance longifolene [FL-no: 
01.047]. In general, the metabolic options for these substances include oxidation of methyl ring 
substituent groups to give the corresponding alcohol and further oxidation products. For the 
substances studied, double bond epoxidation has also been demonstrated. In addition, ring cleavage 
has also been observed, e.g. for beta-pinene resulting in the formation of monocyclic terpenoid 
derivatives like alpha-terpineol. Hydroxylated metabolites (i.e. alcohols) or further metabolic 
products may be eliminated as conjugates e.g. with glucuronic acid. However, given the diversity of 
this group, the lack of data on any of the candidate substances except longifolene for which the 
mass balance is incomplete, it cannot be concluded that the candidate substances in this subgroup  
[FL-no: 01.022, 01.023, 01.030, 01.044, 01.047, 01.052, 01.056, 01.060, 01.066 and 01.067] can be 
metabolised to innocuous products. 
Macrocyclic Non-Aromatic Hydrocarbons (Candidate and Structurally Related Supporting 
Substances from Subgroup VI) 
No data are available for the two substances in subgroup VI [FL-no: 01.042 and 01.043] or for any 
supporting substance. Due to the lack of experimental data it cannot be concluded that these 
substances are metabolised to innocuous products.  
III.5 Summary on Absorption, Distribution, Metabolism and Excretion  
Given the diverse nature of the chemical structures of the candidate flavouring substances in this 
FGE, it is impossible to draw conclusions, which are applicable to all substances. The amount on 
information on kinetics of either candidate or supporting substances is very limited. For these 
reasons, the available information is presented here in a subgroup-wise manner.  
III.5.1. Absorption, Distribution and Elimination 
Subgroup I 
From the available studies it may be concluded that the candidate alkane substances in subgroup 1 
will be absorbed after oral exposure. The extent of absorption is not known, but may be high, given 
their lipophilic character and their low molecular weight. The ease with which these substances 
cross the membranes of the respiratory tract further supports the assumption that these substances 
will also be absorbed after oral intake. Data indicate that straight-chain alkanes will predominantly 
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be to carbon dioxide at low dose levels. At high dose levels, biotransformation becomes saturated 
and other metabolites will be generated which will be excreted via the urine. 
Subgroup II 
For the candidate and supporting substances in subgroup 2, the acyclic alkenes, data were only 
available for beta-myrcene [FL-no: 01.008] and 2-methylbuta-1,3-diene [FL-no: 01.049]. Given the 
narrow range of molecular weights of the candidate substances (between ~ 68 and 206 D) and their 
lipophilic nature (estimated or meassured Log Kow values e.g. 2.4 (2-methylbuta-1,3-diene), 6.1 
(dodec-1-ene), 4.17 (beta-myrcene) or 4.8 (cis-3,7-dimethyl-1,3,6-octatriene)), it is assumed that 
these candidate flavouring substances may be absorbed from the gastrointestinal tract. Mass balance 
data for beta-myrcene are incomplete. For 2-methylbuta-1,3-diene a mass balance of elimination 
has been presented, which also shows elimination via the exhaled air (~ 50 % of the dose), but as 
this substance was administered via the intraperitoneal route, the elimination pattern may be 
different after oral dosing with a lower fraction of the dose exhaled, e.g. because of more efficient 
first-pass biotransformation after oral dosing. 
Subgroup III 
For the candidate and supporting substances in subgroup III (cyclohexene derivatives), data were 
only available for d-limonene [FL-no: 01.045]. For this substance, data show a considerable 
absorption from the gastrointestinal tract. In humans, elimination of the substance followed a 
triphasic pattern, but still 55-83 % of an oral dose could be found in the urine within 72 hours post-
dosing, with the major part excreted within 24 hours. Also in other species urinary elimination was 
most important accounting for up to 82–96 % of the dose within 72 hours. Hence, it may be 
anticipated that monocyclic cyclohexene derivatives, such as d-limonene, administered orally, are 
absorbed and distributed throughout the body. Following oral administration to humans, d-limonene 
was distributed preferentially to fatty tissues, as indicated by a high oil-blood partition coefficient 
and a long half-life during the slow elimination phase. Because of the limited molecular weight of 
the candidate substances in this group (range ~ 136–204 D) and their lipophilic character (e.g. 
estimated or measured log Kow values for beta-phellandrene, beta-bisabolene and d-limonene are 
approximately 4.7, 7.1 or 4.6, respectively) it may be assumed that all of the substances in this 
group may be absorbed, although the extent of absorption for individual substances cannot be 
accurately estimated from these physico-chemical properties. 
Subgroup IV 
No data are available on the absorption, distribution of elimination of any candidate or supporting 
substance in subgroup IVa (benzene hydrocarbons). But there are several data available on the 
candidate substances in subgroup IVb (naphthalene hydrocarbons). The data show that naphthalene 
[FL-no: 01.053] will be absorbed after oral administration and will be eliminated predominantly via 
the urine, in the form of various metabolites, conjugated with e.g. glucuronic acid or with 
glutathione. In bile duct cannulated animals, considerable elimination into the bile was also 
observed, but as in intact animals urinary elimination exceeds by far faecal excretion, the material 
eliminated via the bile is reabsorbed. The glucuronide conjugate of 1-naphthol represents a 
significant urinary metabolite of naphthalene. Glutathione conjugates of naphthalene are catabolised 
to (pre)mercapturic and mercapturic acids, particularly in rodents, before excretion in bile or urine. 
In primates and humans, conjugation with glutathione seems to be less important. Less data are 
available for 2-methylnaphthalene [FL-no: 01.051], but the available data show that 2-
methylnaphthalene is also absorbed from the gastrointestinal tract and eliminated predominantly via 
the urine. For both substances the data indicate that 85–89 % of the dose is excreted within three 
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days after dosing. With respect to the one candidate substance (diphenylmethane [FL-no: 01.036]) 
in subgroup IVc, it may be concluded that the metabolites of this substance will be eliminated from 
the body after intraperitoneal injection. No conclusions can be made on absorption from the 
gastrointestinal tract and the rate of elimination as no oral ADME studies and mass-balance data are 
available. 
Subgroup V 
For the substances in subgroup V (bi- and tricyclic non-aromatic hydrocarbons), the available data 
from oral studies are incomplete. These studies have only addressed the excretion of some 
supporting and one candidate substance (longifolene) in the form of metabolites via the urine. No 
mass-balance data were provided. So these studies only show that these substances will be absorbed 
to some extent. The same may be anticipated for the other candidate substances in this subgroup. 
For the supporting substances alpha- and beta-pinene and delta-carene information on kinetics is 
available from humans exposed via inhalation, in occupational settings. These studies show that 
these substances can be absorbed after inhalation exposure and that metabolites will be excreted 
into the urine e.g. as glucuronide conjugates. The elimination follows a triphasic pattern with rather 
long terminal half-lives and the absorbed amount will be eliminated within several days. Based on 
the lipophilic character of these substances it may be anticipated that they will preferentially 
distribute in the adipose tissues, which is supported by the slow terminal elimination rates. 
Subgroup VI 
No data were available on candidate or supporting substances in subgroup VI (macrocyclic non-
aromatic hydrocarbons). The two substances in this group have a molecular weight of ~ 204. They 
are also rather lipophilic (estimated log Kow are 4.6 and 7.0 for [FL-no: 01.042] and [FL-no: 
01.043], respectively). Based on these data it may be assumed that these two candidate chemicals 
will be absorbed from the gastrointestinal tract. For humulatriene, given the rather high Kow, the 
extent of absorption may be relatively low. 
III.5.2. Metabolism 
Subgroup I 
The substances in subgroup 1 can be expected to be metabolised through omega-oxidation which 
will lead to the formation of alcohols, and after subsequent further oxidation to carboxylic acids, 
which may be further oxidised via beta-oxidation to yield carbon dioxide. Extensive mass balance 
data are not available, but in some of the available studies excretion of carboxylic acids and carbon 
dioxide has been reported. Formation of keto-acids has also been reported, and these may be 
thought to be formed from omega-oxidation at one end of the molecule and omega-1 or -2 oxidation 
at the other end. More interest has been put in the identification of metabolites, which did not 
undergo substantial chain shortening. These metabolites will arise from oxidation of the non-
terminal carbon atoms, e.g. via omega-1, -2, -3 or even -4 oxidation. The resulting secondary 
alcohols can be conjugated with e.g. glucuronic acid and excreted via the urine, or can be further 
oxidised to yield ketones. A subsequent introduction of another secondary hydroxyl group may 
result in the formation of diketones. With n-hexane the resulting 2,5-hexanedione (a gamma-
diketone) has been demonstrated to be responsible for hexane-induced neurotoxicity. Neurotoxicity 
is a common feature of gamma-diketones, and for that reason, candidate substance 3-methylhexane 
[FL-no: 01.050] cannot be anticipated to be metabolised into innocuous compounds. In addition, it 
is known that methyl-branching of the carbon chain potentiates the neurotoxicity of the gamma-
diketone (Topping et al., 1994; EFSA, 2004e). The two other hexane derivatives in this group [FL-
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no: 01.033 and 01.034] cannot be oxidised to give a gamma-diketone, due to the presence of methyl 
groups on the C2 and C5 carbon atoms. Therefore, these substances may be considered as being 
metabolised to innocuous metabolites. For the longer chain alkanes in this group it would require 
oxidation of the more central carbon atoms in order to be converted into gamma-diketones. Such 
oxidations are less favourable than omega, omega-1 or -2 oxidations and therefore it is concluded 
that oxidation of these higher alkanes will not result in toxicologically relevant levels of gamma-
diketones, also because of rapid conjugation of the precursor alcohols. Already for heptane it was 
shown that this substance does not result in neurotoxicity (Bahima et al., 1984), although the 
gamma-diketone itself (2,5-heptanedione) is known to be neurotoxic (Topping et al., 1994). The 
remaining three candidate flavouring substances in this group [FL-no: 01.038, 01.054 and 01.057] 
can be expected to be metabolised to innocuous products. 
Subgroup II 
The data available on the metabolism of one supporting and one candidate substance for subgroup 
II show that metabolic options for the chemicals in this group are epoxidation of double bonds, 
ultimately resulting in diols, which can be further conjugated. With the supporting substance beta-
myrcene, further metabolism of the diols into carboxylic acids has also been reported. Both in rats 
and rabbits, the principal urinary metabolite following gavage administration of beta-myrcene is 
myrcene-3,10-glycol, formed from the hydration of the epoxide intermediate in both species. 
Epoxidation of the 3,10-double bond was favoured over epoxidation of the 1,2-double bond. 
The studies indicate that the formation of diols from the myrcene-epoxides is very efficient. It is 
noted, however, that the diols and the related carboxylic acids are all the result of epoxidation of 
double bonds in which one of the carbon atoms has only hydrogen substituents, but no further 
carbon chains. In this respect, the candidate substance cis-3,7-dimethyl-1,3,6-octatriene [FL-no: 
01.064] is most similar to beta-myrcene. With beta-myrcene no diepoxide metabolites or further 
reaction products thereof have been reported, but it is noted that mass balance data are highly 
incomplete, so some metabolites may have been overlooked. 
With the candidate substance, 2-methyl-buta-1,3-diene, epoxidation of the 1,2-double bond is 
favoured over epoxidation of the 3,4-double bond. While the 1,2-epoxide is readily hydrolysed, the 
3,4-epoxide is far more stable. Both metabolites can be converted to the corresponding diols and at 
least one hydroxy-carboxylic acid (2-hydroxy-2-methyl-3-butenoic acid) has been identified. In 
addition, in particular the 3,4-epoxide metabolite can be oxidised for a second time, resulting in the 
formation of a diepoxide metabolite, which is known to be reactive and has been suggested to be 
responsible for 2-methylbuta-1,3-diene-induced DNA damage. For candidate substance dodec-1-
ene [FL-no: 01.037], diol- and alpha-hydroxy-carboxylic acid formation may also be expected. In 
addition, this substance may also undergo omega and omega-1 or -2 oxidation at the other 
(saturated) end of the carbon chain (similar to the candidate substances in subgroup 1). 
Apart from beta-myrcene and 2-methylbuta-1,3-diene, terminal double bonds appear also in 
candidate substances [FL-no: 01.037 and 01.064]. In contrast to corresponding substances in 
FGE.07 and FGE.18 there are no other functional groups in the molecule (e.g. hydroxyl- or keto-
group) that could provide a more direct option for detoxication e.g. via conjugation with 
glucuronide or sulphate. In the two FGEs mentioned above, the presence of such groups was an 
argument to conclude that the metabolism of the particular candidate substances would give rise to 
innocuous products. It would not be possible to conclude similarly for the candidate substances in 
FGE.25. The other candidate substances in this subgroup (II) might also be oxidised in the various 
methyl groups but no data are available to substantiate this. Because of these considerations, it 
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cannot be concluded that the candidate substances in this subgroup [FL-no: 01.032, 01.035, 01.037, 
01.049 and 01.064] will be metabolised to innocuous products.  
Subgroup III 
No data are available on the metabolism of the candidate substances in subgroup III. In comparison 
with the structures of the candidate substances in subgroup III, the structure of the one supporting 
chemical d-limonene is comparatively simple. Major differences between d-limonene and the 
candidate substances are the length of the ring substituents and the number of double bonds. In 
addition, based on the data available for one of the candidate substances, beta-phellandrene [FL-no: 
01.055], with a double bond directly on the ring and in conjugation with double bond in the 
cyclohexene ring, it cannot be anticipated that it can be metabolised to innocuous products. 
Allylic oxidation is by far the major pathway for metabolism of limonene in humans. Minor 
pathways in limonene metabolism reported for the rat include epoxidation of either the 1,2- or the 
8,9-double bond and subsequent hydrolysis to the diol. Given the many metabolic options for this 
substance, a myriad of metabolites has been found, including conjugates, and for a change mass 
balance data are available, which show that in various animal species the substance is completely 
eliminated within three days, predominantly via the urine. No genotoxicity of limonene epoxides 
could be detected, and it may well be concluded that d-limonene is metabolised to innocuous 
substances. However, although it is very likely that the candidate substances may undergo the same 
metabolic conversions (allylic oxidations and double bond epoxidation) the conclusion for d-
limonene cannot be extrapolated to all of the the candidate substances because of the structural 
dissimilarities and the absence of any further data on molecules with closer resemblance to the 
candidate substances. However, for bisabola-1,8,12-triene [FL-no: 01.027], beta-bisabolene [FL-no: 
01.028] and delta-elemene [FL-no: 01.039] it may be concluded that these are metabolised to 
innocuous products. 
It is noted that d-limonene (metabolites) causes alpha2u-microglobulin accumulation in male 
kidneys, an event known to be associated with male rat specific nephropathy10, and irrelevant for 
human toxicological risk assessment. 
Subgroup IV 
No data are available for the two substances in subgroup IVa [FL-no: 01.031 and 01.058]. Based on 
information available on p-cymene, it may be anticipated that these substances may be oxidised at 
the ring-substituent methyl groups (resulting in the formation of hydroxymethyl groups). These 
metabolites may subsequently be excreted after conjugation. Also epoxidation of the 3,4-double 
bond in [FL-no: 01.031] may be expected. Oxidative attack on the aromatic ring seems less likely. 
Due to the lack of experimental data it cannot be concluded that these substances are metabolised 
into innocuous products. 
Data are available on the biotransformation of naphthalene [FL-no: 01.053] and its 2-methyl 
derivative [FL-no: 01.051] in subgroup IVb. With naphthalene, the primary products resulting from 
epoxidation can be further metabolised to naphtoquinones and other metabolites, which have been 
brought into connection with the toxicity of this substance. Whereas epoxidation is the main 
metabolic option for naphthalene, methyl group oxidation is the major metabolic pathway in the 
case of 2-methylnaphthalene. However, also with 2-methylnaphthalene, epoxidation may occur to 
some extent, and 2-methylnaphthalene-induced depletion of glutathione stores, possibly as a result 
of conjugation, has been suggested to be related to epoxidation reactions. However, although 
                                                 
10 For introduction into this area see e.g. the referred paper by Lehman-McKeeman et al. (1989) 
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biotransformation does play a role in the toxicity of 2-methylnaphthalene, the exact mechanism of 
toxicity and the metabolites which are involved have not been clearly identified. Hence, neither for 
naphthalene [FL-no: 01.053] nor for 2-methylnaphthalene [FL-no: 01.051], can it be concluded that 
they are metabolised into innocuous substances. 
For the one candidate substance in subgroup IVc (diphenylmethane [FL-no: 01.036]) only a very 
limited amount of metabolites have been identified in the urine. One of these is an aromatic 
hydroxylation product, which may be generated from epoxidation. Because of lack of further data it 
cannot be concluded that diphenylmethane [FL-no: 01.036] is metabolised to innocuous products. 
Subgroup V 
Metabolism data for subgroup V are available for the supporting substances pinenes, camphene, 
caryophyllene, delta-3-carene, pinane and carane and the candidate substance longifolene [FL-no: 
01.047]. In general the metabolic options for these substances include oxidation of methyl ring 
substituent groups to give the corresponding alcohol and further oxidation products. For the 
substances studied, double bond epoxidation has also been demonstrated. In addition, ring cleavage 
has also been observed, e.g. for beta-pinene resulting in the formation of monocyclic terpenoid 
derivatives like alpha-terpineol. Hydroxylated metabolites or further metabolised products may be 
eliminated as conjugates e.g. with glucuronic acid. However, given the diversity of this group, the 
lack of data on any of the candidate substances except longifolene for which the mass balance is 
incomplete, it cannot be concluded that the candidate substances in this subgroup [FL-no: 01.022, 
01.023, 01.030, 01.044, 01.047, 01.052, 01.056, 01.060, 01.066 and 01.067] can be metabolised to 
innocuous products. 
Subgroup VI 
No data are available for the two candidate substances in subgroup VI [FL-no: 01.042 and 01.043] 
or for any supporting substance. Due to the lack of experimental data it cannot be concluded that 
these substances are metabolised to innocuous products.  
III.6 Overal Conclusion on Absorption, Distribution, Metabolism and Elimination. 
Generally, the available data indicate that the aliphatic and aromatic hydrocarbons participate in 
similar pathways of metabolic detoxication. Being lipophilic and of low molecular weight, these 
hydrocarbons may be assumed to be absorbed by the gastrointestinal tract. Subsequently, they are 
oxidised to more polar oxygenated metabolites e.g. by CYP-450 enzymes. The phase I metabolites 
are then conjugated and excreted mainly in the urine. The candidate substances and supporting 
substances are oxidised either by side chain oxidation or epoxidation of the exocyclic or endocyclic 
double bond. Oxidation initially yields hydroxylated metabolites that may be excreted in conjugated 
form or undergo further oxidation, yielding more polar metabolites that are also excreted. If a 
double bond is present, epoxide metabolites may form that are further metabolised either by 
hydrolysis to yield diols or by conjugation with glutathione to yield mercapturic acid derivatives. 
The aromatic hydrocarbons that do not contain alkyl substituents may undergo ring hydroxylation 
to form phenolic metabolites that are subsequently conjugated with sulphate or glucuronic acid and 
excreted in the urine. The saturated alkanes in this group may be metabolised via omega and 
omega-1, -2, -3 or -4 oxidation. Whereas omega oxidation would ultimately lead to the formation of 
carboxylic acids, the other oxidations would give rise to secondary alcohols and ketones. The 
carboxylic acids may be expected to participate in the endogenous fatty acid metabolism. 
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However, for most of the subgroups the information was incomplete and the similarity between 
supporting and candidate substances was limited. In addition, proper mass balance data were not 
available. Some mass balance data available indicated slow elimination. For several subgroups no 
data were available at all. In Table III.2 the final conclusions for each of the candidate substances 
has been presented, together with a brief explanatory statement, about the conclusion reached. It is 
noted that the subgroup III supporting substance d-limonene causes alpha2u-microglobulin 
accumulation in male kidneys, an event known to be associated with male rat specific nephropathy, 
and irrelevant for human toxicological risk assessment.  
 
Table III.2 Can innocuous metabolites be expected to be formed based on available data? 
FL–no: Substance name Innocuous metabolites? 
Subgroup I:  ACYCLIC ALKANES 
01.033 2,2-Dimethylhexane Yes 
01.034 2,4-Dimethylhexane Yes 
01.038 Dodecane Yes 
01.050 3-Methylhexane No (potential formation of neurotoxic gamma-diketone) 
01.054 Pentadecane Yes 
01.057 Tetradecane Yes 
Subgroup II:  ACYCLIC ALKENES 
01.032 2,3-Dihydrofarnesene No (lack of supporting data) 
01.035 2,6-Dimethylocta-2,4,6-triene No (lack of supporting data) 
01.037 Dodec-1-ene No (presence of terminal double bond which may give rise to 
reactive metabolites without counteracting metabolic 
options) 
01.049 2-Methylbuta-1,3-diene No (known biotransformation to reactive metabolite 
responsible for toxicity and genotoxicity) 
01.064 cis-3,7-Dimethyl-1,3,6-octatriene No (presence of terminal double bond which may give rise to 
reactive metabolites without counteracting metabolic 
options)  
Subgroup III:  CYCLOHEXENE HYDROCARBONS 
01.055 beta-Phellandrene No (lack of supporting data) 
01.027 Bisabola-1,8,12-triene Yes 
01.028 beta-Bisabolene Yes 
01.039 delta-Elemene Yes  
Subgroup IV: AROMATIC HYDROCARBONS 
Subgroup IVa:  BENZENE HYDROCARBONS 
01.031 1,2-Dihydro-1,1,6-trimethylnaphthalene No (lack of supporting data) 
01.058 1,2,3,4-Tetrahydro-1,1,6-trimethylnaphthalene No (lack of supporting dat) 
Subgroup IVb:  NAPHTHALENE HYDROCARBONS  
01.051 2-Methylnaphthalene No (known metabolism to toxic metabolites) 
01.053 Naphthalene No (known metabolism to toxic metabolites) 
Subgroup IVc: DIPHENYLMETHANE  
01.036 Diphenylmethane No (lack of supporting data) 
Subgroup V: BI- and TRICYCLIC, NON-AROMATIC HYDROCARBONS 
01.022 alpha-Cedrene No (lack of supporting data) 
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Table III.2 Can innocuous metabolites be expected to be formed based on available data? 
FL–no: Substance name Innocuous metabolites? 
01.023 1(5),11-Guaiadiene No (lack of supporting data) 
01.030 beta-Cubebene No (lack of supporting data) 
01.044 Isolongifolene No (lack of supporting data) 
01.047 Longifolene No (lack of supporting data) 
01.052 alpha-Muurolene No (lack of supporting data) 
01.056 alpha-Santalene No (lack of supporting data) 
01.060 1,1,7-Trimethyltricyclo[2.2.1.0.(2.6)]heptane No (lack of supporting data) 
01.066 2-Cedrene No (lack of supporting data) 
01.067 8(14)-Cedrene No (lack of supporting data) 
Subgroup VI: MACROCYCLIC, NON-AROMATIC HYDROCARBONS 
01.042 Germacra-1(10),4(14),5-triene No (lack of supporting data) 
01.043 3,7,10-Humulatriene No (lack of supporting data) 
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ANNEX IV: TOXICITY 
Oral acute toxicity data are available for eight candidate substances of the present flavouring group evaluation from chemical group 31, and for 
17 supporting substances evaluated by JECFA at the 63rd meeting. The supporting substances are listed in brackets. 
TABLE IV.1: ACUTE TOXICITY 
Table IV.1: ACUTE TOXICITY 
Chemical Name [FL-no]  Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
Tetradecane [01.057] Rat NR Oral > 5000 (Enichem Augusta Ind., 1987) Study not available 
 Rat NR Oral > 5000 (PETRESA, 19??b) Study not available 
(Undeca-1,3,5-triene [01.061])  Rat M, F Oral > 8000 (Pellmont, 1973c) Data not possible to interprete 
 Mouse M, F Oral 2000 - 4000 (Pellmont, 1973c) Data not possible to interprete 
Dodec-1-ene [01.037] Rat NR Oral > 3200 (Jones, 1969) No information given on study design 
 Rat NR Oral > 1000 (Ethyl Corporation, 1973) Study not available 
2-Methylbuta-1,3-diene [01.049] Rat M, F Gavage 2043 – 2210 (Kimmerle & Solmecke, 1972) Study not available 
(Myrcene [01.008]) Rat M Oral > 5000 (Moreno, 1972j) Identity of compound not stated as other than code 
number 
(beta-Ocimene [01.018])  Rat NR Oral 5000 (Moreno, 1976z) One dose tested 
(d-Limonene [01.045])  Rat M Oral > 5000 (Moreno, 1972m) Identity of compound not stated as other than code 
number 
 Rat M, F Oral M: 4400 
F: 5100 
(Tsuji et al., 1975a) Study is on dogs, rats not mentioned in English 
text. Study in Japanese 
 Mouse M, F Oral M: 5600  
F: 6600 
(Tsuji et al., 1975a) Study is on dogs, mice not mentioned in English 
text. Study in Japanese 
(Terpinolene [01.005]) Rat NR Oral 4.39 ml/kg (3784) (Levenstein, 1975o) Observation period not given. 
(alpha-Terpinene [01.019])  Rat NR Oral 1680 (Moreno, 1973ah)  
(gamma-Terpinene [01.020])  Rat M, F Oral 3650 (Moreno, 1973ag)  
(alpha–Phellandrene [01.006]) Rat M, F Oral > 5700 (Moreno, 1972k) Submitted study is on dermal toxicity. 
 Rat M, F Oral 1.87 ml/kg 
(1590) 
(Brownlee, 1940) Substance mixed with acacia.  6 animals per dose 
group 
beta-Bisabolene [01.028] Rat NR Oral > 5000 (Moreno, 1974l) One dose tested 
 Mouse M, F Oral > 13,360 (Hoffman-LaRoche, Inc., 1967b) No of dose levels not given. 
(delta-3-Carene [01.029])  Rat M Oral 4800 (Moreno, 1972l) Identity of compound not stated 
(Pin-2(3)-ene [01.004])  Rat M, F Oral 3700 (Moreno, 1972n) Identity of compound not stated 
(Pin-2(10)-ene [01.003])  Rat NR Oral > 5000 (Moreno, 1975q) One dose tested. 
(Camphene [01.009])  Rat NR Oral > 5000 (Moreno, 1974m) One dose tested  
(delta-3-Carene [01.029])  Rat NR Oral > 5000 (Keating, 1972a) Mixture of isomers. Only one dose tested 
(Valencene [01.017]) Rat M Oral > 5000 (Moreno, 1980m) One dose tested 
(beta–Caryophyllene [01.007]) Rat M, F Oral > 5000 (Hart & Wong, 1971) One dose tested 
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Table IV.1: ACUTE TOXICITY 
Chemical Name [FL-no]  Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
(1(5),7(11)-Guaiadiene [01.026])  Rat NR Oral > 5000 (Moreno, 1976aa) One dose tested 
Longifolene [01.047] Rat NR Oral > 5000 (Moreno, 1977ai) One dose tested 
Diphenylmethane [01.036] Rat NR Oral 2250 (Moreno, 1973ai)  
Naphthalene [01.053] Rat NR Oral > 2000 (Hazleton France, 1990a; Hazleton 
France, 1990b) 
Study not available 
 Rat NR Oral > 2000 (Vaughn & Keeler, 1976) No information on study design 
 Rat M, F Oral 2400 (Birch, 1978a)  5 animals per dose group 
 Rat M, F Oral 2800 (Birch, 1978b) 5 animals per dose group 
 Rat M, F Oral 19004 (Birch, 1978c) 5 animals per dose group 
 Rat NR Oral 2000 (Hazleton France, 1990c) Study not available 
 Rat F Gavage 9430 (Carpenter et al., 1949)  
 Mouse M, F Gavage M: 533  
F: 710 
(Shopp et al., 1984)  
(1-Methylnaphthalene [01.014]) Rat NR Oral 1840 (Izmerov et al., 1982)  Study not available 
2-Methylnaphthalene [01.051] Rat NR Oral 1630 (Izmerov et al., 1982) Study not available 
1 Administered as a 25 % solution in olive oil. 
2 Dowtherm A, which was a mixture of biphenyl (26 %) and diphenyl oxide (72 %), was tested 
3 Administered as a 20 % solution in corn oil. 
4 Administered as a 10 % solution in corn oil. 
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Subacute / subchronic / chronic / carcinogenic toxicity data are available for two candidate substance of the present flavouring group evaluation 
from chemical group 31 and for five supporting substances evaluated by JECFA at the 63rd meeting. The supporting substances are listed in 
brackets. 
TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Table IV.2: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
(Undeca-1,3,5-triene [01.061])  Rat; M, F 
10 
Diet Calculated to provide 10 mg 
Galbelica/kg bw/day corresponding to 2 
mg undecatriene, 8 mg pinene and the 
rest dodecene.   
14 days Corresponding to 2 mg 
undecatriene 
(Shapiro, 1988) Not valid.  
Study is on Galbelica, a formulation 
containing 80 % pinene and the rest a 
mixture of  undecatriene and dodcecene. 
(d-Limonene [01.045])  Rat; M 
5 
Gavage 0, 75, 150 or 300 mg/kg bw/day 5 days a 
week 
6 or 27 days  
(5 or 25 doses) 
75 (Kanerva et al., 1987) Study is on kidney toxicity specifically.  
 Rat; M 
5 – 10 
Gavage 0, 2, 5, 10, 30 or 75 mg/kg bw/day, 5 
days/week 
13 weeks 5 (Webb et al., 1989) Study is on kidney toxicity specifically. 
 Dog; M, F 
6 
Gavage 0, 0.4, 1.2 or 3.6 ml/kg bw/day 
corresponding to 0, 340, 1000 or 3000 
mg/kg bw/day 
180 days M: 340  
F:  340 
(Tsuji et al., 1975a) Study is in Japanese, only summary and 
tables in English. Quality of study not 
possible to assess.  
 Dog; M, F 
10 
Gavage 
(divided doses) 
0, 0.12 or 1.2 ml/kg bw/day 
corresponding to 0, 100 or 1000 mg/kg 
bw/day.  
180 days 100 (Webb et al., 1990)  
 Mouse; M, F 
10 
Gavage 0, 413, 825, 1650, 3300 or 6600 mg/kg 
bw/day for 12 days over 16-day period 
16 days 1650  (NTP, 1990e)  
 Mouse; M, F 
20 
Gavage 0, 125, 250, 500, 1000 or 2000 mg/kg 
bw/day 5 days per week 
13 weeks M: 500  
F: 500  
(NTP, 1990e) Clinical signs of rough hair coat and 
decrased activity were observed at the two 
highest doses.  
 Mouse; M, F 
M:50 F:50 
Gavage M: 0, 250 or 500 mg/kg bw/day 
F: 0, 500, 1000 mg/kg bw/day 
5 days per week 
103 weeks M: 250  
F: 500 
(NTP, 1990e)  
 Rat; M, F 
10 
Gavage 0, 413, 825, 1650, 3300 or 6600 mg/kg 
bw/day for 12 days over 16-day period 
16 days 1650 (NTP, 1990e)  
 Rat; M, F 
20 
Gavage 0, 150, 300, 600, 1200 or 2400 mg/kg 
bw/day 5 days per week 
13 weeks M: None 
F: 1200 
(NTP, 1990e) Dose-dependent nephropathy in all treated 
males.  
 Rat; M, F 
M:50 F:50 
Gavage M: 0, 75 or 150 mg/kg bw/day 
F: 0, 300 or 600 mg/kg bw/day 
5 days per week 
103 weeks M: None  
F: 300 
(NTP, 1990e)  
(Pin-2(10)-ene [01.003])  Rat; M, F 
10 
Diet Calculated to provide 10 mg 
Galbelica/kg bw/day corresponding to 8 
mg pin-2(10)-ene 
14 days Corresponding to 8 mg 
pin-2(10)-ene 
(Shapiro, 1988) Study is on Galbelica, a formulation 
containing 80 % pinene and a mixture of 
undecatriene and dodcecene.  
(Camphene [01.009]) Rat; M, F 
10 
Gavage 0, 62.5, 250, 1000 mg/ kg bw/day 28 days M: None 
F: 250 
(Hoechst, 1991b) Study report very limited in details. Study 
according to OECD Guideline 407.   
Naphthalene [01.053] Rat; M, F Gavage 0, 25, 50, 100, 200 or 400 mg/kg 13 weeks 100 (Battelle Columbus Unpublished study that is not submitted. It 
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Table IV.2: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
20 bw/day, 5 days/week (LOAEL 200) Laboratory, 1980a)  is therefore not possible to assess the 
quality of the study. Study is referred to in 
US EPA 1998.   
Naphthalene [01.053] cont. Rat; NR 
28 
Diet 10-20 mg/kg bw/day 700 days 425 (Schmähl, 1955) Study not considered valid. 
 Mouse; M, F 
116 – 156 
Gavage 0, 5.3, 53, 133 mg/kg bw/day 90 days 53 (Shopp et al., 1984) No histopathology was conducted, study 
not considered valid. 
 B6C3F1 
Mouse, M,F 
Inhalation 0, 10, 30 ppm, 5 days/week 
estimated to be 0, 3.6-3.9, 10.7-11.4 
mg/kg bw/day 
105 weeks None (NTP, 1992g) Valid study.  
 F344/N rat, M, 
F 
Inhalation 0, 10, 30, 60 ppm, 5 days/week 
estimated to be 0, 3.6-3.9, 10.7-11.4, 
20.1-20.7 mg/kg bw/day 
105 weeks None (NTP, 2000d) Valid study.  
 Mouse; M, F 
20 
Gavage 0, 12.5, 25, 50, 100 or 200 mg/kg 
bw/day, 5 days/week 
13 weeks (LOAEL 200) (Battelle Columbus 
Laboratory, 1980b)  
Unpublished study that is not submitted. It 
is therefore not possible to assess the 
quality of the study. Study is referred to in 
US EPA 1998. 
(1-Methylnaphthalene [01.014]) Mouse; M, F 
20 
Diet 0, 0,0163, 0.049, 0.147, 0.44 or 1.33 % 
in diet calculated to correspond to 0, 16, 
47, 142, 425 or 1259 mg/kg bw/day 
13 weeks 0.147  % (142) (Murata et al., 1993) Dose-finding study.  
 Mouse; M, F 
100 
Diet 0, 0.075 or 0.15 % in diet, average daily 
doses calculated to correspond to 0, 73 
or 142 mg/kg bw/day  
81 weeks None (Murata et al., 1993) Exposure related increase in incidence of 
pulmonary alveolar proteinosis.  
2-Methylnaphthalene [01.051] Mouse; M, F 
100 
Diet 0, 0.075 or 0.15 %. Average daily doses 
calculated by the authors to correspond 
to 50.3-54.3 resp. 107.6-113.8 mg/kg 
bw/day 
81 weeks No NOAEL derived.  (Murata et al., 1997) Study considered valid. Pulmonary 
alveolar proteinosis developed in all 
treated animals. 
Mixture of (1-Methylnaphthalene 
[01.014]) and 2-Methylnaphthalene 
[01.051] 
B6C3F1 
Mouse; F 
4, 11, 32 
Cutaneous 
application 
0, 2.7, 118.8 mg/kg bw twice a week 61 weeks No NOAEL derived. (Emi & Konishi, 1985) The lesions were diagnosed as 
endogenous lipid pneumonia. Frequency 
of animals with these lesions were 0/4 
control, 3/11 low dose and 31/32 high 
dose animals. 
1Study performed using a dose of 10 mg/kg body weight per day of Galbelica, which is a solution composed of 80 % beta-pinene and 20 % 1,3,5-undecatriene and dodecene.  
2This study was performed at either a single dose level or multiple dose levels.   
3Study performed using a dose of 10 mg/kg body weight per day of Galbelica, which is a solution composed of 80 % beta-pinene and 20 % 1,3,5-undecatriene.  
4 Study evaluated the carcinogenicity of 1-methylnaphthalene. The results were negative in the females. The males in both treatment groups showed a statistically significant increase in the number of lung adenomas from the control group; 
however, it may be concluded that because of a lack of tumours in females and at other sites (particularly the liver), it is unlikely that 1-methylnaphthalene is a carcinogen or promoter. 
5True NOEL not determined. Only a single dose level was selected for a lifetime carcinogenicity study.  Naphthalene was considered not to be carcinogenic. 
6 Study evaluated the carcinogenicity of 2-methylnaphthalene. The results were negative, with the exception of the males in the 0.075 %-dose group. It was concluded that although the total number of lung adenomas and adenocarcinomas was 
statistically significant in the 0.075 %-dose group, they were in the range of spontaneous tumours. 
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Developmental and reproductive toxicity data are available for one candidate substance of the present flavouring group evaluation from 
chemical group 31 and for three supporting substance evaluated by JECFA at the 63rd meeting. Supporting substance listed in brackets. 
TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Table IV.3: Developmental and Reproductive Toxicity Studies 
Chemical Name [FL-no]  Study type 
Durations  
Species/Sex 
No / group 
Route  Dose levels NOAEL  (mg/kg bw/day),  
Including information of possible 
maternal toxicity 
Reference  Comments 
(Myrcene [01.008]) Developmental Toxicity:  
Gestation Days 6 - 15 
Rat; F 
16 - 29 
Gavage 250, 500 or 1200 
mg/kg bw/day 
Maternal: 5002  
Foetal: 500 
(Delgado et al., 1993a) Study considered valid.  
 Peri- and Postnatal 
Developmental Toxicity:  
Gestation Day 15 to Postnatal 
Day 21 
Rat; F 
12 - 18 
Gavage 0, 250, 500, 1000, 
1500 mg/kg bw/day 
Maternal: 5003 
Peri- and  
Post-natal: 250 
(Delgado et al., 1993b) Study considered valid.  
 Reproductive and 
developmental toxicity: Prior to 
mating until postnatal day 21 
Rat; M, F 
60 
Gavage 0, 100, 300, 500 
mg/kg bw/day 
Maternal/paternal: 500 mg/kg bw/day 
Foetal: 300 mg/kg bw/day 
(Paumgartten et al., 1998) Study considered valid.  
(d-Limonene [01.045]) Developmental Toxicity:  
Gestation Days 9 - 15 
Rat; F 
20 
Oral 0, 591 or 2869 mg/kg 
bw/day 
Maternal: 591  
Foetal: 591 
(Tsuji et al., 1975b) Study in Japanese, only summary and tables in 
English. Quality of study not possible to assess. 
 Developmental Toxicity: 
Gestation Days 7 - 12 
Mouse; F 15 Oral 0, 591 or 2363 mg/kg 
bw/day 
Maternal: 591  
Foetal: 591 
(Kodama et al., 1977b) Study in Japanese, only summary and tables in 
English. Quality of study not possible to assess. 
 Developmental toxicity: 
gestation days 6 - 18 
Rabbit; F  
10, 18 in 
highest dose 
group 
Oral 0, 250, 500 or 1000 
mg/kg bw/day 
Maternal: 250 
Foetal: 1000 
(Kodama et al., 1977c) Study in Japanese, only summary and tables in 
English. Quality of study not possible to assess.  
(Pin-2(3)-ene [01.004]) Developmental toxicity:  
Gestation days 9 - 14 
Rat; F 
12 - 17 
Oral Not relevant Not relevant (Hasegawa & Toda, 1978) Study is not considered valid.  
Study is on a mixture of menthol, menthone, pinene, 
borneol cineol, camphene rheochrysin in olive oil. 
Pin-2(3)-ene content is 17 %. Study in Japanese.  
 Developmental toxicity:  
Gestation Days 6 - 15 
Rat; F 
20 
Gavage  Maternal: 2504 
Foetal: 1000 
(Leuschner, 1992; LPT 
Research, 1992) 
Study not available. 
Naphthalene [01.053] 
 
Developmental toxicity:  
Gestation Days 6 - 15 
Rat; F 
25 - 26 
Gavage 0, 50, 150 or 450 
mg/kg bw/day 
Maternal LOAEL:  50 
Foetal: 450 
(Navarro et al., 1991) Study considered valid.  
 Developmental toxicity:  
Gestation days 7 - 14 
Mouse; F 
33 
Gavage 0 or 300 mg/kg/day Not possible to derive a NOAEL1 (Booth et al., 1983; Plasterer 
et al., 1985) 
Only one dosage.  No assessment of visceral or 
skeletal foetal development.  
 Developmental toxicity:  
Gestation Days 6 - 18 
Rabbit; F 
18 
Gavage 0, 40, 200 or 400 
mg/kg bw/day 
Maternal: Not determined  
Foetal: 400 
(Naismith & Matthews, 
1986) 
Study is considered valid, although only code 
number is given as identity of test substance.  
 Developmental toxicity:  
Gestation days 6 - 19 
Rabbit; F 
25 - 27 
Gavage 0, 20, 80 or 120 mg/kg 
bw/day 
Maternal: 120  
Foetal: 120 
(Navarro et al., 1992) Study considered valid.  
1NOEL not determined; only a single dose level was tested.  Naphthalene decreased the number of surviving dams, maternal body weight, number of live pups and litter weights, but not the weight per pup.  However, it was concluded by the 
authors that maternal toxicity would manifest before high levels of developmental toxicity would occur.  
2Test substance was beta-myrcene.  
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3Study performed using a dose of 10 mg/kg body weight per day of Galbelica, which is a solution composed of 80 % beta-pinene and 20 % 1,3,5-undecatriene. 
4Test substance was 78 % pure.  
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In vitro mutagenicity/genotoxicity data are available for six candidate substances of the present flavouring group evaluation from chemical 
group 31 and for ten supporting substances evaluated by JECFA at the 63rd meeting. Supporting substances are listed in brackets. 
TABLE IV.4: GENOTOXICITY (IN VITRO) 
Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
Dodecane [01.038] Ames test S. typhimurium  
TA98; TA100 
NR Negative1 (Tummey et al., 1992) 
 
Only part of abstract available. Validity of 
the study cannot be evaluated due to 
insufficient report of experimental details 
and results. 
 Mammalian cell gene mutation test 
(mouse lymphoma assay) 
Mouse lymphocytes NR Negative1 (Tummey et al., 1992) 
 
Only part of abstract available. Validity of 
the study cannot be evaluated due to 
insufficient report of experimental details 
and results. 
 Mammalian cell gene mutation test V79 Chinese hamster ovary cells 0.12 mM (20 µg/ml) Negative3 (Lankas et al., 1978) 
 
Published non-GLP study. Some important 
details of study design and results are not 
reported. Thus, the validity of the study 
cannot be evaluated. Study designed to 
evaluate the ability of various alkanes to 
enhance the mutagenicity induced by the 
chemical carcinogen methylazoxymethanol 
acetate. Dodecane showed no mutagenic 
activity per se, but increased the mutagenesis 
induced by pretreatment with the carcinogen. 
Tetradecane [01.057] Ames test S. typhimurium  
TA98; TA100; TA1535; TA1537; TA1538
50, 150, 500, 1500, 5000 
µg/plate 
Negative1 (PETRESA, 19??a) 
 
(Study carried out by Huntingdon Research 
Centre, Report PEQ 5C/85914, sponsored by 
PETRESA; year not indicated) 
Unpublished GLP-study carried out in 
accordance with OECD guideline 471 as 
stated in the IUCLID datasheet submitted. 
IUCLID abstract available only. Validity of 
the study cannot be evaluated. 
 Mammalian cell gene mutation test V79 Chinese hamster ovary cells 0.12 mM (23 µg/ml) Negative3 (Lankas et al., 1978) 
 
Published non-GLP study. Some important 
details of study design and results are not 
reported. Thus, the validity of the study 
cannot be evaluated. Study designed to 
evaluate the ability of various alkanes to 
enhance the mutagenicity induced by the 
chemical carcinogen methylazoxymethanol 
acetate. Tetradecane showed no mutagenic 
activity per se, but increased the mutagenesis 
induced by pretreatment with the carcinogen. 
 Ames test  
(preincubation method) 
S. typhimurium  
TA98; TA100; UTH8414; UTH8413 
0, 50, 100, 500, 1000, 2000 
µg/plate 
Negative1 (Conner et al., 1985)  
 
Published non-GLP study with insufficient 
report of some details of method and results. 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
Thus, the validity of the study cannot be 
evaluated. Cytotoxicity not reported. 
 
Dodec-1-ene [01.037] Ames test S. typhimurium  
TA98; TA100; TA1535; TA1537; TA1538 
E. coli WP2uvrA 
0.2 to 2000 µg/plate Negative1 (Dean, 1980) 
 
Unpublished GLP-study. IUCLID abstract 
available only. Details of study design and 
results are not reported. Thus, the validity of 
the study cannot be evaluated. 
 
2-Methylbuta-1,3-diene [01.049] Ames test S. typhimurium  
TA98; TA100; TA1530; TA1535; TA1538
25% atmosphere 
concentration 
Negative1 (De Meester et al., 1981) 
 
Published non-GLP study not in accordance 
with OECD guideline 471. Part of a larger 
study evaluating the effects of various 
experimental conditions (different liver cell 
preparations and concentrations) on the 
mutagenic activity of butadiene, 
hexachlorobutadiene and isoprene. Some 
important details of study design and results 
are not reported. Thus, the validity of the 
study cannot be evaluated. Plates were 
exposed to a 25 % 2-methylbuta-1,3-diene 
atmosphere for 24 hours.  
 
 Ames test 
(preincubation method) 
S. typhimurium   
TA98; TA100; TA1535; TA1537 
0, 100, 333, 1000, 3333, 
10000 µg/plate 
Negative1 (Mortelmans et al., 1986) 
 
Published summary report including detailed 
results from studies on 270 compounds tested 
in various laboratories within the NTP to a 
large extent in accordance with OECD 
guideline 471. 
 
 Ames test S. typhimurium   
TA102; TA104 
NR Negative (Kushi et al., 1985) 
 
Published abstract only, of which part of the 
text including results is missing. No 
information on the use of a metabolic 
activation system. Validity of the study 
cannot be evaluated. 
 
 Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535 
E. coli WP2uvrA/pKM101 
0, 500, 1000, 2000, 5000 
μg/plate 
Negative1 (Madhusree et al., 2002) Published non-GLP study  with limited 
report of experimental details and results. 
Thus, the validity of the study cannot be 
evaluated. 
 Sister chromatid exchange test Chinese hamster ovary cells 0, 50, 160, 500, 1600 μg/ml 
(-S9)  
0, 160, 500, 1600, 5000 
μg/ml (+S9). 
Negative1 (NTP, 1999 ; (Galloway et al., 
1987) 
Published summary report including detailed 
results from studies on 108 chemicals tested 
within the NTP to a large extent in 
accordance with OECD guideline 479. 
 Chromosomal aberration assay Chinese hamster ovary cells 0, 1600, 3000, 5000 μg/ml Negative1 (NTP, 1999 ; (Galloway et al., 
1987) 
Published summary report including detailed 
results from studies on 108 chemicals tested 
within the NTP to a large extent in 
accordance with OECD guideline 473. 
(Myrcene [01.008]) Chromosomal aberration assay Human lymphocytes 1000 µg/ml Negative1 (Kauderer et al., 1991) 
 
4 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
 Mammalian cell gene mutation 
assay 
Chinese hamster ovary V79 cells 1000 µg/ml Negative1 (Kauderer et al., 1991) 
 
4 
 Sister chromatid exchange test Human lymphocytes 1000 µg/ml Negative1 (Kauderer et al., 1991) 
 
4 
 Sister chromatid exchange test Chinese hamster ovary cells and hepatic 
tumour cell line 
500 µg/ml Negative1 (Röscheisen et al., 1991) 
 
4 
(d-Limonene [01.045]) Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0.03, 0.3, 3, 30 µM/plate 
(4.1, 41, 410, 4100 
µg/plate) 
Negative1 (Florin et al., 1980) 
 
4 
 Ames test S. typhimurium  
TA98; TA100; TA1535; TA1537; TA1538
150,000 µg/plate Negative1 (Heck et al., 1989) 4 
 Ames test S. typhimurium TA102 5000 µg/plate Negative1 (Müller et al., 1993) 4 
 Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537 
3333 µg/plate Negative1 (Haworth et al., 1983) 4 
 Ames test 
(preincubation method)  
S. typhimurium   
TA98; TA100, UTH8414 and UTH8413 
0, 10 to 500 µg/plate  
(5 concentrations) 
Negative1 (Conner et al., 1985) 4 
 Forward mutation assay L5178Y Mouse  
lymphoma 
100 µg/ml Negative1 (Heck et al., 1989) 4 
 Forward mutation assay L5178Y Mouse Lymphoma 100 nl/ml  
(84.1 µg/ml) 
Negative1 (Myhr et al., 1990) 4 
 Chromosomal aberration assay Chinese hamster  
ovary cells 
500 µg/ml Negative1 (Anderson et al., 1990) 4 
 Sister chromatid exchange test Chinese hamster ovary cells 162 µg/ml Negative1 (Anderson et al., 1990) 4 
 Sister chromatid exchange test Chinese hamster ovary cells 1000 µM  
(136.2 µg/ml) 
Negative (Sasaki et al., 1989) 4 
 
(gamma-Terpinene [01.020]) Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
50,000 µg/plate Negative1 (Heck et al., 1989) 4 
 Unscheduled DNA synthesis Rat hepatocytes 30 µg/ml Negative (Heck et al., 1989) 4 
(alpha–Phellandrene [01.006]) Sister chromatid exchange test Chinese hamster ovary cells 1000 µM(136.2 µg/ml) Negative (Sasaki et al., 1989) 4 
(delta-3-Carene [01.029])  Ames test 
(plate incorporation method) 
S. typhimurium TA98; TA100; TA102 up to 5 µl/plate  
(up to 4300 µg/plate; 5 
concentrations) 
Positive3 
Negative2 
(Kurttio et al., 1990) Published non-GLP study with insufficiently 
reported results. Limited validity. Positive 
without metabolic activation in TA100 and 
TA102 and at doses of 2.5 μl/plate and 
higher. 
 
(Pin-2(3)-ene [01.004]) Ames test S. typhimurium  
TA98; TA100 
100 µl/plate 
(85,800 µg/ plate) 
Negative2 (Rockwell & Raw, 1979) 4 
 
 
Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537 
0.03, 0.3, 3, 30 µM/plate  
(4.1, 41, 410, 4100 µg/ 
plate) 
Negative1 (Florin et al., 1980) 4 
 Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
25000 µg/plate Negative1 (Heck et al., 1989) 4 
 Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
25 µl/plate 
(21,450 µg/ plate) 
Negative1 (Jagannath, 1984) 4 
 Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
5 µl/plate  
(4290 µg/plate) 
Negative1 (DeGraff, 1983a) 4 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
 Ames test S. typhimurium TA98; TA100; UTH8414; 
UTH8413 
0, 10 to 500 µg/plate  
(5 concentrations) 
Negative1 (Conner et al., 1985) 4 
 Unscheduled DNA synthesis Rat hepatocytes 10000 µg/ml Negative (Heck et al., 1989) 4 
(Pin-2(10)-ene [01.003]) Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
5000 µg/plate Negative1 (Heck et al., 1989) 4 
 Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0.03, 0.3, 3, 30 µM/plate  
(4.1, 41, 410, 4100 
µg/plate) 
Negative1 (Florin et al., 1980) 4 
 Sister chromatid exchange Chinese hamster ovary cells 1000 µM (136.2 µg/ml) Negative (Sasaki et al., 1989) 4 
(Camphene [01.009]) Ames test S. typhimurium  
TA98; TA100 
100 µl/plate  
(84,500 µg/ plate) 
Negative2 (Rockwell & Raw, 1979) 4 
 Ames test S. typhimurium TA98; TA100; UTH8414; 
UTH8413 
0, 10 to 1000 µg/plate (5 
concentrations) 
Negative1 (Conner et al., 1985) 4 
 Sister chromatid exchange test Chinese hamster ovary cells 1000 µM (136.2 µg/ml) Negative (Sasaki et al., 1989) 4 
(beta–Caryophyllene [01.007]) Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
150,000 µg/plate Negative1 (Heck et al., 1989) 4 
 Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
150 µl/plate Negative1 (Lorillard, 1984) 4 
 Ames test  
(plate incorporation method) 
S. typhimurium TA98; TA100; TA102; 
TA1535; TA1537 
10,000 µg/plate Negative1 (Longfellow, 1998) 4 
 Sister chromatid exchange test Chinese hamster ovary cells 1000 µM (204.4 µg/ml) Negative (Sasaki et al., 1989) 4 
Naphthalene [01.053] Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0.03, 0.3, 3, 30 µM/plate 
(3.9, 39, 385, 3850 g/plate) 
Negative1 (Florin et al., 1980) Published non-GLP study. Part of a larger 
mutagenicity screening study evaluating 239 
compounds. Due to the limited report of 
experimental details and results the validity 
of the study cannot be evaluated. 
Cytotoxicity observed at doses >3 µM/plate.  
 
 Ames test  
(plate incorporation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537; TA1538
0, 3, 10, 30, 100, 300 
µg/plate 
Negative1 (Godek et al., 1985) Unpublished GLP study carried out 
according to OECD guideline 471. 
 
 Ames test  
(plate incorporation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537; TA1538
0, 3, 10, 30, 100, 300 
µg/plate 
Negative1 (Stankowski, 1987) Unpublished GLP study carried out 
according to OECD guideline 471. Repeat 
confirmation of Ames test by Godek et al, 
1985. 
 Ames test  
(preincubation method) 
S. typhimurium  
TM677 
0, 1, 2 mM (0, 128, 256 
µg/ml) 
Negative2 (Kaden et al., 1979 ) Published non-GLP study of limited validity 
(only one strain, concentrations used were 
cytotoxic, insufficient report of experimental 
details and results). 
 
 Ames test  
(plate incorporation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
up to 100 µg/plate Negative2 (McCann et al., 1975) Published summary report of a large study 
evaluating the mutagenic potential of 300 
chemicals. Due to the limited report of 
experimental details and results the validity 
of the study cannot be evaluated. 
 Ames test  S. typhimurium  0, (0.3,) 1, 3.3, 10, 33, 100 Negative1 (Mortelmans et al., 1986)  Published summary report including detailed 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
(preincubation method) TA98; TA100; TA1535; TA1537 µg/plate (NTP, 1992g) results from studies on 270 compounds tested 
in various laboratories within the NTP to a 
large extent in accordance with OECD 
guideline 471. Study design and detailed 
results on naphthalene also included in NTP, 
1992g. In the absence of metabolic activation 
the concentration of 100 microgram/plate 
was completely toxic and not tested any 
more in the second trial when 0.3 
microgram/plate was used as additional 
concentration. In the presence of metabolic 
activation the highest concentration was 
slightly toxic. 
Naphthalene [01.053] cont. Ames test  
(plate incorporation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537; TA1538
0, 5, 10, 25, 50, 100, 300 
µg/plate (-S9) 
0, 10, 25, 50, 100, 300, 900 
µg/plate (+ S9) 
Negative1 (Lawlor, 1994) Unpublished GLP study carried out in 
accordance with OECD guideline 471. 
Cytotoxicity was observed in a preliminary 
study at 66.7 microgram/plate and above in 
the absence of S9 mix and at 333 
microgram/plate and above in the presence of 
S9 mix. 
 Ames test  
(preincubation method) 
S. typhimurium  
TA98; TA100; UTH8414; UTH8413 
0, 100, 500, 1000, 2000 
µg/plate 
Negative1 (Conner et al., 1985) Published non-GLP study with insufficient 
report of some details of method and results. 
Thus, the validity of the study cannot be 
evaluated. Cytotoxicity not reported. 
 Ames test  
(plate incorporation method) 
S. typhimurium  
TA97; TA98; TA100 
0, 5, 10, 50, 250 µg/plate Negative1 (Sakai et al., 1985) Published non-GLP study of acceptable 
quality. Cytotoxicity was observed at the 
highest concentration with complete toxicity 
in TA97 (+/-S9) and in TA100 (-S9) and a 
reduced number of mutants in TA100 (+S9) 
and in TA98 (+/-S9). 
 Ames test  
(plate incorporation) 
S. typhimurium 
TA98; TA100; TA1535; TA1537; TA1538
0, 3.3 to 10,000 µg/plate  Negative1 (Longfellow, 1991) Only summary from CCRIS database 
available from. Validity of the study cannot 
be evaluated. 
 Ames test  
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537  
E. coli WP2uvrA 
1 to 100 µg/plate 
 
10 to 10,000 μg/plate 
Negative1 (Japan Chemical Industry) Only summary from CCRIS database 
available from. Validity of the study cannot 
be evaluated. 
 Rec assay E. coli  
WP2 and WP100 uvrA- recA- 
0 to 2000 µg/plate 
(≥ 4 concentrations) 
Negative2 (Mamber et al., 1984) Published non-GLP study with adequate 
study design, however, deficient in the report 
of some details on method and results (no 
single doses, no detailed results, no data on 
cytotoxicity reported). 
 Inductest  
(prophage induction test) 
E. coli  
GY5027 envA- uvrB- (λ ); GY4015 ampR 
0 to 2000 µg/plate 
(≥ 4 concentrations) 
Negative2 (Mamber et al., 1984) Published non-GLP study with adequate 
study design, however, deficient in the report 
of some details on method and results (no 
single doses, no detailed results, no data on 
cytotoxicity reported). 
 Unscheduled DNA synthesis test Primary rat hepatocytes 0, 0.16, 0.5, 1.6, 5, 16, 50, Negative (Barfknecht et al., 1985) Unpublished GLP-study according to OECD 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
166, 500, 1666, 5000 µg/ml guideline 482. Excessive cytotoxicity 
observed at 50 to 5000 microgram/ml. 
 
Naphthalene [01.053] cont. 
Sister chromatid exchange test Chinese hamster ovary cells 0, 2.7, 9, 27, 45, 90 µg/ml 
(-S9) 
0, 9. 15, 27, 90 µg/ml (+S9)
Positive1 (NTP, 1992g) Valid study in accordance with OECD 
guideline 479. No data on cytotoxicity 
reported. According to the study protocol the 
highest dose chosen was limited by 
cytotoxicity. 
Significant dose-related increase in 
frequency of SCE at concentrations from 27 - 
90 µg/ml (without metabolic activation) and 
15 - 27 µg/ml (with metabolic activation). 
Maximum values for the percent increase in 
SCEs/chromosome in cultures exposed to 
naphthalene relative to those exposed to 
solvent of 40 and 50 % were reached at the 
highest dose tested in the presence and 
absence of S9, respectively, whereas values 
of 360-640 % were reached with the positive 
control mitomycin C. Result is considered 
positive by NTP since the increase over 
solvent control observed is ≥20 % (NTP, 
1992g; Galloway et al., 1987). 
Results would be considered negative by UK 
HSE as the increase in SCEs per cell does 
not reach the required minimum of at least 
100 %).(EU RAR, 2003). 
 Sister chromatid exchange test Human peripheral mononuclear leukocytes 100 µM 
(13 µg/ml) 
Negative1 (Tingle et al., 1993; Wilson et 
al., 1995) 
Published non-GLP study of limited validity 
(only one concentration tested). Naphthalene 
was not cytotoxic to the dividing 
lymphocytes with and without metabolic 
activation at the concentration tested. 
 Mammalian cell gene mutation test 
(Mouse lymphoma assay) 
Mouse lymphocytes L5178Y tk+/tk- 0, 22 to 87 µg/ml (-S9) 
0, 8 to 30 μg/ml (+S9) 
Negative3 
Positive2 
(Longfellow, 1991) Only summary from CCRIS database 
available. Validity of the study cannot be 
evaluated. 
 Chromosomal aberration assay Chinese hamster ovary cells 15 to 75 µg/ml (-S9) 
30 to 67.5 µg/ml (+S9) 
Negative3 
Positive2 
(NTP, 1992g) Study carried out in accordance with OECD 
guideline 473, except that data on 
cytotoxicity are not reported. According to 
the study protocol the highest dose chosen 
was limited by cytotoxicity. Study is 
considered valid. The structural aberrations 
did not include gaps. In the presence of S9 
the percent of cells with structural 
aberrations was significantly (p≤0.05) 
elevated at all concentrations tested 
compared to controls and the increase was 
significantly dose-related (p≤0.001). A 
maximum of 32 % of cells with aberrations 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
was reached at the highest concentration vs. 
0-1.5 % in negative and up to 52 % in 
positive controls. Result is considered 
positive by NTP since a statistically 
significant difference is observed for two or 
more doses (Galloway et al., 1987). 
(1-Methylnaphthalene [01.014]) Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0.03, 0.3, 3, 30 µM/plate 
(4.3, 43, 427, 4266 
μg/plate) 
Negative1 (Florin et al., 1980) 4 
 Ames test  
(preincubation method) 
S. typhimurium  
TM677 
0, 0.7, 3.5, 7 mM (0, 498, 
995 µg/ml) 
Negative2 (Kaden et al., 1979 ) 4 
 
(1-Methylnaphthalene [01.014]) 
cont. 
Chromosomal aberration assay Human lymphocytes 0, 1, 2 mM (0, 142, 284 
µg/ml) (-S9) 
 
0, 0.25, 0.5, 1, 2 mM (0, 
36, 71, 142, 284 μg/ml) 
(+S9) 
Negative1 (Kulka et al., 1988) 4, Published non-GLP study largely in 
accordance with OECD guideline 473. Even 
if cytotoxicity data are not reported, the study 
is considered acceptable. The highest dose 
did not impair cell proliferation. No evidence 
for differences in the incidences of structural 
chromosomal aberrations (chromatid breaks, 
no exchanges seen) and gaps between treated 
and untreated cells (p≤0.05). 0.5 to 2.0 % of 
treated cells showed aberrations (gaps 
excluded) vs. 1 % of control cells. 
 Sister chromatid exchange test Human lymphocytes 0, 1, 2 mM (0, 142, 284 
µg/ml) (-S9) 
 
0, 0.25, 0.5, 1, 2 mM (0, 
36, 71, 142, 284 μg/ml) 
(+S9) 
Negative3 
 
Positive2 
(limited 
evidence) 
(Kulka et al., 1988) Published non-GLP study largely in 
accordance with OECD guideline 479. 
Cytotoxicity data not reported. The highest 
dose did not impair cell proliferation. In the 
presence of S9 the SCE frequency was 
significantly increased at each dose. An 
increase of 43 % was reported at the highest 
dose compared to the control. The effect was 
dose-related, but with a less marked increase 
at higher doses (saturation). 
According to OECD and NTP criteria the 
result in the presence of S9 is considered 
positive (significant increase, dose-relation, 
increase ≥20 % over solvent control). The 
authors of the study refer to the UK HSE 
guidelines on mutagenicity testing that 
require at least a doubling in SCE frequency 
for a positive response. 
2-Methylnaphthalene [01.051] Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0.03, 0.3, 3, 30 µM/plate 
(4.3, 43, 427, 4266 
µg/plate) 
Negative1 (Florin et al., 1980) Published non-GLP study. Part of a larger 
mutagenicity screening study evaluating 239 
compounds. Due to the limited report of 
experimental details and results the validity 
of the study cannot be evaluated. Bacterial 
toxicity observed at doses >3 µM/plate. 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
 
2-Methylnaphthalene [01.051] 
cont. 
Chromosomal aberration assay Human lymphocytes 0, 2.0, 4.0 mM (0, 284, 569 
microgram/ml) (-S9) 
 
0, 0.25, 0.5, 1.0, 2.0, 4.0 
mM (0, 35.6, 71.1, 142, 
284 and 569 
microgram/ml) (+S9) 
Negative3 
 
 
Positive2 
(limited 
evidence) 
(Kulka et al., 1988) Published non-GLP study largely in 
accordance with OECD guideline 473. Even 
if cytotoxicity data are not reported, the study 
is considered acceptable. The highest dose 
did not impair cell proliferation. In the 
presence of S9 a statistically significant but 
weak increase (6.5-fold above control) of 
structural aberrations (chromatid breaks, no 
exchanges seen) was observed at the highest 
tolerated dose (4 mM). The percent of cells 
with structural aberrations (excluding gaps) 
showed a dose-related increase (up to 5 % vs. 
1.0 % in negative and 40 % in positive 
controls), however, the increase was not 
reported as statistically significant. A dose-
dependent weak increase of gaps was also 
noted over the concentration range tested in 
the presence of S9. According to OECD and 
NTP criteria there is a weak evidence for a 
positive response since a statistically 
significant difference for structural 
aberrations per cell is observed for one dose 
(NTP, 1992g; Galloway et al., 1987) and the 
effect was dose-related (OECD guideline 
473). 
 Sister chromatid exchange test Human lymphocytes 0, 2.0, 4.0 mM (0, 284, 569 
microgram/ml) (-S9) 
 
0, 0.25, 0.5, 1.0, 2.0, 4.0 
mM (0, 36, 71, 142, 284 
and 569 microgram/ml) 
(+S9) 
Negative3 
 
 
Positive2 
(limited 
evidence) 
(Kulka et al., 1988) Published non-GLP study largely in 
accordance with OECD guideline 479. Even 
if cytotoxicity data are not reported, the study 
is considered acceptable. The highest dose 
did not impair cell proliferation. In the 
presence of S9 the SCE frequency was 
significantly increased at each dose. An 
increase of 80 % was reported at the highest 
dose compared to the control. The effect was 
dose-related. 
According to OECD and NTP criteria the 
result in the presence of S9 is considered 
positive (significant increase, dose-relation, 
increase ≥20 % over solvent control). The 
authors of the study refer to the UK HSE 
guidelines on mutagenicity testing that 
require at least a doubling in SCE frequency 
for a positive response. 
NR: Not Reported 
1 With and without S9 metabolic activation.  
2 With metabolic activation.  
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3 Without metabolic activation 
4 Abstracted by JECFA at their 63rd meeting (JECFA, 2006a) 
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In vivo mutagenicity/genotoxicity data are available for two candidate substances of the present flavouring group evaluation from chemical 
group 31 and for two supporting substances evaluated by JECFA at the 63rd meeting. Supporting substances are listed in brackets. 
TABLE IV.5: GENOTOXICITY (IN VIVO) 
Table IV.5: GENOTOXICITY (in vivo) 
Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments 
2-Methylbuta-1,3-diene [01.049] In vivo Chromosomal 
aberration assay 
Mouse (B6C3F1) bone 
marrow 
(male mice) 
Inhalation 0, 438, 1750, 7000 ppm for 6 
hours/day for 12 exposures over a 
period of 16 days (Trial 1) 
 
0, 70, 220, 700 ppm for 6 hours/day 
for 12 exposures over a period of 
16 days (Trial 2) 
Negative (Tice et al., 1987; Tice, 
1988; Shelby, 1990) 
Unpublished study report and published summary report of a valid 
multiple endpoint cytogenicity study sponsered by NTP, roughly in 
accordance with OECD guideline 475 (special dosage regimen used). 
 In vivo Sister chromatid 
exchange test 
Mouse (B6C3F1) bone 
marrow 
(male mice) 
Inhalation 0, 438, 1750, 7000 ppm for 6 
hours/day for 12 exposures over a 
period of 16 days (Trial 1) 
 
0, 70, 220, 700 ppm for 6 hours/day 
for 12 exposures over a period of 
16 days (Trial 2) 
Positive 
 
(Tice et al., 1987; Tice, 
1988; Shelby, 1990) 
Unpublished study report and published summary report of valid 
cytogenicity study sponsered by NTP. The study is considered valid. 
Significant (0.01<p<0.05) increase in the frequency of SCE in the bone 
marrow cells at all concentrations. In addition, a significant delay in 
bone marrow cellular proliferation kinetics (lengthening of the 
generation time) was detected. The mitotic index was not significantly 
altered. 
 In vivo Micronucleus test Mouse (B6C3F1) 
peripheral blood cells 
(male mice) 
Inhalation 0, 438, 1750, 7000 ppm for 6 
hours/day for 12 exposures over a 
period of 16 days 
Positive 
 
(Tice et al., 1987; Tice, 
1988) 
Unpublished study report and published summary report of valid 
cytogenicity study sponsored by NTP, roughly in accordance with 
OECD guideline 474 (special dosage regimen used). The study is 
considered valid.  
Significant (p<0.001) increase in the frequency of micronucleated 
polychromatic and normochromatic erythrocytes, and percentage of 
PCE. A significant (p<0.001) and dose-dependent decrease in the 
percentage of circulating polychromatic erythrocytes (suppression of 
erythropoiesis) was noted. 
 In vivo Micronucleus test Mouse(B6C3F1)  
peripheral blood cells 
(male and female 
mice) 
Inhalation 0, 70, 220, 700, 2200, 7000 ppm 
for 13-weeks 
Positive 
 
(Jauhar et al., 1988) Study carried out within NTP. Only short summary and tabulated 
results available from NTP TR 486 (NTP, 1999). Percentage of 
polychromatic erythrocytes among erythrocytes in peripheral blood 
was increased probable due to a possible adaptation to cytotoxicity 
with chronic exposure. Due to the limited details available on this 
study, the validity cannot be evaluated. 
 In vivo Micronucleus test Rat lung fibroblasts 
(male and female rats) 
Inhalation 0, 220, 700, 7000 ppm for 13-
weeks 
Negative (Khan & Heddle, 1991) Study carried out within NTP. Only tabulated results available from 
NTP TR 486 (NTP, 1999). Unusual study protocol. Validity of the 
study cannot be evaluated.  
(Myrcene [01.008]) In vivo Chromosomal 
aberration assay 
Rat (Wistar) bone 
marrow 
Gavage 0, 100, 500, 1000 mg/kg bw (single 
exposure) 
Negative (Zamith et al., 1993) 1 
 In vivo Micronucleus test Mouse (B6C3F1)  
peripheral blood cells 
Gavage 0, 250, 500, 1000, 2000 mg/kg bw 
(single exposure) 
Negative (NTP, 2003c) 1 
(d-Limonene [01.045]) In vivo Comet assay Mouse (ddY) / Rat 
(Wistar). 
Oral 0, 2000 mg/kg  Negative (Sekihashi et al., 2002) 1 
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Table IV.5: GENOTOXICITY (in vivo) 
Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments 
 In vivo Mammalian spot 
test 
Mouse embryos from 
C57BL/6JHan x T 
stocks 
Intraperitoneal 
injection 
215 mg/kg bw  Negative (Fahrig, 1984) 1 
Naphthalene [01.053] In vivo Unscheduled 
DNA synthesis 
Rat hepatocytes Gavage 0, 600, 1000, 1600 mg/kg bw Negative (Research Toxicology 
Center, 1999) 
Summarised report of unpublished study carried out in accordance 
with OECD guideline 486. Although some minor details of the results 
are not reported (viability of cells, individual slide values for nuclear 
grains and cytoplasmic grains) the study is considered valid. 
 In vivo Micronucleus test Mouse (Swiss ICR) 
bone marrow 
Gavage 50, 250, 500 mg/kg bw (single 
exposure) 
Negative (Harper et al., 1984) Published non-GLP study not fully in accordance with OECD 
guideline 474 (only males tested, sampling time not indicated, effect 
on PCE/NCE ratio not reported). Due to the limited report of 
experimental details and results the validity of the study cannot be 
evaluated. 
At the dose of 500 mg/kg bw two of ten animals died. The dose of 
1500 mg/kg bw was toxic (lethal) to all animals. Induction of 
micronuclei in benzene-treated mice was significantly enhanced by co-
treatment with naphthalene at 50 and 250 mg/kg bw. 
 In vivo Micronucleus test Mouse (CD-1) bone 
marrow 
Intraperitoneal 
injection 
250 mg/kg bw (single exposure) Negative (Sorg et al., 1985) Unpublished valid GLP-study carried in accordance with OECD 
guideline 474. Naphthalene was negative in the micronucleus test at 
the dose of 250 mg/kg bw at all of the time intervals tested. A harvest-
time dependent depression in the PCE/NCE ratio was observed in 
animals treated with the test substance, which was statistically 
significant (p ≤ 0.05) at sacrifice time of 72 hrs. 
1 Abstracted by JECFA at their 63rd meeting (JECFA, 2006a) 
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